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Introduction 
1.1 Colorectal cancer 
 
1.1.1 Colorectal carcinogenesis 
The distal tract of the human digestive apparatus consists of the colon and rectum, starting 
at the end of the small intestine and terminating at the anus. The surface of the large bowel 
comprises a single layer of epithelial cells. These cells arise from stem cells at the bottom of 
the crypts present in the colon. They multiply in the bottom third and differentiate in the 
upper two thirds of the crypt after which they migrate further into the luminal surface. In this 
fashion, intestinal cells are continuously renewed, with each proliferative cell within the crypt 
dividing twice a day, resulting in the production of about 300 cells per crypt per day.(1). This 
adds up to around 1011 cells that are shed into the lumen of the large bowel each day (2). 
Colorectal tumors arise from defects in the delicate balance between stem cell renewal and 
differentiation resulting in clonal expansion of colonic epithelial cells. Colorectal cancer is a 
multistage process, in which the tumor develops through a series of distinct 
histopathological steps, each accompanied by specific genetic alterations. A model of this 
process, as proposed by Fearon and Vogelstein in 1990 (3), describes how the tumor 
proceeds from the earliest stage of aberrant crypt foci to various adenoma stages and 
eventually into malignant metastasizing carcinoma. This process is characterized by a series 
of genetic alterations in oncogenes, tumor suppressor genes and caretaker genes, as well 
as epigenetic events. Cells that have a selective advantage over others within the tumor 
through the acquisition of mutations enhancing their survival are selected, leading to clonal 
expansion. The genes involved in this process have been studied in detail and the key 
genes among many others include two genes disrupting the Wnt signaling pathway, the 
adenomatous polyposis coli (APC) gene and β-catenin gene, K-RAS, important in 
progression from small to larger adenomas and TP53, mainly in the later stages of tumor 
development. Other events include loss of heterozygosity of chromosome 18q, mutations in 
PRL3 leading to metastasis, and microsatellite instability (4-6). 
 
1.1.2 Epidemiology 
1.1.2.1 Incidence 
Colorectal cancer is the second leading cause of cancer deaths in the Western world. In the 
US it is estimated that 1 in 17 men and 1 in 18 women will develop colorectal cancer at 
some point in their life. This adds up to an estimated 145000 incident cases in 2005 in the 
US alone, with nearly 57000 estimated deaths due to colorectal cancer, accounting for 10% 
of all cancer deaths (7). In the Netherlands, the incidence and mortality rates reflect the 
rates of the US and other Western countries, with over 9500 new cases and nearly 4400 
colorectal cancer deaths in the year 2002 (8). Interestingly, in western countries the 
incidence rates seem to be steadily declining, while in Japan colorectal cancer incidence is 
rapidly increasing (9). 
 
1.1.2.2 Risk factors 
There are several factors, both genetic and environmental, that influence the formation and 
development of colorectal cancer. Individuals can be at increased risk due to their genetic 
constitution. Genetic predisposition to colorectal cancer will be discussed in more detail in 
section 1.2.  
Other high risk groups include individuals with adenomas, since approximately 5% of 
adenomas develop into carcinomas. Also inflammatory bowel diseases like ulcerative colitis 
and Crohn’s disease can confer increased risk of colorectal cancer, indicating that 
inflammation also plays an important role in colon tumorigenesis. Although the mechanism 
by which inflammation influences tumorigenesis is not completely understood, there are 
several inflammation-induced changes observed in cells and tissues which might play a role 
in this process. These include changes in cytokine environment, prostaglandin formation, 
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glycosylation, apoptosis and angiogenesis (10,11). Moreover, inhibition of inflammatory 
mediators has been shown to inhibit tumor formation (12). 
Epidemiological studies have indicated that a “Western lifestyle” is one of the main risk 
factors in colorectal cancer. This is illustrated by classical ecological studies involving 
Japanese immigrants to the US. Colorectal cancer incidence in Japan, where the traditional 
diet differs substantially from the Western diet, has always been much lower than in Western 
countries. This difference between populations is reduced when Japanese migrate to the US 
and adopt a more Western diet, subsequently increasing cancer incidence to reflect that of 
the adoptive country (13). Excess alcohol intake and diets high in red and processed meat 
are suggested to increase risk, while adequate levels of folate, calcium and vitamin D intake 
appear to be protective (14). The possible involvement of fatty acid composition will be 
discussed in more detail in section 1.3.2. 
Other lifestyle and environmental factors that might influence the risk of colorectal cancer 
include low physical activity, excess body weight, smoking earlier in life and use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) the latter of which will be discussed in 
section 1.3.3 (15).  
 
 
1.2 Genetic predisposition to colorectal cancer 
Colorectal cancer is traditionally divided in two distinct types, familial and sporadic cases, 
with familial cases being genetically predisposed to the disease on the account of inherited 
mutations in the germline, whereas in sporadic cases similar mutations accumulate in 
somatic cells, principally as the result of the involvement of endogenous and environmental 
risk factors. In a large study on nearly 45000 twin pairs it was estimated that 35% of 
colorectal cancer cases is due to heritable factors, indicating that our knowledge of the 
genetics of cancer is very limited (16). Moreover, a 2-fold increased risk in first-degree 
relatives of sporadic colorectal cancer patients has been observed, which suggest a mild 
predisposition and the involvement of low penetrance alleles. Taken together, this data 
suggests that familial and sporadic colorectal cancer are two very extremes with a large grey 
area in between. This grey area contains patients with no apparent or unknown family 
history as well as individuals with a weak family history. Only a few low penetrance alleles 
have been identified at present accounting for some of these cases, but many more are 
likely to be identified (17). Most, if not all of these low penetrance alleles will also require the 
involvement of environmental risk factors to result in the colorectal cancer phenotype. 
Quoting Judith Stern: “While genetics loads the gun, the environment pulls the trigger. 
Predisposition to colorectal cancer is therefore only in some exceptional cases just a 
straightforward matter of inheriting a high penetrance allele resulting in a familial syndrome 
and a very high chance of developing the disease, but in the majority of cases the presence 
of a combination of low penetrance alleles together with specific environmental factors (18). 
 
1.2.1 High penetrance alleles 
It is believed that high penetrance mutations play a role in up to 20% of colorectal cancer 
cases, whereas known high penetrance alleles giving rise to familial syndromes account for 
around 5% of cases (19). These syndromes are divided in two categories on the basis of 
presence or absence of polyposis. The polyposis syndromes consist of at least four 
members, familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, juvenile 
polyposis and MYH-polyposis, of which only FAP will be briefly described because of the 
involvement of the Wnt signaling pathway in sporadic colorectal cancer. FAP, accounting for 
less than 1% of colorectal cancer cases, is an autosomal dominant disease characterized by 
the formation of multiple adenomas in the colon during the second or third decade of life, 
leading to malignant tumors in near 100% of patients by the age of 40 to 50 years (19). The 
disease is initiated by a germline mutation in the adenomatous polyposis coli (APC) gene 
(first hit), resulting in disregulation of the Wnt signaling pathway and genetic instability (6). 
10 
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For the formation of an adenoma a second hit, resulting in complete loss of functional APC, 
seems required. Similar loss of APC function is estimated to be essential in about 80% of 
sporadic colorectal cancer cases, although this involves other APC mutations compared to 
FAP and also includes epigenetic events. However, more recently contradictory reports on 
the absolute frequency of APC mutations in colorectal cancer have been published (20). 
Hereditary non-polyposis colorectal cancer (HNPCC), also called Lynch syndrome, is the 
most common inherited colorectal cancer syndrome, accounting for approximately 3% of 
cases (21). This syndrome is characterized by early onset of disease (approximately 45 
years of age) as compared to sporadic cancer, and a relatively large predisposition to other 
cancers as well. In this syndrome the progression from adenoma to carcinoma is 
accelerated to 2-3 years as opposed to 10-15 years in FAP or sporadic forms, so although 
adenomas form at a later age compared to FAP, the age of onset of adenocarcinomas is 
similar (22). HNPCC is caused by inactivating mutations in the family of mismatch repair 
(MMR) genes. The majority of mutations have been found in MLH1 and MSH2 (23-25), 
although rare mutations in other MMR genes exist. In sporadic colorectal cancer MLH1 is 
also frequently inactivated by the epigenetic event of hypermethylation of its promoter 
region. Carriers with a germline mutation have a lifetime risk of developing the disease of 
60-80%, indicating that environmental factors and modifier genes (see 1.2.2.1) may also 
play a role. 
Other rare high penetrance alleles include mutations in AXIN2, POLD, TGFβR2, LKB1, 
SMAD4, BMPR1 and MYH (18). 
 
1.2.2 Susceptibility genes 
To avoid confusion regularly observed in the literature concerning the terms modifier genes 
and low penetrance susceptibility alleles, the following distinction, as put forward by Balmain 
in his endnote, has been followed: Modifier genes modify the phenotype of tumors induced 
by a specific pathway, whereas low penetrance alleles confer weak susceptibility (26).  
 
1.2.2.1 Low penetrance susceptibility alleles 
The above mentioned alleles are rare as they only account for a small proportion of the 
familial clustering (3-5%) observed for colorectal cancer cases. This indicates that most 
genetic susceptibility to CRC will probably be the result of many genetic variants each with a 
modest individual effect on tumor susceptibility. Because these multiple variant alleles are 
generally low in penetrance and therefore only marginally contribute to tumor susceptibility, 
they are likely to have low estimates of relative risk (RR) when examined in association 
studies. However, if the frequency of a weak susceptibility allele is relatively high within a 
population, the proportion of cases attributable to this allele can be substantial, and account 
for a large proportion of cases in the previously described grey area. This is illustrated by a 
low penetrance variant in the TGFβR1 gene. This gene, encoding for one of the two 
canonical receptors of the TGFβ signal transduction pathway, contains a polyalanine tract of 
variable length in the first exon. In the general population, approximately 14% of individuals 
carry an allele with six Ala repeats (TGFβR1*6Ala). This allele has been shown to confer a 
modest RR of 1.2 (27). However, due to the high carrier frequency, the population 
attributable risk of this allele is estimated at 3% of all colorectal cancer cases; a substantial 
proportion of cases. 
Genetic heterogeneity within human study populations results in conflicting outcomes, which 
have led some researchers to investigate susceptibility alleles in genetically homogenous 
mice strains (26,28). Moreover, large sample sizes are required to be able to show 
moderate but statistically significantly RRs. These points make it difficult to identify low 
penetrance variations in humans, but some promising candidates are summarized in table 1. 
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Table 1: Candidate low penetrance alleles involved in predisposition to colorectal cancer 
Gene Polymorphism Relative risk (95%CI) Ref 
APC Ile1307Lys (Ashkenazi) 1.5-2.22 (1.21-2.07) (29) 
TGFβR1 6Ala repeat 1.20 (1.01-1.43) (27) 
HRAS1 Tandem repeat 2.50 (1.54-4.05) (30) 
MTHFR C677T 0.76 (0.62-0.92) (30) 
BLM 2281delATCTGAinsTAGATTC 2.4 (1.5-3.7) (31) 
HFE C282Y or H63D 1.40 (1.07-1.87) (32) 
CCND1 G870A 1.7 (1.0-2.66) (33) 
 
1.2.2.2 Modifier genes 
A powerful alternative approach to the difficult search for low penetrance alleles is the use of 
mouse models to identify loci that alter the phenotype of that mouse model. Mapping these 
loci to identify the responsible modifier gene could help pinpoint the homologous gene in 
humans. An example of a locus that has been found to modify the phenotype of ApcMin mice 
is the modifier of Min (Mom1) locus (34). The modifier gene on this locus encodes a 
phospholipase A2 (Pla2g2a) enzyme, as discussed in more detail in section 1.2.3. Other 
recent examples include the identification of mouse Ptprj, encoding a receptor-type protein 
tyrosine phosphatase, as a candidate for the colon cancer susceptibility locus Scc1. The 
human homologue of this gene, PTPRJ, is frequently deleted in human cancers. Moreover, 
human tumors containing missense mutations in PTPRJ have been identified (35). Another 
recently identified modifier is the locus encompassing Aurora2 (Stk6 in mouse and STK15 in 
humans), a gene involved in mitotic chromosomal segregation. A functional polymorphism in 
the human gene has been identified and shown to interfere with mitosis which results in 
aneuploidy in colon tumors (36). 
 
1.2.3 Genetic variation 
1.2.3.1 Single Nucleotide Polymorphisms (SNPs) 
The most abundant form of genetic variation in the human genome are single nucleotide 
polymorphisms (SNPs), positions at which more than one nucleotide can occur when 
genomes of different individuals are compared and that are present by definition in 1% or 
more in the population. One of the current hypotheses is that a large part of the low 
penetrance alleles yet to be identified will turn out to be SNP alleles. These SNPs are 
estimated to occur approximately at 1 out of 200-300 bases, with around 30% of minor 
alleles occurring at 5% or more in the population. Approximately 20% of SNPs are 
polymorphic in all 4 major ethnic groups (African, Asian, Caucasian and Hispanic-Latino).  
The vast majority of SNPs is located in non-coding regions, either in introns within genes, in 
the non-coding regions between genes, or in 5’ and 3’ regulatory regions. It is not clear to 
which extent the first two types of SNPs have any functional relevance, although there is 
increasing evidence of regulatory sequences being present in introns. Even if it is unlikely 
that a SNP has any functional effect, due to its location, it could still be very useful for the 
identification of susceptibility allele in association studies, acting as a marker by linkage to 
another causal variant. However, SNPs in regulatory regions of a gene, for example the 
promoter, intron-exon boundaries or untranslated regions of exons, are potentially 
functionally relevant as they may exert an effect on several aspects of gene regulation, 
including expression levels, mRNA stability, splicing, transport and many others. SNPs in 
coding regions can either cause an amino acid substitution, the so-called non-synonymous 
SNP (nsSNP), or, despite the change in codon, encode the same amino acid, resulting in an 
unchanged protein, the so-called synonymous SNP (sSNPs).  About half of all coding SNPs 
are synonymous (37). The functional relevance of synonymous SNPs has been subject to 
debate since the expressed protein is not affected. However, it has been shown more 
recently that there are consensus sequences within exons that facilitate splicing, the so-
called exonic splice enhancers (ESE) (38). Changes within ESEs or other exon-specific 
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regulatory sequences can therefore interfere with the splice machinery, and may, amongst 
others, result in a change in the ratio of splice variants of the protein. Also, as with non-
coding SNPs, sSNPs can act as markers of other variants.  
nsSNPs are thought to have the most potential to contribute to disease phenotype since 
altered proteins are produced. An additional distinction is made between conservative and 
non-conservative amino acid substitutions, with the latter having a clear effect on protein 
function since the substituted amino acid is more likely to affect intrinsic properties of the 
wild-type protein.  
The potential of SNPs to aid the mapping of disease genes and contribute to the 
understanding of complex diseases, has resulted in tremendous efforts to generate a SNP 
map of the human genome, with as major contributors the International SNP Map Working 
Group (39) and the SNP Consortium (40). Not all the SNP data that became available in the 
first few years could be directly applied to association and mapping studies since most of 
these SNPs were not validated and can only be considered as candidate SNPs. However, 
within the last two years hundreds of thousands of SNPs have undergone validation by 
population specific resequencing efforts and are publicly available on the internet in SNP 
databases of which dbSNP is the best known and most widely used (41). 
 
1.2.3.2 Haplotypes 
Every SNP is the result of a single mutation event and may be associated to other alleles 
present on that chromosome at the time of the mutation. The combination of a specific set of 
adjacent alleles that are formed this way on a part of a chromosome, is called a haplotype. 
Different haplotypes are formed when new mutations arise, or when recombination occurs in 
between two alleles within a haplotype, resulting in a new chromosome containing both 
maternal and paternal material components. When two SNP alleles are relatively close to 
each other and are consistently co-inherited, they are associated within a population, and 
are denoted to be in linkage disequilibrium (LD). The likelihood that recombination occurs 
between two alleles increases with distance, which means that the level of LD decreases 
with distance. A recent hypothesis relative to recombination is that it occurs at distinct 
hotspots with little or no recombination occurring between them, thus resulting in haplotype 
blocks that remain intact within a population (42). The number of haplotypes could in theory 
reach 2n, where n is the number of independent SNPs; however in a chromosomal interval 
with little or no recombination the real number is closer to n+1. Several studies have 
investigated the nature and extent of these haplotype blocks and have showed great 
diversity in block structures, with some blocks extending only a few kb whereas others 
encompassing more than 100 kb (43,44). 
The presence of strongly associated SNPs indicates that, although there can be many SNPs 
present within a chromosomal region, these are organized in only a few haplotypes. This 
means that for association studies, the selection of SNPs can be limited to those SNPs that 
are representative for a certain haplotype, the so-called haplotype tagging SNPs (htSNPs). It 
is estimated that out of the 15 million SNPs in the human genome over 1,000,000 can be 
considered as htSNPs (45). With this in mind, a large scale project has been set up called 
the International HapMap Project, aiming to create a genome wide map containing 
haplotype blocks from which htSNPs can be selected (46). The most informative SNPs for 
association studies, the so-called tagging SNPs, can also be selected by using the measure 
of LD across all SNPs within candidate genes (47). 
An informative way of determining haplotypes is by using parental material from which the 
haplotype of the offspring can be deduced. In most cases however, this is not available and 
haplotypes can either be determined by physically separating the chromosomes (48), or 
more commonly, by estimation using algorithms designed for this purpose (49). A recent 
review on haplotype blocks and LD structure in the human genome is provided by Wall and 
Pritchard (50). 
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1.2.4 Arachidonic acid pathway genes as low penetrance candidate genes of CRC 
1.2.4.1 Dietary polyunsaturated fatty acids 
Several lines of evidence implicating arachidonic acid (AA) pathway genes in colon 
tumorigenesis have led to the hypothesis that functional polymorphisms in these genes may 
represent low penetrance susceptibility alleles. In the AA pathway shown in figure 1, dietary 
polyunsaturated fatty acids (PUFAs) are converted into prostanoids and leukotriens. 
 
 
 
Figure 1: the AA pathway, from Larsson et al. 2004 (51). 
 
The main PUFA in our diet is linoleic acid (LA; 18:2n-6), a member of the n-6 family of 
PUFAs which have their first double bond at the 6th carbon from the methyl terminus. The n-
3 PUFA family, with the first double bond at the 3rd carbon atom, has as its parent compound 
α-linolenic acid (ALA; 18:3n-3). Both LA and ALA are converted in several steps by 
elongases and desaturases, including the rate limiting Δ-6 desaturase, into AA (20:4n-6) and 
eicosapentaenoic acid (EPA; 20:5n-3). The latter two can both be obtained from the diet as 
well. These eicosanoid precursors are incorporated and stored into cell membranes until 
they are released by different members of the phospholipase A2 (PLA2) family of enzymes.  
 
1.2.4.2 Phospholipases 
PLA2 enzymes release AA and EPA by hydrolysis of the ester bond at the sn-2 position of 
phospholipids, thereby producing free fatty acids (52). Numerous lines of evidence implicate 
the PLA2 family of enzymes in colon carcinogenesis. Several studies have suggested a 
tumor suppressing role for the gene encoding group 4A cytosolic PLA2 (PLA2G4A). 
Upregulation of this enzyme results in release of free AA which can act as a signal for 
apoptosis via formation of ceramide (53), unless PTGS2 (see section on cyclooxygenases) 
is simultaneously upregulated in which case the increased free AA is converted into 
prostanoids, and the apoptosis signal is lost, as shown in figure 2. 
14 
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A. Upregulation of PLA2G4A  B. Upregulation of PLA2G4A and PTGS2 
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Figure 2: AA as a signal for apoptosis. 
 
This hypothesis is reinforced by the inverse relationship found between Pla2g4a and Ptgs2 
in chemically induced mouse tumors (54). The importance of Pla2g4a is also demonstrated 
by a study in which an increase in tumor number in the colon was observed in mice with a 
deleted Pla2g4a gene despite a reduction in PGE2 production (55). In addition, Pla2g4a 
heterozygous and null mice showed an increase in chemically induced colon tumors and a 
decrease in apoptosis within the epithelium (55,56). However, these effects seem to be 
specific for the colon, since mouse models for spontaneous intestinal cancer which 
predominantly develop polyps in the small intestine, show a protective effect on tumor 
multiplicity upon Pla2g4a deletion (57,58). This might be explained by differences in Pla2g4a 
expression between colon and small intestine, since, although Pla2g4a is expressed in the 
colon, its expression is barely detectable in the small intestine (55). Experiments on the 
secreted form of this enzyme (PLA2G2A) are not entirely consistent. Pla2g2a was first 
identified as the candidate gene for the modifier of Min (Mom1) locus in ApcMin mice. An 
inactivating mutation in Pla2g2a negatively affects polyp multiplicity in ApcMin mice (59).  
Efforts to confirm this effect in humans have been less convincing when using microsatellite 
markers around the PLA2G2A locus on chromosome 1 since these showed only weak 
associations (34,60). Since then, considerable effort has gone into elucidating the role of 
PLA2G2A in colon tumorigenesis and both overexpression and loss of the gene in human 
tumors has been found (61,62). However, numerous other studies have reported no 
association between alterations in the gene or gene expression levels and colorectal tumors 
(63-66), and also no functional polymorphisms or mutations have been found in patients with 
attenuated FAP as yet (67). 
 
1.2.4.3 Cyclooxygenases 
Free AA and EPA share the same enzymes for their conversion into 2-series prostanoids 
and 4-series leukotriens in the case of AA, and 3-series prostanoids and 5-series leukotriens 
in the case of EPA. The cyclooxygenase (COX) enzymes, also called prostaglandin-
endoperoxide synthase (PTGS) catalyze the formation of prostanoids, including 
prostaglandins (PGs) and thromboxanes (TXs) via two distinct reactions, a cyclooxygenase 
reaction where two O2 molecules are utilized to form the highly unstable intermediate PGG, 
and a peroxidase reaction where PGG is reduced into PGH (68). There are three PTGS 
isozymes, the constitutively expressed PTGS1, the inducible PTGS2, and the recently 
identified PTGS3 which is actually a splice variant of PTGS1 (69). Expression of PTGS2 is 
induced by numerous growth factors, cytokines and oncogenes, and regulated both 
transcriptionally and posttranscriptionally, through increased mRNA stability.  Several 
pathways are involved in PTGS-modulation, some acting predominantly at the 
15 
Chapter 1 
transcriptional level (for example the Rho B pathway), whereas others predominantly 
regulate mRNA stability (for example the Akt/protein kinase B pathway) (70). Recently, it has 
been shown that the NF-κΒ pathway is also one of the key regulators of PTGS2 expression 
(71). Extensive research has gone into unraveling the mechanisms involved in the tumor 
promoting effect of PTGS2. Numerous studies have indicated PTGS2 as one of the key 
players in colon carcinogenesis, mainly based on the increased expression of the enzyme in 
colorectal tumor tissue (72-74). Further evidence for the relevance of PTGS2 in tumor 
formation was obtained through animal studies. Apc mutant mouse models showed a 
significant decrease in intestinal tumor multiplicities when the Ptgs2 gene was knocked out 
(75) or inhibited (76,77). Also, treatment with PTGS inhibitors (nonsteroidal anti-
inflammatory drugs, discussed in more detail in section 1.3.2) resulted in a decrease in 
adenoma number in FAP patients (78-80). There are several mechanisms by which elevated 
PTGS2 levels promote tumorigenesis, either PG dependent or PG independent. The NF-κΒ 
pathway is an example of a PG independent pathway, which will not be discussed further in 
this thesis. The PG dependent mechanisms will be discussed in more detail in section 
1.2.3.1. 
 
1.2.4.4 Lipoxygenases 
The lipoxygenase (LOX) family of enzymes, including ALOX5, ALOX8, ALOX12 and 
ALOX15, catalyze the formation of leukotriens, hydroxy fatty acids and lipoxins. The 
ALOX15 enzyme has the unique ability to directly convert linoleic acid (LA) into a specific 
apoptosis inducer, namely 13-S-hydroxyoctadecadienoic acid (13-S-HODE). Two forms of 
ALOX15 have been identified as having anti-carcinogenic properties, and with respect to 
colorectal cancer, the main part of research has focused on the role of ALOX15-1 (81). It 
was found that ALOX15-1 expression and its metabolite 13-S-HODE, was decreased in 
colorectal tumors. In vitro studies revealed that 13-S-HODE induced cell cycle arrest, 
apoptosis and reduced cell proliferation (82,83). The mechanism by which 13-S-HODE can 
exert these effects have been further investigated and it is hypothesized that this eicosanoid 
can bind to the nuclear receptor peroxisome proliferator-activated receptor (PPAR) δ, 
thereby reducing its gene expression and activity, which in turn leads to apoptosis of cancer 
cells (84). The anti-carcinogenic effect of ALOX15 is further illustrated by a study on 
ALOX15-2, the other subtype of ALOX15 where its tumor suppressive effect was 
demonstrated for prostate cancer both in vitro and in vivo (85). At present the role of 
lipoxygenases in colorectal cancer is incompletely understood though a general working 
model is shown in figure 3, as adapted from Shureiqi and Lippman (81). 
 
 
Figure 3: Lipoxygenase enzyme family and tumorigenesis. Adapted from Shureiqi and Lippman, 2001 
(81)  
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1.2.4.5 Prostanoid signaling 
The AA derived eicosanoids, which includes prostaglandins and leukotriens, represent 
potent lipid mediators. They are synthesized in cells which have been activated by 
mechanical trauma or numerous other stimuli including growth factors and cytokines. 
Leukotriens are predominantly produced in activated inflammatory cells, including 
leukocytes and macrophages. The eicosanoids derived from the precursor AA are in general 
pro-inflammatory, whereas the EPA derived eicosanoids are thought to contain anti-
inflammatory properties (86). In addition to their pro-inflammatory action, several studies 
have implicated AA derived eicosanoids to play a role in tumorigenesis. PGH2 is the 
precursor prostanoid formed by PTGS from AA after which, in a cell specific manner, other 
PGs and TXs are produced (87). It has been shown that the level of PGE2 is increased in 
both human and mouse colorectal tumor cells when compared to normal mucosal cells 
(88,89). This has prompted researchers to investigate the role of this and other eicosanoids 
in tumorigenesis. Several in vitro studies have indicated a decrease in apoptosis after cells 
were treated with PGE2 and PGD2 (90,91). In human colorectal cancer cell lines HT-26 and 
SW1116, it was shown that most AA derived prostanoids, with the exception of prostacyclin 
(PGI2), increased cell proliferation (92). PGE2 has also been implicated to play a role in cell 
migration, adhesion, metastatic potential and growth of cancer cells (93-95) partly via 
activation of the Ras-MAPK cascade (96), and it has been shown to promote angiogenesis 
in murine tumors (97). Moreover, ApcΔ716 mice with a homozygous deletion of the PGE2 
receptor EP2, showed a decrease in polyp size and multiplicities similar to Ptgs2 knock-out 
mice, indicating that the PGE2 tumor-promoting signal is mediated through the EP2 receptor 
(98). The mechanism by which PGE2 induces apoptosis may be related to the increased 
expression of the proto-oncogene Bcl-2 (99). 
 
1.2.4.6 Interaction with Wnt signaling pathway 
More clues that genes in the AA pathway might represent low penetrance alleles leading to 
increased susceptibility or resistance to colorectal cancer, have come from its interaction 
with the main pathway that is activated in most colorectal tumors, namely the Wnt signaling 
pathway. Wnt signaling activation by mutations in APC or β-catenin, leads to accumulation 
and nuclear translocation of β-catenin which in turn leads to transcription of oncogenic target 
genes (100). The putative link between the AA and Wnt pathways is among others 
suggested by interactions with peroxisome proliferator-activated receptors (PPARs). The 
PPARs are a family of ligand activated transcription factors that belong to the nuclear 
hormone receptor superfamily (101). Once activated by a ligand, they form a heterodimer 
with the RXR receptor after which the complex binds to the promoter of a target gene 
encompassing a peroxisome proliferator response element (PPRE). Depending on co-
activators, this process induces or blocks transcription of the target genes. The PPARs are 
linked to the AA pathway since their ligands include PUFAs, in addition to specific 
eicosanoids produced via the AA pathway as well as nonsteroidal anti-inflammatory drugs 
(NSAIDs). For example, LA can act as a ligand for all three isotypes (α, β/δ and γ), whereas 
AA is mainly a PPARα activator. More selective eicosanoid ligands include PGI2 for PPARδ, 
13-S-HODE for PPARγ and LTBB4 for PPARα (102,103). 
Both PPARδ and PPARγ have been suggested to interact with the Wnt signaling pathway. 
PPARδ has been identified as one of the downstream Wnt signaling targets, suggesting that 
the tumor promoting effects of mutant APC are at least in part due to changes in 
transcription caused by PPARδ expression. Moreover, decreased tumorigenesis was 
observed in mice inoculated with human colorectal cancer cells containing only one copy of 
the PPARδ gene (104). However, in a study investigating this cross-talk, the expected 
increase in Pparδ mRNA due to inactivation of Apc was not observed. Moreover, deletion of 
the Pparδ gene in ApcMin mice did not result in decreased tumor number, but rather in 
increased tumor size (105). However, a decrease of tumor burden in ApcMin mice was shown 
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upon Pparδ inhibition (106). Also, transactivation of Pparδ by PGE2 through PI3K/Akt 
signaling resulted in increased adenoma formation in this mouse model (107). Overall, 
removing or inactivating PPARδ has little effect but activation of PPARδ signaling plays an 
important role in stimulating intestinal polyp formation in vivo. 
Several studies have investigated the relation between PPARγ and Wnt signaling. One study 
showed that loss of one copy of the Pparγ gene already resulted in an increase in tumor 
multiplicity and β-catenin accumulation in these tumors, but only in mice wild-type for Apc 
(108).  This suggests a regulatory role for PPARγ in the Wnt signaling pathway, when this 
pathway has not been constitutively activated by mutations in APC. Although the latter 
results are rather controversial, even in cells carrying APC mutations, it has been shown that 
PPARγ activation causes β-catenin degradation (109). This is in line with findings that 
induction of PPARγ results in a decrease in β-catenin levels in adipocytes (110). Whether β-
catenin is regulated by PPARγ, or PPARγ is a downstream target of Wnt signaling still 
remains to be elucidated suggested Jansson et al. as elevated PPARγ levels were observed 
upon induction of the Wnt signaling pathway in vitro (111).  
PPARγ has also been implicated in colorectal cancer risk through association studies with 
SNPs. Both SNPs investigated in this thesis (P12A and H477H) have previously been 
shown to influence the risk of colorectal tumors. The P12A SNP has been associated with 
colorectal cancer by one study (112), which could not be replicated by another (113), and 
with colorectal adenomas (114). The H477H SNP has only been reported in one study on 
colorectal cancer, in which an association with colorectal cancer was found (113). These 
genetic associations provide further evidence that PPARγ plays an important role in 
colorectal tumorigenesis. 
 
 
1.3 Environmental factors 
In addition to genetic modifiers, environmental factors also play an important role in 
colorectal cancer susceptibility. Environmental factors that have been investigated in this 
thesis are discussed in more detail in the following sections. 
 
1.3.1 n-3 polyunsaturated fatty acids 
The hypothesis that n-3 PUFAs have a protective effect against colorectal cancer originates 
from studies with Greenland Eskimos a population characterized by a significantly lower 
incidence of colorectal cancer, and by a fish-enriched diet containing substantially more n-3 
PUFAs compared to Western diets (115). A similar effect is also seen in Japanese 
populations consuming diets rich in fish. This protective effect is lost after migration to 
Western countries like the US, and adoption of the Western lifestyle (13). Epidemiological 
prospective studies however, have not been very consistent. For example, cancer incidence 
and fish consumption as a dietary proxy of n-3 PUFAs were found to be inversely associated 
in some studies (116-118), but not in others (119-121). In studies using nutrient calculations 
from food frequency questionnaires from which n-3 PUFA intake is deduced, similar 
inconsistencies were observed. One case-control study showed an inverse association 
between n-3 PUFA intake and colorectal cancer (122), whereas one case-control and one 
prospective study showed no association (123,124). Only recently, actual serum 
measurements of fatty acids have been used to investigate associations with colorectal 
cancer. Total n-3 PUFA, EPA and DHA content represent more reliable markers and have 
confirmed the inverse association with colorectal cancer incidence (125). 
Animal and in vitro studies reinforce a potential protective effect of increased n-3 PUFA 
intake on colorectal cancer. For example, dietary supplementation with fish oil and/or 
EPA/DHA decreases tumor number in chemically-induced animal models of colorectal 
tumors (126) as well as in ApcMin mice (127,128). N-3 PUFAs have also been shown to 
induce apoptosis and suppress cell growth in cell lines (129,130). 
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There are several proposed mechanisms by which n-3 PUFAs can exert their protective 
effect on tumor formation, as reviewed by Larsson et al. (51). One of the major mechanisms 
leads to the suppression of n-6 PUFA derived eicosanoids. Higher intake of n-3 PUFAs, 
compared to the n-6 variety, would result in a decrease in available AA for eicosanoid 
production through the incorporation of the n-3 PUFAs into membrane phospholipids (131). 
This effect is further enhanced by competition between n-3 and n-6 PUFAs for the 
elongases and desaturases that convert these PUFAs, since n-3 PUFAs have a higher 
affinity for these enzymes (87). N-3 PUFAs can also directly inhibit PTGS2 (132,133) and 
compete with n-6 PUFAs for PTGS2 to form prostanoids (134). Moreover, EPA is the 
preferred substrate for the LOX enzymes that utilize both AA and EPA, resulting in an 
increase in n-3 PUFA derived leukotriens (135). 
Besides these direct effects on the AA pathway, dietary n-3 PUFAs or their metabolites can 
exert their effect by changing the ligand spectrum of PPARδ and PPARγ, and thereby 
modifying the signaling pathways of these two nuclear receptors (136,137). Other pathways 
might also play a role in the protective effect of n-3 PUFAs, for example the NF-κΒ signaling 
pathway (138) or decreased signaling by activated ras oncogene (139). 
 
1.3.2 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs, of which aspirin is the best known example, are a class of drugs mainly used for 
analgesic purposes and to reduce inflammation, and are also used as anti-coagulants for 
individuals at increased risk of cardiovascular disease. From the effects on high risk 
individuals (Gardner syndrome), it became apparent that NSAIDs also played an active role 
in the protection against colorectal cancer. Numerous epidemiological studies have found 
associations between regular use of NSAIDs and decreased risk of colorectal cancer and 
adenomas, as reviewed by Thun et al. (140). Clinical trials with two NSAIDs, sulindac and 
celecoxib, have shown that treatment with these drugs can inhibit adenoma growth and 
cause regression of existing polyps in patients with FAP, one of the hereditary forms of 
colorectal cancer (78-80,141). Animal studies have also given clear indications about the 
protective effect of NSAIDs. In rat and mouse models of colorectal cancer, a significant 
reduction in tumor number was observed after treatment with sulindac and aspirin (142,143). 
The effect of aspirin was questioned however when one study found a reduction in tumor 
number in ApcMin mice after treatment with indomethacin but not with aspirin (144). It seems 
that ApcMin mice only have the beneficial effect of aspirin use when exposure to the drug has 
been life-long, and not just in adult life (145), although this has not been replicated by others 
(R. Smits, personal communication). How this translates to humans is not clear, but 
exposure at adult age seems to be effective in providing protection (146). 
The mechanism of action of NSAIDs are generally divided into PTGS-dependent and PTGS-
independent mechanisms. The ability of NSAIDs to inhibit the PTGS enzymes was originally 
thought to represent the main underlying mechanism of action, thereby reducing the 
production of prostanoids and increasing the pool of free AA, resulting in immune 
modulation, inhibition of tumor angiogenesis and promotion of apoptosis (147). Since 
inhibition of the constitutively expressed PTGS1 isoform is thought to be responsible for 
adverse gastro-intestinal effects, selective PTGS2 inhibitors may provide an alternative 
(148,149). Several animal studies have shown that treatment with selective PTGS2 
inhibitors in mouse models for intestinal cancer resulted in reduced numbers of tumors 
(76,150).  Moreover, genetic evidence suggests that both Ptgs1 and Ptgs2 are important in 
intestinal tumorigenesis as illustrated by the dose dependent decrease in polyp number in 
rats and mice after treatment with a selective Ptgs1 inhibitor (151). It has also been shown 
that genetic disruption of Ptgs1, as well as Ptgs2, results in a reduced tumorigenesis in 
ApcMin mice (89). 
One of the first clues that other enzymes might play a role in the mechanism of action of 
NSAIDs, the PTGS-independent mechanisms, came from studies on the sulindac 
metabolites sulfone, which has no anti-inflammatory activity, and sulindac sulfide, the active 
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metabolite and PTGS inhibitor. It was shown that although treatment of ApcMin mice with 
sulindac sulfide resulted in a larger reduction in tumor burden, there was a trend toward a 
decrease in tumor number for mice treated with sulindac sulfone, which might be enhanced 
by higher dosages (152). Moreover, although treatment with sulindac caused a decrease in 
tumor number of ApcMin mice, this did not coincide with the expected changes in PG or LT 
levels (153), although later results were not consistent with this finding (154). Other 
enzymes within the pathway have therefore been considered as targets for NSAIDs. Several 
in vitro studies have implicated ALOX15 as a target of NSAID action. Cancer cells treated 
with sulindac showed increased expression of ALOX15-1 and 13-S-HODE levels, as well as 
reduced growth and increased apoptosis. Inhibition of the enzyme blocked this effect, which 
was restored by addition of 13-S-HODE, indicating that in this cell line the effect of NSAIDs 
is caused in part by activation of ALOX15-1 (155). This same group demonstrated that the 
apoptotic effect of NSAIDs is independent of PTGS2 status within the cells (156), and that it 
is not limited to colorectal cancer (157). In gastric cancer cells the effect of NSAIDs on 
ALOX15-1 was even found for a selective PTGS2 inhibitor (158). Some first in vitro 
experiments have shown that inhibition of PLA2G4A might also be one of the mechanisms 
by which aspirin exerts one of its PTGS-independent protective effect (159). 
Two subtypes of the PPAR family, which are activated by the products of the AA pathway, 
can also act as direct targets of NSAIDs. Sulindac can bind to PPARδ after which its activity 
and protein expression is down-regulated, inducing apoptosis (106). NSAIDs can also act as 
ligands for another receptor subtype, PPARγ (160). In contrast to PPARδ, this subtype has 
been shown to be activated by sulindac, which resulted in growth inhibition and apoptosis of 
cancer cells (161,162). 
Besides their effect on the AA pathway, other pathways like the NF-κΒ signaling pathway 
might play a major role in the mechanism by which NSAIDs exert their effect on colorectal 
cancer (163,164). Also, the Wnt signaling pathway has recently been implicated as a target 
of NSAID action, as it was shown that after treatment with sulindac the tumors of FAP 
patients and colorectal cancer cell lines showed reduced β-catenin expression and hence a 
decreased expression of target genes (165). 
 
 
1.4 Gene-gene and gene-environment interactions 
There have been a large number of studies that have attempted the identification of low-
penetrance alleles in candidate modifier genes of sporadic colorectal cancer (17). However, 
in the case of complex common diseases like cancer, numerous genetic and environmental 
factors interact in complex fashions and contribute to the development of the disease. It has 
been possible to detect associations between single SNPs or haplotypes in one gene and 
disease given large sample sizes and standardized experimental set up. Yet, it is generally 
assumed that most common diseases are due to multiple weak interacting loci (26). 
Therefore the effect of one SNP or haplotype might be dependent on the presence of 
another, and the association only becomes apparent when combinations of SNPs or 
haplotypes in different genes are investigated. This might explain part of the inconsistencies 
observed between the genetic association studies published to date in the literature.  
Demographic differences in disease incidence indicate that apart from the above mentioned 
genetic modifiers also environmental factors play a very important role in disease 
development and progression, and are likely to interact with specific genetic determinants. 
This might partly explain the inconsistent results observed in genetic association studies. 
One of the problems with testing for gene-environment interactions is the fact that 
environmental factors are often “self-reported” (e.g. obtained through questionnaires filled in 
by individual cases and controls), and therefore prone to error (166). An example of an 
environmental factor for which it is difficult to obtain reliable data is diet. Despite the large 
improvements in the way food frequency questionnaires are set up, retrospectively recording 
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of dietary habits remains a challenge. A solution to this problem might be the use of 
measurable intermediates not influenced by the disease that could act as a proxy for the 
environmental factor under investigation (166), as exemplified by n-3 PUFA levels in 
adipose tissue or serum for fish consumption. However, intermediates are not always very 
obvious, and even when a clear correlation exists between a given environmental factor and 
the intermediate, they might not interact with the genetic factors in the same way, as 
demonstrated in this thesis in Chapters 3 and 5. By studying gene-environment interactions 
in association studies, a better estimate of the attributable risk of both separate factors to the 
disease is obtained. Moreover, associations between environmental factors and disease are 
strengthened when they are studied in genetically susceptible or resistant individuals (167). 
Ultimately, an individual tailored advise on disease prevention or treatment will become 
available in the foreseeable future. 
 
 
1.5 Outline of this thesis 
As discussed, it is likely that low penetrance alleles contribute to a large proportion of all 
colorectal cancer cases. These low penetrance alleles are likely to have a marginally 
detectable effect when analyzed individually but can interact with other variants or with 
environmental factors. We hypothesized that low penetrance alleles in the form of SNPs in 
genes involved in the AA pathway could influence colorectal cancer risk. To test this 
hypothesis we first attempted to generate a map of the common variation and 
accompanying haplotypes of the seven candidate genes, PTGS1, PTGS2, ALOX15, 
PPARδ, PPARγ, PLA2G2A and PLA2G4A, as described in Chapter 2. The associations 
between SNPs in our candidate genes and colorectal adenomas and the possible interaction 
between these SNPs and fish consumption in relation to colorectal adenomas is described 
in Chapter 3. Whether these associations are the same for colorectal cancer is investigated 
in Chapter 4. As the interactions shown between fish consumption and SNPs for colorectal 
adenomas is based on the hypothesis that fish consumption acts as a proxy for n-3 PUFAs, 
we investigated whether the SNPs interacted in the same way with serum n-3 PUFA levels, 
which is described in Chapter 5. In Chapter 6 we tested whether fish consumption as a 
proxy of n-3 PUFAs, and fatty acid tissue levels from fat biopsies were associated with 
colorectal adenomas. In Chapter 7 we tested the interaction of another protective factor, 
regular use of NSAIDs, with SNPs in relation to colorectal adenomas. The last Chapter of 
this thesis discusses the findings, puts them into context, and contains concluding remarks 
and thoughts for future research.  
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Genetic variation in AA pathway genes 
 
Abstract 
Epidemiological and experimental evidence indicates that lipid metabolism, in particular the 
arachidonic acid (AA) pathway, plays a critical role in colorectal tumor development. 
Polymorphisms in key genes of this pathway may therefore contribute to susceptibility to 
colon cancer in the general population. In this study, the genetic variation of seven 
candidate genes from the AA pathway, PTGS1, PTGS2, ALOX15, PPARδ, PPARγ, 
PLA2G2A and PLA2G4A, has been determined in the Dutch population by direct 
sequencing of coding and regulatory regions. The fifty-eight single nucleotide 
polymorphisms (SNPs) identified, including thirteen newly described SNPs, were evaluated 
for their use in association studies.  
Possible functional effects of the SNPs were evaluated by in silico tools. Thirteen SNPs 
were predicted to affect either protein function or splicing. Two software programs were 
used to compare estimated haplotypes and haplotype block structures, and some 
differences between publicly available haplotypes and our estimations were found. For 
example, although the block structure of PPARγ was consistent with both programs, the 
publicly available haplotypes for PPARδ were derived from insufficient SNP data to resolve 
the two blocks in the 3’UTR identified in our data.  
These data may help to determine which SNPs are likely to be functionally important either 
at the protein or mRNA level and might therefore be candidates for association studies. Our 
study underlines the importance of re-sequencing of a number of subjects from the study 
population, especially in those genes where publicly available SNP and haplotype data is 
limited. 
 
 
Introduction 
Among others, diet and in particular lipid metabolism is thought to play a critical role in colon 
cancer. The fatty acids from our diet are in part converted into prostaglandins and 
leukotriens via the arachidonic acid (AA) pathway. There has been evidence from 
epidemiological studies and animal experiments that the enzymes and receptors in the AA 
pathway play an important role in colon tumorigenesis. Non-steroidal anti-inflammatory 
drugs (NSAIDs) for example, cause a considerable reduction in adenoma numbers in 
familial adenomatous polyposis patients(1) and in mouse models of intestinal cancer(2). It 
has been demonstrated that they exert their effect on the colon epithelium in part through 
the inhibition of the enzyme cyclooxygenase-2 also known as prostaglandin synthase-2 
(PTGS2)(3). More recently it has also been shown that NSAIDs can have modulating effects 
on other players in the AA pathway as well, which might all contribute to the effect seen on 
colon cancer(4-6).  
Variation in genes involved in the AA pathway in the form of Single Nucleotide 
Polymorphisms (SNPs) may modify the risk associated with colorectal cancer. The recent 
developments in SNP discovery have resulted in the availability of a multitude of SNP data. 
Publicly available databases (eg dbSNP), give access to lists of identified SNPs within any 
gene of interest. Besides the location of the SNP, data on validation status, population 
specificity and allele frequencies are often available. However, in order to obtain an 
overview of the genetic variation within a gene and population of interest, it is recommended 
to re-sequence a sample population(7).  
Besides the use of SNPs individually as markers or functional variants in an association 
study, it is now commonly accepted that more specific information is gained from the 
combination of several SNP alleles on a chromosome, the so-called haplotypes. Our genetic 
material contains regions where little recombination occurs, resulting in a so-called block 
formation of highly variable sizes. SNPs present within these blocks are in linkage 
disequilibrium (LD) with each other which makes it feasible to estimate haplotypes(8). The 
SNPs within a block that are representative for the most common haplotypes are therefore 
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useful for association studies and are termed haplotype tagging SNPs (htSNPs)(9). The 
most informative SNPs for association studies can also be selected by using the measure of 
LD across all SNPs within candidate genes(10). The International HapMap project has as its 
main goal to determine common patterns of DNA sequence variation in the human genome. 
In particular, it aims at the estimation of the distribution of haplotypes across all 
chromosomes in four populations to identify those SNPs that are representative for all 
common haplotypes(11). Although the latter is very useful for SNP selection of whole 
genome association studies, for a candidate gene approach the SNPs evaluated by this 
project might, at present, be sparse within the genes of interest. 
Another factor often considered in selecting candidate SNPs for association studies is the 
functional consequences of the specific polymorphisms. Possible biological explanations for 
specific associations are more plausible when it has been shown that a given SNP allele has 
a functional effect, for example by causing a change in protein function splicing or gene 
expression. In a recent review, the importance of other cis-acting elements, besides the 
consensus sequences at splice sites, to regulate splicing is underlined(12). These elements 
are termed exonic splice enhancers (ESE) for their location within exons. These sequences 
are thought to play an important role in splicing, especially when the consensus splice 
sequence at the exon-intron boundary is affected.  
The aim of this study on colorectal cancer is to evaluate the genetic variation in seven 
candidate genes in the Dutch population, for use in further association studies. The 
candidate genes were selected for being involved in the AA pathway. Furthermore, each 
gene in this study, PTGS1 and PTGS2(13), 15-lipoxygenase (ALOX15)(14), secreted 
phospholipase A2 (PLA2G2A)(15) and cytosolic phospholipase A2  (PLA2G4A)(16), 
peroxisome proliferated activated receptor δ (PPARδ)(17) and γ (PPARγ)(18), has been 
implicated individually to play a role in colon cancer progression. Five of the seven 
candidate genes have been screened for SNPs by direct sequencing of all coding and 
regulatory regions. Some exons of the remaining two genes have been sequenced to 
validate SNP data from other laboratories. Possible functional effects of the identified SNPs 
have been evaluated in silico, and common haplotypes and haplotype block structure were 
estimated and compared to publicly available data. 
 
 
Materials and Methods 
DNA samples 
To detect genetic variants with a frequency > 1%, blood samples from 100 unrelated 
randomly selected healthy individuals from the Dutch population, incorporated in the so 
called REGENBOOG study were obtained(19). In this large Dutch health examination study, 
a random sample of the Dutch population was interviewed and 30% of those individuals 
participated in an additional health examination at a municipal health center. There were no 
major differences, with respect to many background and health related variables between 
participants at home and those who underwent physical examination. DNA was extracted 
from buffy coats by digestion with proteinase K, followed by salting out with potassium 
acetate and chloroform/isoamyl alcohol extraction(20). 
 
Identification of polymorphisms 
Off all genes involved, with the exception of PTGS1 and PTGS2 the complete coding 
sequences as well as the regulatory regions like promoter and 3’-UTR were sequenced. For 
PTGS1 and PTGS2 partial resequencing was performed based on published information(21) 
as well as on personal communication (Frederico Canzian, IARC), see also table 1. PCR 
Primers were selected using the Primer 3.0 program (http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi). Annotations of the genes involved and the sequences of the 
primers used are shown in table 1. 
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 Table 1: PCR primers for sequencing genes 
 
Gene 
(accession 
number) 
Exon Sequence Gene Exon Sequence 
PTGS1 
NM 000962 
7           For 
             Rev 
gcgtatgtcatcgacagtgg 
ctttgccagggaagaccat 
PLA2G4A 8           For 
             Rev 
cccggccttattttcttctt 
tgtggcatcaaactggaaag 
 9           For 
             Rev 
cttggctgaccctatttcca 
caccaacatggaggtgttga 
 9           For 
             Rev 
tgtgccttctttctttggaga 
ggggagaatgggctcagta 
 10         For 
             Rev 
gaccactgctgtgcttctctc 
atccaggaaacagctgctca 
 10         For 
             Rev 
tgaatagcattctttctgtgtctg 
gggaaactgcaattcagagg 
 
 
11         For 
             Rev 
tgcttgtcattccagagtgc 
ttctggcagaccaaatgaga 
 11         For 
             Rev 
ccatgccatagcattttcct 
actgccccagacacctaaaa 
PTGS2 
NM 000963 
Prom     For 
             Rev 
tcacatgctcctccctgag 
ctccctgatgcgtggattat 
 12         For 
             Rev 
aaccccttgcatttcttaatgg 
tgagttttataacctcagtgtcaaa 
 1           For 
             Rev 
ccctcagacagcaaagccta 
ctgggatagacccaggaggt 
 13         For 
             Rev 
cactctgtggttttgctcaga 
tcctttcctcatggatctgg 
 3           For 
             Rev 
ggctccctccctttcttcgtcttcttg 
aggctaaaaaccttagaaag 
 14         For 
             Rev 
cagcccaaagatcccttttt 
tcctgcattagctcccacta 
 10         For 
             Rev 
aagaacgaaagtaaagatgtttgaa 
tcaaattattgtttcattgctgattt 
 15         For 
             Rev 
aagcctgagggcctaatcat 
ggcaagcaagagaatgtggt 
ALOX15 
NM 001140 
Prom1   For 
             Rev 
tgaggcagagaattgcttga 
cagtggcatttgaggaaggt 
 16         For 
             Rev 
ggtcagaccaactgaatcaatg 
tgtcagtttcgtcccctactt 
 Prom2   For 
             Rev 
caaaaggaatgagtcccagtg 
gttgttggaaccggcataga 
 17         For 
             Rev 
ggactcccactgctgtcttt 
ggcatattttgggtggtgtc 
 1           For 
             Rev 
agaccaggaacacctccctct 
gtcctccccggtatttgact 
 18a       For 
             Rev 
tgtgtatgcatgactcgtagattt 
tcaacatcatttgtcaacctaactt 
 2           For 
             Rev 
cccgatacgtctcctcctct 
gcttctcacacagcccaga 
 18b       For 
             Rev 
tgatcatgagagactggctga 
ttttgcgtttgaaagcagtg 
 3+4       For 
             Rev 
gggtgctgaggctctcct 
atcctgggccagtccaat 
PPARγ 
NM 015869 
Prom    For 
             Rev 
ttttgggcttcacaaatcag 
catggaataggggtttgctg 
 5           For 
             Rev 
gcctgtggtcgtcatgttag 
cagagggacccaagtctctg 
 B           For 
             Rev 
tcaagcccagtcctttctgt 
caaacacaacctggaagacaaa 
 6           For 
             Rev 
accccagtatgtctcccaac 
ctccgcagctactctcgtgt 
 1           For 
             Rev 
tctgaaactctgtgagattgctg 
ggttactgagagatgaggtccaa 
 7           For 
             Rev 
tggaggaatccgagtaggaa 
tgataaggggctgagctttc 
 2           For 
             Rev 
aattatcctctcacatgtctcca 
ggggttctgctgaaatgaaa 
 8           For 
             Rev 
gaacaggtttggaggacgaa 
cctggggcagagatagtgg 
 3           For 
             Rev 
taggttgctgcttccatgtg 
tccactggtctggcagctat 
 9+10     For 
             Rev 
ctcctctgactctgcccttc 
atgtcttctccacccccact 
 4           For 
             Rev 
tcatcctgtcattcctcttcc 
ccccaatgaagacagcagaa 
 11         For 
             Rev 
aggaggtctgcgtctggtt 
tcttgggctttgtgtctgag 
 5           For 
             Rev 
acctgggatggcattcact 
accatcatcccaccctcttt 
 12+13   For 
             Rev 
ctctgagcgtctgccctact 
cacagctgcctccttcctta 
 6           For 
             Rev 
ctgaaccccctgttgtgttt 
gaagggaaatgttggcagtg 
 14         For 
             Rev 
catttcaagactagaataggggga 
catcaagcatatgaacccagaa 
PPARδ 
NM 006238 
Prom1  For 
             Rev 
aatcactcatccagatagctag 
aacctcctcatcttccagtga 
PLA2G2A 
NM 000300 
Prom+1For 
             Rev 
tgctggagagcaatgaaaaa 
gattgctcccttctgctcaa 
 Prom2  For 
             Rev 
tgatctcctccagtggacct 
cagaattctcccgctcctg 
 2           For 
             Rev 
gagcggctgaatgaatgagt 
tctgctcttgacaggacatca 
 1           For 
             Rev 
gcggagaggcagaattagg 
ctacatggcaacgcacgac 
 3           For 
             Rev 
caccctggacttaggttgga 
caagagtgcttcccttctgg 
 2           For 
             Rev 
cctggcacctgtcagctaaa 
cctgtgtcagtggtggtcag 
 4           For 
             Rev 
tagcagagaggggcagagag 
cctgggccagagtctaggag 
 3           For 
             Rev 
gattcgctctccaccacatt 
tcagaggagcaactggcata 
 5           For 
             Rev 
tggagctgtgggacaagag 
ccccagcactgtctaaacaaa 
 4           For 
             Rev 
aggtccatctgcgttcagac 
gtcccctgccagtcctct 
 6           For 
             Rev 
cccacaagaagccactgaat 
gtgcatagggcaatgcatac 
 5           For 
             Rev 
cagctgttaagtggctgagg 
gaaagctttgtggagggtca 
PLA2G4A 
NM 024420 
1           For 
             Rev 
ggagaccagcccacatttta 
aagctaaggagggtgggaga 
 6           For 
             Rev 
acctcctggtggcctttc 
accttggtttcaggctgtgt 
 2           For 
             Rev 
gaactgcatccaagaggaag 
agaccccctccaagaaagaa 
 7           For 
             Rev 
taaagggatggggatgtcag 
gacccagagcccaggatg 
 3           For 
             Rev 
aaatgaggttctatgttggaagc 
cctccgatttgtcaaggaac 
 8           For 
             Rev 
cccgaggcctgatctctaa 
ccaggacgactgggtgtg 
 4           For 
             Rev 
cagattcattgagaataaactgacaa 
ctctcaacatgaatcacaacca 
 9           For 
             Rev 
cacctcttggggtggaagt 
ctggccccattggagtct 
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(accession 
number) 
Exon Sequence Gene Exon Sequence 
 5           For 
             Rev 
ccatgggaaattttatttttgtg 
acccaacttcccagaatcaa 
 10         For 
             Rev 
ctccctgtgccctctctc 
ggaaccctgcctacttcca 
 6           For 
             Rev 
gggtcttcatggagctgtgt 
tggatcactcacaatatttctca 
 11a       For 
             Rev 
tccccctgctcctttctcta 
gcttgaaccccagttctcct 
 7           For 
             Rev 
gctacctggatggaaaacca 
tggggaaattgtccaagcta 
 11b       For 
             Rev 
gggcatgccatgtctgag 
tgtaagccccaggaaaaaca 
 
Each PCR contained 5μl 2X hotstar master mix (Qiagen), 1μM of each primer, in some 
cases 2μl Q solution provided with the hotstar master mix, and 10 ng genomic DNA, in a 
total volume of 10μl. PCR reactions were carried out in a Perkin-Elmer 9600 thermal cycler 
under the following conditions: 95ºC for 15 min, 35 cycles of 94ºC for 45 s, 57ºC for 45 s, 
72ºC for 1 min, followed by 72ºC for 10 min. 
DNA Sequencing. Each PCR product was directly sequenced on an Applied Biosystems 
3700 capillary sequencer, after purification with QIAquick multiwell PCR purification plates. 
The sequence reaction contained 1μl BigDye Terminator Reaction Kit, 200mM Tris, 5mM 
MgCl2, 0.16 μM primer and 3-20ng PCR product in a total volume of 20μl. PCR reactions 
were carried out in a Perkin-Elmer 96 thermal cycler under the following conditions: 25 
cycles of 96ºC for 10 s, 50ºC for 5 s, and 60ºC for 4 min. 
Sequence analysis. Trace files of sequencing reactions were imported into the Seqman part 
of the Lasergene software program (DNAstar Inc). Polymorphisms were identified as 
conflicts in the sequence by the software. 
 
In silico functional analysis 
SIFT. Sorting intolerant from tolerant (SIFT)(22) is a sequence homology based software 
program. It is based on the premise that functionally important amino acids in a protein will 
be conserved within the protein family. It can thus predict the probability, by considering the 
type of amino acid change and the extent of conservation, whether an amino acid 
substitution is allowed at that position. A low probability (p<0.05) predicts an impact on 
protein function. Data for SIFT prediction was submitted at 
http://blocks.fhcrc.org/~pauline/SIFT_seq_submit2.html. 
PolyPhen. Several parameters are used by PolyPhen to predict the possible outcome of an 
amino acid substitution on protein function. The prediction is based on analysis of the 
sequence, polygenetic and structural information of the protein. Results are classed as 
benign, possibly damaging or probably damaging. Data for PolyPhen prediction was 
submitted at http://www.bork.embl-heidelberg.de/PolyPhen/(23).  
RESQUE-ESE. This program identifies hexanucleotide sequences as candidate ESEs on 
the basis that they have both significantly higher frequency of occurrence in exons than in 
introns and also significantly higher frequency in exons with weak (non-consensus) splice 
sites than in exons with strong (consensus) splice sites(24). Sequences for ESE 
identification were submitted at http://genes.mit.edu/burgelab/rescue-ese/. 
 
Haplotype analysis 
For each gene, haplotypes were estimated using PHASE v2.1 on the basis of individual 
genotype scores using default settings(25,26). The PHASE output file with the estimated 
haplotype scores for each individual was subsequently used to screen for haplotype block 
structure within each gene using HaploBlockFinder V0.7, also using default settings(27). 
PHASE can be found at: HTTP://www.stat.washington.edu/stephens/software.html. 
HaploBlockFinder V0.7 can be found at: HTTP://cgi.uc.edu/cgi-
bin/kzhang/haploBlockFinder.cgi/. PTGS1 and PTGS2 were excluded from haplotype 
analysis, since we did not sequence the whole gene and therefore had no genotype data of 
all SNPs present in the gene. The haplotype blocks identified by HaploBlockFinder were 
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compared to block estimates obtained from Haploview with genotypes form the HapMap 
database, found at http://www.hapmap.org/index.html.en. 
 
 
Results 
Identification of polymorphisms 
All polymorphisms identified in the seven selected candidate genes in our random selection 
of 100 healthy Dutch individuals are shown in table 2.  
Screening our genes of interest for variants has resulted in the identification of fifty-eight 
SNPs. Of these, 78% (n=45) were already described in databases, thus showing that 22% 
are newly described SNPs. Out of the fifty-eight SNPs, seventeen were located within 
coding regions. Of these, only nine resulted in an amino acid substitution, the so-called non-
synonymous SNP (nsSNP) (15.5% of total), illustrating the relatively low frequency at which 
these SNPs are present in the genome. Of the remaining forty-one SNPs, eighteen were 
located in intronic regions, usually in the proximities of exons, whereas twenty-one were 
situated in regulatory regions, either in the promoter, 5’UTR or 3’UTR. In two cases, the 
SNPs were situated just outside the gene. The minor allele frequencies of the SNPs ranged 
from 0.005 (0.5%) to 0.450 (45%). Most of the nsSNPs, eight out of nine, occurred at 
frequencies lower than 0.05, generally considered too low for association studies. Only one 
SNP in PPARγ revealed a higher frequency (0.093). The low frequencies illustrate the 
selective pressure on nsSNPs, as they may negatively affect protein function.  
 
Table 2: Overview of identified polymorphisms 
 
Gene  SNP name  Location Sequence Minor allele 
frequency 
Databaseb
PTGS1 L237M   exon 7 TGGAGACAAT[C/A]TGGAGCGTCA 0,033 5789 
 c.762+15delA   intron 7 GTGCTGGGCC[A/-]GGGGGTAGGG 0,094 3215925 
 V348E   exon 9 GAGGAGTACG[T/A]GCAGCAGCTG 0,006  
 S439S   exon 10 CCTACACCTC[C/T]TTCCAGGAGC 0,006  
 V444I   exon 10 CCAGGAGCTC[G/A]TAGGTGAGCA 0,012 5794 
       
PTGS2 c.-1329A>G  promoter TGAAATTCCA[A/G]CTGTCAAAAT 0,218 689466 
 V102V   exon 3 TGAGTTATGT[G/C]TTGACATGTA 0,250 5277 
       
 c.2242T>C  3’UTR TACTTTTGGT[T/C]ATTTTTCTGT 0,296 5275 
ALOX15 c.-272G>T  Promoter GCGTGTTTTC[G/T]GTCCAAATCC 0,200 7220870 
 c.-217G>C  Promoter TCCACTCCCT[G/C]CTCTCGCCAG 0,200 2664592 
 c.-185G>C  Promoter TTTGGACTGG[G/C]GCTGAATTCT 0,200 2664593 
 c.136-37G>A x Intron 1 CCTCCCGCCA[G/A]GCCCCACCGG 0,106 11568141 
 D90H x exon 2 CGGAGCCGGG[G/C]ACGAGGTCAG 0,005 11568142 
 c.337+8C>T x Intron 2 CCGGTAAGCG[C/T]GGGGCTGAGG 0,308 11078528 
 c.542+150C>T x Intron 4 ACCCTTTGCC[C/T]CATCCTGCCC 0,016  
 F253F   exon 6 GCCTAGTGTT[C/T]CCTCCAGGCA 0,295 11568103 
 G324V  x exon 8 CCCCGCACAG[G/T]ATCCCCACCA 0,005  
 T485T  x exon 11 ACTATAAGAC[A/G]GACGTGGCTG 0,062 743646 
 c.1641+22C>G  Intron 12 AGATGGGCAG[C/G]TGGGAATTTG 0,030  
 c.1641+63G>A  Intron 12 GTCTGTGTGC[G/A]GGTGGACCAC 0,456 6502804 
 c.1641+91C>T  Intron 12 GCGTGCTTGG[C/T]AGGCACTGAC 0,456 2619112 
 T560M   exon 13 GCACCCTGCA[C/T]GATGCGGCTG 0,030  
       
PLA2G2A c.-218+94G>A x Intron 1 ATATGAGACA[G/A]GGGTGGAGGA 0,006  
 c.-217-240C>T x Intron 1 GTCTCTGCCC[C/T]CCTTAGAGGC 0,027 11573155 
 c.-217-96A>C x Intron 1 CCAATCCTCA[A/C]CTCTGTCCTG 0,007 1796923 
 c.-180C>G x 5’UTR CCAGAGGGAG[C/G]AGCTATTTAA 0,289 11573156 
 T32T  x exon 4 TCAAGTTGAC[G/C]ACAGGAAAGG 0,145 2236771 
 Y44Y  x exon 4 ATGGCTTCTA[C/T]GGCTGCCACT 0,274 4744 
 c.185+16C>T x intron 4 GCCACCTATC[C/T]CTCCCTACCC 0,274 2307246 
 R143H  x exon 6 AGCACCCCTC[G/A]TTGCTGAGTC 0,011  
 c.665C>T x 3’UTR AGCTGTACTC[C/T]GGGGGGTCTC 0,155 11677 
 c.700+2T>A x Outside TAGCAAATCA[T/A]GTATATGTGT 0,126 876018 
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Databaseb
PLA2G4A c.-109A>C x 5’UTR AAGGATCCTG[A/C]CTGAAAGCTA 0,006 12720485 
 c.559-43G>A  Intron 7 TGTATTTTAT[G/A]ATTTTTACTT 0,031 12720586 
 c.918+23C>T x Intron 9 TCAATCTACA[C/T]TGCTTTTATA 0,195 2307200 
 c.918+31A>G x Intron 9 CACTGCTTTT[A/G]TAACAAGTAG 0,012 12720597 
 c.919-22T>C x Intron 9 TAAAGTCATC[T/C]TTTTCTTTCT 0,021 2307195 
 c.1264-57T>A x Intron 12 TTATATTAAA[T/A]TTAATTGTTA 0,067 4650709 
 c.1336+3G>A x Intron 13 ACCCAAAGGT[G/A]AGTGAGCCGG 0,062 6661772 
 R651K  x exon 16 AGAAAGTACA[A/G]GGCTCCAGGT 0,025 2307198 
 c.2605G>A x 3’UTR ATAAGACCTC[G/A]CATTATGTAT 0,094 12720707 
 c.2721+17T>A  Outside GATAACTGAG[T/A]TTTTTGTTAA 0.035 12720709 
       
PPARγ P12A  x exon B TCCTATTGAC[C/G]CAGAAAGCGA 0,088 1801282 
 H477H  x exon 6 TCACGGAACA[C/T]GTGCAGCTAC 0,114 3856806 
       
PPARδ c.-1180C>T x Promoter AAGGTGTGGC[C/T]GAAGGAGAGG 0,006  
 c.-1175G>T x Promoter GTGGCCGAAG[G/T]AGAGGGGAGG 0,006  
 c.-789C>T x Promoter TCCAGTGGAC[C/T]TAGCACTGGG 0,051  
 c.-126A>G x 5’UTR CCGTGGAGCA[A/G]TGATCTCTAC 0,010 1883323 
 c.285+11G>C x Intron 5 GTACGGACTG[G/C]GGGGAGCGGT 0,005  
 N163N x exon 7 TGACTGCAAA[T/C]GAGGGGAGCC 0,215 2076167 
 c.1443G>A x 3’UTR CTCTTTCTCA[G/A]TTCCTCTTTC 0,022 9658167 
 c.1867G>A x 3’UTR CAGGCTGAGA[G/A]CCAGATGCCT 0,017 9658170 
 c.1973G>A x 3’UTR GACACCCAGT[G/A]TCCTTCCATC 0,011 9658172 
 c.2021T>C x 3’UTR TGAAGCTGCC[T/C]CTCCAGCACA 0,189 3734254 
 c.2246G>C x 3’UTR TGTTCATTCT[G/C]ATGTCCATTT 0,006  
 c.2589G>A x 3’UTR GGAGCCATTCT[G/A]TGTGTGACTC 0,052 1053046 
 c.2629T>C x 3’UTR CCTGCCCCTA[T/C]GGGCGCTGCA 0,266 1053049 
 c.2806C>G x 3’UTR TCCCTGCCCC[C/G]ACCCGGGTCT 0,188 9794 
aDue to missing data, only SNPs with x were used for haplotype analysis. 
brs number in dbSNP. Missing number means SNP is previously undescribed. 
 
In silico functional analysis 
SIFT/PolyPhen. All nsSNPs were screened by the software programs SIFT and PolyPhen, 
to determine putative effects on protein function. Of the nine nsSNPs identified in this study, 
three were predicted by SIFT to affect protein function, namely PTGS1 V348E, ALOX15 
T560M and PLA2G2A R143H. PolyPhen predicted probably damaging effects for two of 
these SNPs, but not for PLA2G2A R143H. Also, a possibly damaging effect was predicted 
for PPARγ P12A. Results are shown in table 3.  
 
Table 3: Prediction of impact on protein function by amino acid substitutions by SIFT and 
Polyphen analysis 
Gene SNP Predicted impact on 
protein function (SIFT) 
Predicted impact on protein function (Polyphen) 
PTGS1 L237M Tolerated Benign 
 V348E Affects protein function Probably damaging - disruption of ligand 
binding site 
 V481I Tolerated Benign 
ALOX15 D90H Tolerated Benign 
 G324V Tolerated Benign 
 T560M Affects protein function Probably damaging – hydrophobicity change at 
buried site 
PLA2G2A R143H Affects protein function Benign 
PLA2G4A R651K Tolerated Benign 
PPARγ P12A Tolerated Possibly damaging 
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RESCUE-ESE. All exonic SNPs (including 5’ and 3’ UTR exons) newly identified or 
validated in our study were screened for the presence of ESE sequences. Out of thirty-one 
SNPs screened, ten were shown to affect an ESE sequence. It is believed that ESE 
sequences play an especially important role in splicing of exons characterized by weak 
consensus splice-sites. Of the ten SNPs interfering with ESE sequences, three were in 
exons with weak splice-sites. Results are shown in table 4. 
 
Table 4: Identification of exonic polymorphisms likely to effect splicing by RESCUE-ESE 
analysis 
Gene SNP Impact of minor allele on ESE-site Weak splice-sites 
PTGS1 L237M New site is created  
ALOX15 T485T Site is lost Weak 5’ splice site 
 T560M New site is created  
PLA2G2A T32T Site is lost  
PLA2G4A c.-109A>C Site changes in other consensus 
sequences 
 
 R651K Site is lost  
PPARγ P12A New site is created Weak 5’ splice site 
 H477H New site is created Weak 3’ splice site 
PPARδ N163N New site is created  
 c.1867G>A New site is created  
 
 
Haplotype determination 
The haplotype block structure for each gene is shown in figure 1. The haplotypes present 
within each block are shown in figure 2. The SNPs that can be selected for genotyping to 
represent all common haplotypes (htSNPs) according to haplotype block finder are shown in 
table 5.  
We were unable to use all SNPs in the ALOX15 gene for haplotype estimation due to 
missing data; therefore, haplotypes have been estimated using six of the fourteen identified 
SNPs. All six SNPs seem to lie within the same haplotype block, with three of them identified 
as htSNPs. The PLA2G2A SNPs are divided over three haplotype blocks. The first and last 
blocks contain only two common haplotypes each, which can be distinguished by a htSNP in 
each block. In the larger middle block, three htSNPs are identified, representing the four 
common haplotypes. There are two haplotype blocks present in PLA2G4A, the first 
encompassing four common haplotypes, with three and one htSNPs in the first and second 
block respectively. There are only two SNPs in PPARγ which are not in a haplotype block, 
therefore both representing htSNPs. The fourteen SNPs of PPARδ are divided into three 
haplotype blocks. The four common haplotypes of block 1 can be identified by three htSNPs, 
which is also the case for block 2, although the latter block only encompasses four SNPs. 
The last SNP of PPARδ is located in a separate block and is therefore by definition a htSNP.  
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Figure 1 
 
Fig 1: Pairwise linkage disequilibrium (LD) estimates (|D’| at the right and r2 at the bottom) and 
haplotype block indications of each gene as given by HaploBlockFinder V0.7. Panel A shows the results 
along a scale where the distance between each SNP was set constant. Panel B shows the same results 
but now according to physical distance between each SNP. |D’| is 1.0 when no recombination has 
occurred between two SNPs, hence they are in complete LD and exist on one haplotype block. The 
measure for r2 is then either 1.0, when the minor alleles of these two SNPs lie on the same haplotype 
allele, or 0.0 when the minor alleles lie on separate haplotypes alleles. 
 
 
Figure 2 
 
Fig 2: Estimated frequencies of the 
four most common haplotypes per 
haplotype block within each gene as 
given by HaploBlockFinder V0.7. 
Frequencies are approximated by 
different colors corresponding to the 
scale on the left. The lines 
separating the blocks indicate 
recombination occurring at these 
sites. 
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Figure 3 
 
 
Fig 3: Pairwise LD plots of |D’| for PLA2G4A (A), PPARγ (B) and PPARδ (C), according to Haploview 
3.0 with data form the HapMap project found at http://www.hapmap.org/index.html.en. Red indicates 
high |D’|, lighter colors indicate lower values of |D’|. Grey indicates high |D’| but low LOD scores. 
Haplotype blocks are indicated by black lines. 
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Table 5: Identification of htSNPs, representative for all major haplotypes 
Gene htSNP Haplotype block 
ALOX15 c.136-37G>A Block 1 
 c.337+8C>T Block 1 
 T485T Block 1 
PLA2G2A c.-217-240C>T Block 1 
 c.-180C>G Block 2 
 T32T Block 2 
 R143H Block 2 
 c.665C>T Block 3 
PLA2G4A c.918+23C>T Block 1 
 c.1264-57T>A Block 1 
 c.1336+3G>A Block 1 
 c.2605G>A Block 2 
PPARγ P12A Block 1 
 H477H Block 2 
PPARδ c.-789C>T Block 1 
 N163N Block 1 
 c.1443G>A Block 1 
 c.2021T>C Block 2 
 c.2589G>A Block 2 
 c.2629T>C Block 2 
 c.2806C>G Block 3 
 
The haplotype blocks obtained from HaploBlockFinder were compared to block estimates 
from Haploview with genotypes from the HapMap project. ALOX15 and PLA2G2A did not 
contain enough genotype data for LD analysis in HapMap, therefore comparisons were 
restricted to PLA2G4A, PPARγ and PPARδ. LD plots with block structures from Haploview 
for these three genes are shown in figure 3. The LD analysis for PLA2G4A reveals a total of 
six blocks. The plots for PPARγ and PPARδ show one point of recombination each, resulting 
in two haplotype blocks. 
 
Discussion 
In this study we have investigated the genetic variation of a number of candidate genes and 
evaluated which polymorphisms might be useful in future association studies. We found that, 
despite the growing amount of information currently available on genetic variation in the 
human genome, it was still useful to conduct a re-sequencing study to identify all potentially 
interesting SNPs and maximize genetic variability. 
As it holds for the whole genome, there are great differences in sequence variation among 
the selected candidate genes, due to different degrees of selective pressure or to their 
location in more or less recombinogenic chromosomal regions. It is therefore difficult to 
estimate the frequency with which SNPs occur in the human genome, which is also 
apparent by the different estimates found in the literature(28,29). The variation in PPARδ for 
example is much greater than in another nuclear receptor, PPARγ, with fourteen 
polymorphisms in 5366 bp for PPARδ compared to two polymorphisms in 3068 bp for 
PPARγ. With respect to variations in functional elements encoded in the human genome our 
still limited knowledge is largely restricted to data collected in databases like TRANSFAC, 
although recently comparative genomic approaches have greatly expanded the number of 
these functional elements, including the number of miRNAs(30).  
 
Direct approach for selecting SNPs 
According to the SIFT software program, three of the nine non-synonymous SNPs found 
were likely to affect protein function, and are therefore candidates to use in an association 
study. Unfortunately, these three SNPs have a minor allele frequency lower than 5%, 
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generally thought to be the minimum frequency required to guarantee sufficient statistical 
power, unless very large cohorts are employed. The other program able to predict impact on 
protein function, PolyPhen, was not consistent with SIFT only in the case of the R143H SNP 
in PLA2G2A. SIFT predicted this SNP to have an effect on protein function whereas 
PolyPhen predicted the substitution to be benign. The reason for this might be the difference 
in prediction criteria used by the two programs. SIFT only uses sequence homology 
whereas PolyPhen uses sequence, polygenetic and structural parameters to derive at its 
predictions. PolyPhen might therefore be the more accurate of the two programs. A SNP 
with a tolerant score from SIFT, P12A in PPARγ, was predicted to be possibly damaging by 
PolyPhen. However, as the score from SIFT was only borderline tolerant (0.07 as compared 
to the cut-off value 0.05), and as PolyPhen predicted only a possible damaging effect, these 
results may considered in agreement rather than contradictory. In general, as with many in 
silico tools, results may differ slightly between software programs due to different rules and 
assumptions for each program. Combining tools however, is likely to lead to more robust 
results. 
One of the four SNPs, ALOX15 T560M, is also predicted by the RESCUE-ESE program to 
interfere with an ESE consensus sequence, and might therefore have an additional effect on 
the overall protein function. A further nine SNPs were identified by the software as 
interfering with ESE consensus sites, making them possible candidates for association 
studies.  
 
Indirect approach for selecting SNPs 
An alternative way of selecting SNPs for association studies, when no functional data are 
present, is by estimating haplotypes and haplotype blocks, and thereby identifying SNPs 
that can distinguish between all the common haplotypes present within that block. Within a 
block, little or no recombination occurs, therefore limiting the number of possible haplotypes. 
Between two blocks, hotspots for recombination occur(8,31). Sebastiani et al.(9) found that 
of the total number of SNPs within a gene, an estimated 10% could be considered as 
htSNPs. In our study this percentage is much higher (52%, twenty-one out of forty SNPs), 
because only SNPs in coding and regulatory regions were available for analysis, whereas 
Sebastiani et al. also employed intronic SNPs for their analysis. 
We have found a clear haplotype block structure in most of the investigated genes, with the 
exception of ALOX15 where all of the investigated SNPs lie within the same block. The 
maximum number of common haplotypes in each block was four, and the maximum number 
of htSNPs per block was three. This method is useful to aid in the selection of SNPs for an 
association study, but there are some limitations as pointed out by Fullerton et al.(32). This 
group analyzed the haplotype structure of the APOA1/C3/A4/A5 gene cluster, by using all 
SNPs identified by re-sequencing, and comparing the results to the structure revealed using 
htSNPs. They found that many gene- and population-specific features of this gene cluster 
could not be identified using the htSNP approach. In particular, the differences in haplotype 
distribution between populations caused the inability to identify and correctly classify the 
estimated haplotypes, when the same set of htSNPs was used for each population. There 
was therefore considerable heterozygosity within haplotype classes. This illustrates a 
disadvantage of using a general set of htSNPs to be applied to all populations. Other 
disadvantages of this approach, as outlined by Jawaid et.al.(7), is that pooling of DNA 
samples, a method to substantially reduce the number of genotype assays needed, is not 
possible for the estimation of haplotypes. Moreover, haplotype maps are often based on 
incomplete SNP data, which might mean that unidentified SNPs could break up the 
estimated block structure. It is therefore recommended that a subset of the population under 
study is re-sequenced, to identify all SNPs present in the genes of interest and select 
htSNPs from this data to use in the association study. In a simulation study, it was 
suggested that as little as 25 individuals are sufficient to identify all common polymorphisms 
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and therefore all common haplotypes(33). However, in practice numbers ranging from 25 to 
60 are more commonly used. 
The need for re-sequencing is illustrated by the haplotype block structure according to 
Haploview analysis for PPARδ, where the relatively small blocks in the 3’UTR could not be 
identified by Haploview, due to the low SNP density in this region. While the Haploview 
results show a separate block towards the end of the gene, our results show a block 
structure which points to two recombination hotspots in the 3’UTR of the gene. Since so far 
only a few SNPs from this region have been analyzed in the HapMap project, no block 
structures have been identified; on the contrary in our study this region has been analyzed in 
more detail with several 3’UTR SNPs, making the haplotype blocks become apparent.  
The results obtained for PPARγ in our study are in line with LD estimated with Haploview, 
although different SNPs were used in the analyses. Our two exonic SNPs seem to lie on 
different haplotype blocks, likely due to a recombination event occurred in between these 
two SNP locations. The Haploview results also show two distinct haplotype blocks, with a 
point of recombination distal to the first exon of the most common splice variant of PPARγ, in 
agreement with our block structure. 
The results for PLA2G4A from Haploview however are not consistent with our results. The 
Haploview results show six regions of LD representing haplotype blocks, whereas our study 
only shows two blocks with the first haplotype block extending beyond exon 13. The reason 
for this inconsistency might reside in the number of SNPs used for the analysis in 
Haploview, which includes many more intronic SNPs. This illustrates the need to include as 
many SNPs as possible in the analysis of haplotype blocks and that intronic SNPs can refine 
the block structure. This same point was recently stressed by a large re-sequencing study, 
where it was shown that using all SNPs within a gene to infer the common haplotypes, as 
compared to coding SNPs only, resulted in most genes in the identification of more common 
haplotypes. These extra haplotypes would have been missed using coding SNPs only(34). 
However, although intronic SNPs add to the haplotype diversity, SNPs in coding regions are 
more likely to have a functional effect on the protein. It remains important to determine the 
relevant htSNPs for the population under study, which is difficult to compare between 
studies as each one employs different SNPs sets.  
In conclusion, our study underlines the importance of re-sequencing of a number of subjects 
from the study population, especially in those genes where a limited number of SNPs has 
been validated and analyzed by the HapMap project. It was recently demonstrated(35) that 
irrespective of the method used to define haplotype blocks it is the density of the SNP 
coverage defining the ultimate reliability of any ht tagging strategy. The more saturated, the 
more different haplotype blocks will be found. As a consequence, more tagging SNPs 
should be used to cover the region of interest, which will render the tagging approach less 
cost effective. Ultimately, a common sense approach not only based on selecting htSNPs 
but also determining possible functional effects of the SNPs, either at the protein or mRNA 
level would result in an optimal htSNP selection. 
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Abstract 
Associations between polymorphisms in genes (SNPs) involved in the arachidonic acid (AA) 
pathway, and colorectal adenomas were investigated in a Dutch case control study including 
384 cases and 403 polyp-free controls. Twenty-one polymorphisms in seven candidate 
genes were studied, and a potential modifying effect of fish consumption was considered.  
A protective effect on colorectal adenomas was found for the CT genotype of SNP H477H in 
PPARγ and the GC genotype of SNP V102V in PTGS2 (OR, 0.63; 95%CI, 0.45-0.89 and 
OR, 0.65; 95%CI, 0.46-0.92 respectively) compared to the homozygote major genotypes. An 
increase in adenoma risk was observed for the TC genotype of SNP c.2242T>C in PTGS2 
(OR, 1.47; 95%CI, 1.07-2.00) compared to the TT genotype. Analysis with estimated 
haplotypes confirmed these associations and revealed three additional associations with 
PTGS2, PLA2G2A and ALOX15 haplotypes. Fish consumption modified the associations 
with PTGS2 and PPARδ genotypes. For SNP c.-789C>T in PPARδ, the major genotype 
showed a decrease in adenoma risk for those in the highest tertile of fish consumption (T3), 
as compared to the lowest tertile (T1) (OR, 0.65; 95%CI, 0.41-1.02). Protective effects were 
also observed for SNPs V102V and c.2242T>C in PTGS2 and high fish intake. The 
interaction between fish consumption and c.2242T>C was statistically significant, with an 
OR for the TT genotype and high fish consumption of 0.52 (95%CI, 0.27-1.01) as compared 
to low fish intake. 
These results indicate that SNPs in genes involved in the AA-pathway are associated with 
colorectal adenoma risk. Part of these associations is modified by fish consumption 
 
 
Introduction 
Epidemiological and experimental evidence indicates that lipid metabolism, in particular the 
arachidonic acid (AA) pathway, plays a critical role in colorectal tumor development, as 
reviewed by Jones et al. (1).  
Prostaglandin endoperoxide synthases 1 and 2 (PTGS1 and PTGS2), also known as 
Cyclooxygenase-1 and cyclooxygenase–2, are two key genes in the AA pathway, encoding 
enzymes that initiate the synthesis of biologically important prostanoids (PGs) and 
eicosanoids (2). Both genes have been demonstrated to be involved in intestinal 
tumorigenesis, by promoting tumor growth, angiogenesis and metastasis. Major evidence 
comes from the study of non-steroidal anti inflammatory drugs (NSAIDs), acting amongst 
others as COX inhibitors, which play an important role in cancer prevention (3). Inactivation 
of these genes in mouse models of intestinal cancer decreases the number of polyps in 
these mice (4,5). Phospholipase A2 (PLA2) enzymes are a family that, besides other 
conversions, catalyze the generation of free fatty acids, such as AA, from membrane bound 
phospholipids. Most important in the AA-pathway are cytosolic PLA2 (PLA2G4A) and 
secretory PLA2 (PLA2G2A), which have both been demonstrated in mouse models to be 
involved in tumorigenesis (6,7). Levels of PLA2G4A mRNA are reduced in mouse and 
human tumors, possibly indicating a tumor protective effect of this enzyme, which is further 
substantiated by the reduction in apoptosis in vitro after inhibiting PLA2G4A (8). A similar 
protective effect is found for the secretory form of the enzyme, PLA2G2A. This gene, present 
on the Mom1 locus, causes an increase in number of polyps when inactiviated in the ApcMin 
mouse model for intestinal cancer (7). Lipoxygenase (LOX), is an enzyme for which AA is 
one of the substrates. Activation of the enzyme 15-LOX might inhibit carcinogenesis via the 
conversion of linoleic acid into 13-S-hydroxyoctadecadienoic (13-S-HODE) acid, which in 
turn downregulates PPARδ thereby restoring apoptosis (9). Peroxisome proliferator-
activated receptors (PPARs) play an important regulatory role in lipid metabolism and 
cancer, and PPARs can be activated by a variety of eicosanoids (10,11). There are three 
distinct types of PPARs, α, δ and γ. Both PPARδ and PPARγ have been implicated to play a 
role in colorectal tumorigenesis, by transcriptionally controlling pathways involved in cell 
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proliferation, differentiation and survival. Activation of PPARδ was shown to increase the 
number and size of intestinal polyps in ApcMin mice (12), whereas inactivation causes 
inhibition of tumor growth in a colorectal cancer xenograft model (13,14). Moreover, recently 
its role as a focal point of cross-talk between prostaglandin and Wnt pathways has been 
suggested (15). Most data of PPARγ suggests a tumor suppressive role, however, there is 
still some controversy about the increase of intestinal polyps in ApcMin mice by ligands of 
PPARγ (16,17).  
Genetic variants represented by Single Nucleotide Polymorphisms (SNPs) in genes 
encoding these key players of the AA-pathway may contribute to variation in susceptibility to 
colorectal cancer. Recently, the focus of attention has shifted from the use of single (putative 
causal) genetic variants in association studies (the ‘direct’ approach) to using sets of genetic 
markers without a priori functional effects, the so called indirect approach (18). By using 
information about the common SNPs in a particular population, combinations of SNP alleles 
called haplotypes can be estimated, after which differences in frequencies between cases 
and controls can be evaluated (19,20). 
Colorectal adenomatous polyps, later referred to as colorectal adenomas, are presumed to 
be the pre-cancerous state of colon cancer (21). Studying colorectal adenomas instead of 
colon cancer may give information about the risk factors in the earlier stages of 
carcinogenesis. 
The fatty acids utilized by the AA pathway include n-3 poly-unsaturated fatty acids (PUFAs) 
from fish. Some, but not all animal experimental studies and epidemiological studies have 
shown that fish consumption may decrease the risk of colorectal tumors (22,23). A high ratio 
of fish fatty acids (Fas) to arachidonic acid (AA) in adipose tissue, as a marker for fatty acid 
intake, has been associated with a lower risk of colorectal adenomas (24). High fish 
consumption can affect the AA pathway by causing a shift in substrates from n-6 to n-3 
PUFAs. SNPs in AA pathway genes may interact with fish consumption by influencing the 
conversion of these PUFAs into eicosanoids. 
In this association study, twenty-one SNPs in genes encoding five enzymes and two nuclear 
receptors have been used. The objective of this study was to assess the association 
between inherited SNPs and haplotypes involved in the AA-pathway, and the occurrence of 
colorectal adenomas. Moreover, the potential modifying effect of fish consumption was 
considered. 
 
 
Methods and materials 
Study population 
A retrospective case-control study was conducted in the Netherlands, between 1997 and 
2001. The study design has been described in detail elsewhere (25,26). In brief, both cases 
and controls were undergoing an endoscopy in one of eight hospitals. They were asked to 
participate without knowing whether they had colorectal adenomas or not. Cases and 
controls were Dutch-speaking persons, of European origin, and aged between 18 and 75 
years at the time of endoscopy. They did not suffer from inflammatory bowel diseases, and 
did not have a history of colorectal cancer or (partial) bowel resection. Cases were defined 
as those subjects diagnosed with at least one histologically confirmed colorectal 
adenomatous polyp ever in their life. Controls were defined as those subjects without a 
history of any type of polyp, including hyperplastic and metaplastic polyps. Suspected cases 
of hereditary colorectal cancer syndromes were excluded (27,28).  
Major indications for endoscopy among cases were complaints (47.7%), including bowel 
complaints, rectal bleeding and defecation problems, and screening (39.5%). For controls 
these numbers were 76.7% for complaints and 1.7% for screening. 
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Pathological anatomy reports provided information about polyp characteristics. Medical 
records were used for additional information on polyp recurrence and general health status 
of the participants.  
The total study population included 925 subjects. The Medical Ethical Committees of all 
participating hospitals and of Wageningen University approved the study and all participants 
have provided written informed consent. 
 
Genetic analysis 
Twenty of the twenty-one SNPs have been selected on the basis of an inventory of the 
genetic variation in the Dutch population of the selected genes as described elsewhere, in 
which fifty-eight polymorphisms were identified (C.Siezen, in preparation). The SNP 
selection was based on allele frequency (with some exceptions only those SNPs with a 
minor allele frequency of 5% or higher were considered), position in the gene (when 
possible divided over the length of the gene), possible impact on protein function (amino 
acid changes), and linkage between the SNPs in one gene (of two or more tightly linked 
SNPs only one was selected). One SNP was selected on the basis of another population 
study on PTGS1 variants (29). 
Genotypes of the 21 SNPs were determined using a technique known as PyrosequencingTM. 
Each PCR contained 5μl 2x Hotstar master mix (Qiagen), 1μM of one primer, 0.1μM of the 
second primer containing a so-called universal tail of 23 nucleotides, 0.9μM of a third primer 
with the same sequence as the tail and labeled with biotin, and 10 ng genomic DNA, in a 
total volume of 10μl. PCR reactions were carried out in a Perkin-Elmer 9600 thermal cycler 
under the following conditions: 95ºC for 15 min, 40 cycles of 94ºC for 45 s, 57ºC for 45 s, 
72ºC for 1 min, followed by 72ºC for 10 min. From the biotinylated PCR products single 
stranded DNA’s were prepared and subsequently genotyped using the PSQ 96MA system 
(Pyrosequencing AB) (http://www.pyrosequencing.com) and SNP reagent kit 
(Pyrosequencing AB), as previously described (30). Primers for each SNP are described in 
table 1 in the appendix. DNA was available from 808 participants. SNPs could not be 
assessed in one of these samples. 
 
Fish consumption and other lifestyle factors 
Information about dietary habits was obtained using a validated food-frequency 
questionnaire (31,32). Participants were requested to recall their dietary and lifestyle habits 
of the year previous to their last endoscopy. Data about fish consumption was collected as 
number of times consumed per day, week, month or year. A distinction was made between 
high fat fish, low fat fish, and shellfish. 
Information on demographic and lifestyle factors, like smoking habits, physical activity level 
(33) and family history, was obtained from a self-administered questionnaire. 
The intake of total energy and of various nutrients from this questionnaire was calculated 
with the computerized Dutch food composition table. 
 
Statistical analysis 
Subjects with incomplete dietary data (n=20) were excluded. The data-analysis thus 
included data of 787 participants: 384 cases and 403 controls. 
Logistic regression analysis was performed to calculate odds ratios (Ors) and 95% 
confidence intervals (95%CI) of separate genotypes when possible. If the numbers were too 
small, analyses were performed using pooled heterozygote and homozygote minor 
genotypes. The only potential confounding variables included in the model were age and 
gender. 
Haplotypes were estimated and Ors calculated using the Hplus program, available online at 
http://qge.fhcrc.org/hplus. Hplus is a SNP analysis tool for performing haplotype estimations, 
according to the distribution of genotypes in a population. It is able to handle datasets that 
include case-control status as well as covariates and SNP location variables (34). 
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Multiple logistic regression analysis was performed to evaluate the modifying effect of fish 
consumption. Fish consumption, in grams per day, was divided in tertiles according to the 
distribution of intake among controls. The lowest fish consumption tertile in combination with 
a homozygote major allele for the SNP of interest was considered as reference group.  
The variables age, BMI, family history of colorectal cancer, gender, indication of endoscopy, 
insulin use, physical activity, education level, smoking, aspirin use, daily energy intake and 
intake of alcohol, calcium, fiber, fruit, red meat, poultry, processed meat, vegetables, β-
carotene, vitamin C and vitamin E were considered as potential confounding factors. 
Besides the variables age and gender, also indication for endoscopy and alcohol 
consumption were included in the model, since these factors changed the β-estimates by 
more than 10%.  
To test for linear trend, we modeled the tertile of fish consumption as a continuous variable 
in the logistic regression model, in which each tertile was assigned its median value. To test 
whether the combination of genotypes and fish consumption deviated from multiplicativity, 
we calculated p-values for interaction by inclusion of a numerical term for genotype, 
multiplied by fish consumption as a continuous variable into our multivariate models. To 
exclude the influence of previous adenomas among cases, and of undetected proximal 
polyps among controls, we repeated our analysis excluding these cases and controls. 
The analyses were conducted using Statistical Analysis Software (SAS) for Windows, 
version 8. 
 
 
Results 
Cases and controls were similar with respect to family history of colorectal cancer, with 
22.5% of cases and 19.2% of controls having a family history of cancer. The variables age 
and gender differed among cases and controls. The median age for cases was 59.9 and for 
controls 52.2, and 53.3% of cases was male versus 38.4% of controls. However, no effect 
modification was observed after stratification for age group and gender. A more detailed 
description of the study population characteristics was published previously (35,36). The 
genotypes of all SNPs studied were in Hardy Weinberg equilibrium. 
 
Genotypes 
Table I shows the associations between genotypes and colorectal adenomas. A statistically 
significant inverse association was observed for the CT genotype of SNP H477H (OR, 0.63; 
95%CI, 0.45-0.89) in the PPARγ gene as compared to the CC genotype. The OR of the TT 
genotype did not reach significance, but the TC and TT genotypes together also showed a 
statistically significant inverse association (OR, 0.64; 95%CI, 0.46-0.90) (data not shown) as 
compared to the CC genotype. For the PTGS2 gene two opposite associations were 
observed; an inverse association for the GC genotype of SNP V102V (OR, 0.65; 95%CI, 
0.46-0.92), and a positive association for the TC genotype of SNP c.2242T>C (OR, 1.47; 
95%CI, 1.07-2.00) as compared to the homozygote major genotypes. In the case of both 
SNPs, the homozygote minor genotypes did not show a statistically significant OR, but 
combining the heterozygotes and homozygotes minor genotypes resulted in a statistically 
significant association (OR, 0.68; 95%CI, 0.49-0.95 and OR, 1.40; 95%CI, 1.04-1.89 
respectively) (data not shown), as compared to the homozygote major genotypes. 
No statistically significant associations were observed for any of the SNPs in PPARδ, 
PTGS1, PLA2G4A, PLA2G2A or ALOX15. 
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Table 1: AA-pathway related genetic variants and colorectal adenomas 
Genotype Cases 
(n=384) 
Controls 
(n=403) 
OR (95%CI) a Genotype Cases 
(n=384) 
Controls 
(n=403) 
OR (95%CI) a
PPARδ     PLA2G4A     
SNP A:    SNP M:    
  c.-789C>T      
    CC 
    CT 
    TT 
 
333 
31 
1 
 
351 
32 
1 
 
1.00 (ref) 
1.04 (0.60-1.79) 
0.64 (0.04-10.65) 
  c.918+23C>T 
    CC 
    CT 
    TT 
 
255 
114 
11 
 
272 
123 
8 
 
1.00 (ref) 
0.93 (0.67-1.28) 
1.26 (0.47-3.37) 
SNP B:    SNP N:    
  N163N 
    TT 
    TC 
    CC 
 
240 
121 
22 
 
245 
143 
15 
 
1.00 (ref) 
0.92 (0.67-1.23) 
1.31 (0.64-2.68) 
  c.1336+3G>A    
    GG 
    GA+AA 
SNP O:
 
344 
40 
 
348 
53 
 
1.00 (ref) 
0.71 (0.45-1.13) 
 
SNP C:      R651K    
  c.2021T>C    
    TT 
    TC 
    CC 
 
249 
118 
17 
 
256 
133 
12 
 
1.00 (ref) 
0.98 (0.71-1.35) 
1.41 (0.63-3.19) 
    AA 
    AG+GG 
SNP P: 
  c.2605G>A 
327 
14 
 
 
353 
18 
 
 
1.00 (ref) 
0.92 (0.43-1.95) 
 
 
SNP D:        GG 269 298 1.00 (ref) 
  c.2589G>A 
    GG 
    GA+AA 
 
347 
37 
 
361 
42 
 
1.00 (ref) 
0.91 (0.56-1.50) 
    GA 
    AA 
 PLA2G2A 
41 
3 
54 
5 
0.74 (0.47-1.18) 
0.66 (0.15-2.95) 
SNP E:    SNP R:    
  c.2806C>G 
    CC 
    CG 
    GG 
 
272 
92 
12 
 
293 
97 
8 
 
1.00 (ref) 
1.08 (0.76-1.53) 
1.44 (0.55-3.79) 
  c.-180C>G 
    CC 
    CG 
    GG 
 
219 
137 
20 
 
217 
162 
19 
 
1.00 (ref) 
0.87 (0.63-1.18) 
1.13 (0.56-2.25) 
PPARγ    SNP S:    
SNP F:      T32T    
  P12A 
    CC 
    CG 
    GG 
 
281 
92 
6 
 
297 
97 
9 
 
1.00 (ref) 
0.92 (0.65-1.31) 
0.72 (0.24-2.20) 
    GG 
    GC 
    CC 
SNP T:   
320 
61 
1 
327 
73 
3 
1.00 (ref) 
0.81 (0.54-1.20) 
0.38 (0.04-4.26) 
 
SNP G:      c.665C>T    
  H477H 
    CC 
    CT 
    TT 
 
276 
84 
7 
 
263 
115 
10 
 
1.00 (ref) 
0.63 (0.45-0.89) 
0.68 (0.24-1.93) 
    CC 
    CT 
    TT 
ALOX15 
297 
75 
6 
319 
77 
3 
1.00 (ref) 
1.14 (0.78-1.66) 
2.47 (0.55-11.06) 
 
PTGS1    SNP U:    
SNP H:      c.-217G>C    
  W8R 
    CC 
    CT 
    TT 
 
334 
38 
1 
 
339 
51 
2 
 
1.00 (ref) 
0.95 (0.59-1.54) 
0.42 (0.04-5.02) 
    GG 
    GC 
    CC 
SNP V:
258 
87 
3 
260 
94 
9 
1.00 (ref) 
0.98 (0.68-1.40) 
0.30 (0.08-1.20) 
 
SNP I:      T485T    
 L237M 
    CC 
    CA+AA 
 
300 
14 
 
332 
12 
 
1.00 (ref) 
1.29 (0.56-2.94) 
    AA 
    AG 
    GG 
301 
57 
5 
293 
73 
10 
1.00 (ref) 
0.80 (0.53-1.19) 
0.50 (0.16-1.58) 
PTGS2             
SNP J:        
  c.-1329A>G 
    AA 
    AG 
    GG 
 
218 
131 
22 
 
355 
122 
16 
 
1.00 (ref) 
1.23 (0.89-1.69) 
1.62 (0.80-3.30) 
        
 
SNP K:        
  V102V 
    GG 
    GC 
    CC 
 
284 
88 
12 
 
267 
121 
15 
 
1.00 (ref) 
0.65 (0.46-0.92) 
0.96 (0.41-2.24) 
    
SNP L:        
  c.2242T>C 
    TT 
    TC 
    CC 
 
159 
185 
35 
 
196 
162 
38 
 
1.00 (ref) 
1.47 (1.07-2.00) 
1.16 (0.68-1.99) 
    
a Univariate adjustment for age and gender 
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Chapter 3 
Haplotypes 
Table II shows the associations between the most common haplotypes estimated and 
colorectal adenoma risk. The haplotypes are represented as a series of 0 and 1, indicating 
for each SNP in that gene whether the major (0) or minor (1) allele is present in that 
haplotype. Five statistically significant associations between a specific haplotype and 
adenoma risk have been found. 
 
Table 2: AA-pathway related haplotypes and colorectal adenomas 
Haplotypea OR (95% CI)bFrequency among 
cases 
Frequency among 
controls 
   PPARδ 
SNP orderc: ABCDE   
  00000 0.780 
  01101 0.146 
  01110 
  11110 
  11000 
0.018 
0.029 
0.016 
0.779 
0.141 
0.028 
0.025 
0.020 
1.00 (ref) 
1.08 (0.80-1.46) 
0.63 (0.32-1.22) 
1.22 (0.63-2.35) 
0.75 (0.35-1.59) 
PPARγ    
SNP orderc: FG   
  00 
  11 
  01 
  10 
0.825 
0.095 
0.038 
0.042 
0.787 
0.104 
0.070 
0.040 
1.00 (ref) 
0.84 (0.59-1.21) 
0.47 (0.28-0.78) 
0.98 (0.58-1.66) 
PTGS1    
SNP orderc: HI   
  00 
  10 
  01 
0.924 
0.053 
0.022 
0.912 
0.070 
0.017 
1.00 (ref) 
0.91 (0.60-1.39) 
1.28 (0.55-2.97) 
PTGS2    
SNP orderc: JKL   
  000 
  001 
  100 
  010 
0.282 
0.336 
0.236 
0.146 
0.318 
0.298 
0.198 
0.186 
1.00 (ref) 
1.34 (1.02-1.76) 
1.37 (1.01-1.86) 
0.93 (0.67-1.28) 
PLA2G4A    
SNP orderc: MNOP   
  0000 
  1000 
  1101 
  0010 
  1001 
  0001 
0.793 
0.109 
0.050 
0.019 
0.014 
0.013 
0.793 
0.089 
0.059 
0.023 
0.018 
0.010 
1.00 (ref) 
1.19 (0.82-1.74) 
0.72 (0.42-1.23) 
0.91 (0.43-1.90) 
0.81 (0.29-2.24) 
1.58 (0.63-3.95) 
PLA2G2A    
SNP orderc: RST   
  000 
  100 
  011 
  010 
  001 
0.640 
0.229 
0.066 
0.017 
0.042 
0.623 
0.246 
0.069 
0.028 
0.028 
1.00 (ref) 
0.93 (0.72-1.22) 
0.88 (0.55-1.40) 
0.58 (0.28-1.21) 
2.10 (1.11-3.95) 
ALOX15    
SNP orderc: UV   
  00 
  10 
  11 
  01 
0.819 
0.089 
0.044 
0.048 
0.795 
0.082 
0.073 
0.050 
1.00 (ref) 
1.20 (0.77-1.86) 
0.51 (0.30-0.87) 
1.17 (0.70-1.97) 
a 0 represents major allele, 1 represents minor allele; 
b Adjusted for age and gender 
c SNP order according to table I 
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A reduction in the risk for colorectal adenomas was observed for haplotype 01 in PPARγ (C 
allele for P12A and T allele for H477H), and 11 in ALOX15 (C allele for c.-217G>C, and G 
allele for T485T). The Ors showed about a 50% reduction of colorectal adenoma risk (OR = 
0.47 and 0.51 respectively), as compared to haplotype 00 (major alleles for both SNPs). The 
remaining 3 haplotypes showed a positive association. Haplotypes 100 and 001 in PTGS2 
(G alleles at position c.-1329 and amino acid 102 and the T allele for c.2242T>C; and A 
allele at position c.-1329, G allele at amino acid 102 and C allele for c.2242T>C) showed 
similar Ors of 1.37 (95%CI, 1.01-1.86) and 1.34 (95%CI, 1.02-1.76), as compared to 
haplotypes 000. An even greater effect was observed for haplotype 001 in PLA2G2A (C 
allele for c.-180C>G, G allele for T32T and T allele for c.665C>T), with an OR of 2.10 
(95%CI, 1.11-3.95), as compared to haplotype 000.  
 
 
Gene-diet interaction 
The associations between genotypes and colorectal adenomas stratified for fish 
consumption are shown in Table III. There was no statistically significant association 
between fish consumption and colorectal adenoma risk (data not shown). A statistically 
significant interaction was observed between fish consumption and SNP c.-789C>T in 
PPARδ, in adenoma risk. An inverse association was observed for those with the CC 
genotype and highest tertile (T3) of fish consumption as compared to those with lowest 
tertile (T1) of fish consumption (OR, 0.65; 95%CI, 0.41-1.02). However, for those with the 
CT or TT genotype, fish consumption increased risk (OR T3 versus T1, CC genotype: 2.22; 
95%CI, 0.78-6.36). 
For PTGS2 the AG and GG genotypes of SNP c.-1329A>G, located in the promoter in 
PTGS2, showed a positive trend towards a reduced risk of adenomas with increasing fish 
consumption (p=0.01 and 0.03 respectively), as compared to those with the AA genotype 
and low fish consumption. Fish consumption strengthened the protective effect of SNP 
V102V in PTGS2, to a statistically significant OR of 0.42 (95%CI, 0.20-0.90) in the highest 
tertile of intake for individuals with the GC genotype, as compared to those with the GG 
genotype and low fish consumption. A statistically significant interaction was observed 
between fish consumption and SNP c.2242T>C, located in 3’UTR in PTGS2 (p=0.01). The 
homozygote major T allele was inversely associated with colorectal adenomas in the highest 
fish consumption tertile. Although not statistically significant, the OR of 0.52 (95%CI, 0.27-
1.01) reflects a reduction of almost 50% in the occurrence of colorectal adenomas, as 
compared to low fish consumption. 
The AA genotype of SNP R651K, an A to G substitution in PLA2G4A was inversely 
associated with colorectal adenomas for individuals in the highest fish consumption tertile 
(OR, 0.64; 95%CI 0.41-0.96), as compared to low fish consumption. The risk of colorectal 
adenomas decreased also for the GG genotype of SNP c.2605G>A in PLA2G4A with high 
consumption of fish (OR, 0.59; 95%CI, 0.37-0.92), as compared to low consumption of fish.  
After stratification for fish consumption, no statistically significant associations were 
observed between genotype and adenomas for either SNPs in PPARγ, or for the SNPs in 
PTGS1. There was also no effect on the associations between the genotypes of SNPs in 
PLA2G2A and ALOX15, and colorectal adenomas.  
A summary of the major findings of this study is provided in Table 4. 
All analyses were repeated for incident cases only (i.e. those with a first polyp at index 
scopy). No differences were observed in comparison to the analyses with the prevalent and 
incident cases together (data not shown). The same analyses were carried out for the cases 
with villous polyps. No marked differences were observed in comparison to the analyses 
with all cases, including cases with tubular and tubulovillous polyps, but the results were 
stronger for the cases with villous polyps (data not shown). Also, similar results were found 
with analyses including only subjects who underwent a full endoscopy (data not shown). 
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SNPs, fish consumption and adenoma risk 
Table 4: Summary of statistical significant results 
  Analysis 
Gene SNP Genotype Risk Haplotype Risk Genotype Effect of fish 
PPARδ c.-789C>T 
 
N163N 
    CT+TT Trenda
Interactionb
Interactionb
PPARγ H477H CT ↓ 01 ↓↓   
PTGS2 c.-1329A>G 
V102V 
c.2242T>C 
 
GC 
TC 
 
↓ 
↑ 
100 
 
001 
↑ 
 
↑ 
AG+GG Trendc
 
Interactionb
PLA2G
4A 
R651K 
c.2605G>A 
    AA 
GG 
T3/↓d
T3/↓ d
PLA2G
2A 
   001 ↑   
ALOX1
5 
   11 ↓   
a Increased adenoma risk with increasing fish consumption 
b Deviation from multiplicativity 
c Decreased adenoma risk with increasing fish consumption 
d Decreased adenoma risk with high fish consumption 
 
 
Discussion 
All AA-pathway genes investigated in this study have been associated with the etiology of 
colorectal tumors in previous in-vitro, animal model and human studies. We investigated 
whether polymorphisms in these genes alone or in combination with fish consumption 
contributed to adenoma risk, and found a number of statistically significant associations. The 
SNPs were selected with great care, however, there are SNPs with lower minor allele 
frequencies that could also influence colorectal adenoma risk, but because of insufficient 
numbers, it is not feasible to evaluate these effects in this study. 
The associations found between SNPs in PTGS2 and colorectal polyps are supported by a 
similar finding by Campa et al. (37), who found a positive association between the minor 
allele of SNP c.2242T>C in PTGS2 and non-small cell lung cancer. This is not in line 
however, with a previously published study in which affected siblings were tested for linkage 
of PTGS2 variants with colon neoplasia (38). The authors suggested that genetic variation in 
PTGS2 is unlikely to contribute to colorectal cancer risk, but as pointed out by Ulrich and 
Potter (39) the population used in this study might not be representative of the general 
population and markers some distance away from the PTGS2 locus were used. Moreover, 
the importance of the 3’UTR region of PTGS2 is illustrated by a strong positive association 
between another SNP in this region and colorectal cancer observed in a study investigating 
a number of polymorphisms in PTGS2 (40). This part of the 3’UTR was previously thought to 
lie outside the gene, hence this SNP was not included in our study. In line with published 
data on the importance of the 3’UTR in posttranscriptional regulation of PTGS2 expression 
(41) it is hypothesized that SNPs in this region interfere with this process.  
We found no associations between the two SNPs in PTGS1 and colorectal adenomas. This 
is in line with two previous studies investigating one of the SNPs in PTGS1 (L237M) neither 
of which showed a significant association (42,43). However, due to the low minor allele 
frequency of this SNP false negative results cannot be ruled out. 
As far as we know H477H in PPARγ has not been tested before for colorectal tumor risk, 
whereas for the other variant in PPARγ, P12A, a modest protective effect of the minor allele 
has been found (44). This finding could not be replicated by our study, which may be 
explained in part by the different study populations; colorectal cancer vs adenoma patients. 
The involvement of this SNP in colorectal cancer development was also implicated by a 
study on colorectal cancer patients where the minor allele was frequently found in tumors 
63 
Chapter 3 
without a K-ras mutation (45), an observation that could not be reproduced by us (data not 
shown). Analyzing the haplotype containing the major allele of P12A and the minor allele of 
H477H strengthened the association we found between H477H in PPARγ and adenomas. 
Moreover, the importance of specific haplotypes containing these SNPs was also illustrated 
by two other studies, on body weight and type 2 diabetes. However, the statistically 
significant association in the second study concerned the haplotype containing the minor 
allele of P12A and the major allele of H477H (also known as C1431T) (46,47). This does 
indicate however, that there is likely a functional effect resulting from the combination of 
these two SNPs, either on protein function or on the amount of protein present. 
We found a positive association between haplotype 001 (C allele for c.-180C>G, G allele for 
T32T and T allele for c.665C>T) of PLA2G2A and adenomas. When the SNPs were 
analyzed separately no associations were apparent, illustrating again the importance of 
specific haplotypes. This positive association is particularly striking since the role of 
PLA2G2A in human colorectal carcinogenesis following the discovery of the gene on the 
Mom-1 locus (7), has been the subject of much debate. Although one study found a 
germline PLA2G2A mutation in a sporadic colorectal cancer patient (48), there have been 
several other results questioning the tumor-suppressing role of human PLA2G2A. No 
somatic mutations in tumors have been found (49) neither do the differing disease 
phenotypes in FAP patients correlate with PLA2G2A mutations (50). Gene expression 
analysis revealed no change in expression levels of PLA2G2A between normal mucosa and 
tumors (51), and even an apparent lack of expression of PLA2G2A in colorectal cancer cell 
lines was observed (52). In line with this, a study investigating the effect of single SNPs, 
corresponding to two of our selected SNPs (c.-180C>G and T32T), on the phenotype of FAP 
patients and on sporadic colorectal cancer, found no associations (53). However, the effect 
of the third SNP (c.665C>T) and the corresponding haplotypes, was not considered in that 
study. Our results reinforce the notion that PLA2G2A is not only an important tumor 
suppressor in mice, but may also play a role in human tumors. 
No previous studies have been reported evaluating associations between SNPs or 
haplotypes in the anticarcinogenic ALOX15 gene and colorectal tumors. However, 
associations with a specific haplotype in another subtype of the lipoxygenase enzyme, the 
procarcinogenic 5LOX gene, have been reported recently (42), indicating again the 
importance of this family of enzymes in colorectal tumorigenesis.  
Fish consumption can affect lipid metabolism through different mechanisms. An increase in 
n-3 PUFAs can lead to an increase in eicosapentaenoic acid (EPA) tissue content, and a 
decrease in n-6 PUFA derived AA. This will lead to an increase in eicosanoid synthesis from 
EPA, resulting in a shift in production of 2-series to 3-series prostaglandins (54,55). Since 
prostaglandins act as ligands for PPARδ (56), fish consumption may interact with PPARδ by 
modifying the spectrum of PPAR ligands. This can be influenced by SNPs, explaining the 
interactions founds between SNPs in PPARδ and fish consumption. Besides changing the 
substrates and therefore the products of the AA-pathway, n-3 PUFA can have a direct effect 
on the genes in the pathway as well. A high concentration of n-3 PUFAs has been shown to 
inhibit PTGS2 directly causing a decrease in the overall production of prostaglandins (57). 
SNPs in PTGS2 might interfere with this process. Inhibition of Δ6-desaturase, the rate-
limiting enzyme in the conversion of LA to AA, by n-3 PUFAs has also been demonstrated 
(58). These interactions between fish consumption, as a proxy for n-3 PUFAs,  and genes in 
the AA-pathway make it plausible that the association between SNPs in these genes and 
colorectal adenomas is modulated by fish consumption, and therefore that some 
associations became apparent and others were strengthened, although the exact 
mechanisms remain far from clear. 
Consideration must be given to the potential limitations of the present study in particular the 
possibility of chance findings due to evaluating a large number of genes and gene-diet 
interactions simultaneously. Although the genes examined have been previously shown to 
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be involved in colorectal carcinogenesis, the results of this study need to be confirmed by 
others. 
In conclusion, this study has shown that polymorphisms in genes involved in the AA-
pathway may be associated with colorectal adenomas. We have shown for the first time that 
these associations could be modified by fish consumption, but further research to 
understand the mechanisms involved is needed. For example, functional studies of the 
SNPs implicated in this study might provide a plausible basis for the associations observed, 
and to minimize information bias and to assess whether n-3 Fas are the active agents 
associated with colorectal tumor risk, measurements of n-3 Fas in plasma samples are 
recommended and presently ongoing.  
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Appendix 
 
Table 1: PCR and sequencing primer sequences for each SNP 
SNP  Sequence (5’-3’) SNP  Sequence (5’-3’) 
PPARδ  Forward aaatcactcatccagatagctag cPLA2  Forward agctctggacaacctgtcacc 
  c.-789C>T      Reverse 
Sequence 
aacctcctcatcttccagtga 
gactcttaacccagtgcta 
  c.918+23C>T 
 
Reverse 
Sequence 
ggggagaatgggctcagta 
tgtctacttgttataaaagc 
  N163N 
 
Forward 
Reverse 
Sequence 
ataaagggatggggatgtcag 
gacccagagcccaggatg 
tgtactggctcccctc 
  c.1336+3G>A   
     
   
Forward 
Reverse 
Sequence 
atgatagctcggacagtgatga 
catgcaacatgcaatcctct 
agtttccggctcact 
  c.2021T>C    
     
Forward 
Reverse 
Sequence 
atccccctgctcctttctcta 
ggagcctgcaggtaaagtga 
atgtgtgtgtgctgga 
  R651K 
 
Forward 
Reverse 
Sequence 
attatgtgtttgatcgggaagg 
tgtcagtttcgtcccctactt 
cctacttacctggagcc 
  c.2589G>A 
     
Forward 
Reverse 
Sequence 
aggctggagtctcagagcaca 
atcctgccagcagagagtga 
ccacccagagtcacac 
  c.2605G>A 
 
Forward 
Reverse 
Sequence 
tgaacttcctgatacaaatgtaggg 
baaaaatagtgttgtctcatggtatgaa 
ttcaatctcaataagacctc 
  c.2806C>G 
     
Forward 
Reverse 
Sequence 
tctctgctggcaggattctt 
btggggctcctagcaaaaata 
cgcgtccctgccc 
sPLA2  
  c.-180C>G 
Forward 
Reverse 
Sequence 
agctccgttggttggtaggta 
tttcacagccacgtc 
cctgctccccttaaat 
PPARγ Forward acaaacccctattccatgctg   T32T Forward acaaatttccttccaggcctac 
  P12A 
     
Reverse 
Sequence 
caaacacaacctggaagacaaa 
aggaatcgctttctg 
     
   
Reverse 
Sequence 
cataactgagtgcggcttcc 
cggcttcctttcctg 
  H477H 
 
Forward 
Reverse 
Sequence 
aaaccaccctgagtcctcaca 
gaagggaaatgttggcagtg 
cctgcagtagctgcac 
  c. 665C>T 
 
 
Forward 
Reverse 
Sequence 
acatccctcacccatcctaga 
catgatttgctaattgctttattca 
ttattcagaagagacccc 
PTGS1 Forward agcccctcatctctctcctc 15LOX Forward ctgtaccaggcgttgattcc 
  W8R 
 
Reverse 
Sequence 
baggagggggttgaaaccag 
tctgcagggagtctctt 
  c.-217G>C 
 
Reverse 
Sequence 
bagagcttcaaggggcagaat 
gatagtggtttccactcc 
 L237M 
  
Forward 
Reverse 
Sequence 
acaggtagacctcggccacat 
ctttgccagggaagaccat 
ttgatactgacgctcca 
  T485T Forward 
Reverse 
Sequence 
agctccgttggttggtaggta 
tcttgggctttgtgtctgag 
tttcacagccacgtc 
PTGS2 Forward aatgctcctccctgagcacta    
  c.-1329A>G 
 
Reverse 
Sequence 
tttcagttgcctgggcttat 
tggaagggagattttg 
   
  V102V 
 
Forward 
Reverse 
Sequence 
cattcccttccttcgaaatg 
bgatggaaggcaaacttaaaagc 
aaatgcaattatgagttat 
   
  c.2242T>C 
  
Forward 
Reverse 
Sequence 
tgtttccaatgcatcttcca 
bgcactgatacctgtttttgtttg 
aattttaaagtacttttggt 
   
aForward tail and forward universal biotin labeled primer: gacgggacaccgctgatcgttta 
bReverse tail and reverse universal biotin labeled primer: agcgctgctccggttcatagatt 
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Abstract 
The objective of this study on colorectal cancer was to investigate the associations between 
SNPs in arachidonic acid (AA) pathway genes, their haplotypes and colorectal cancer. 
Moreover, interactions between SNPs and fish consumption were considered. In this study a 
total of 508 cases and 772 controls were included, originating from two prospective cohorts, 
the Monitoring Project on Cardiovascular Disease Risk Factors (PPHV) and Diagnostisch 
Onderzoek Mammacarcinoom (DOM). Genotypes of twenty-three SNPs in seven candidate 
genes were determined and the modifying effect of fish consumption was considered. A 
protective effect of the minor allele of SNP V102V in PTGS2 was observed (OR, 0.37; 
95%CI, 0.16-0.87). The haplotype representing this allele showed a weaker inverse 
association, indicating that two alleles are necessary to obtain this protective effect. Fish 
consumption data was available for 209 cases and 418 controls. Increased fish consumption 
was inversely associated with cancer, although not statistically significant (OR, 0.83; 95%CI, 
0.57-1.20). Despite the substantial reductions in cancer risk for some genotypes in 
combination with high fish intake, no statistically significant interactions between any SNP 
studied and fish consumption were observed. We have previously described an association 
between colorectal adenomas and SNP V102V in PTGS2 and have now confirmed this 
association for colorectal adenocarcinomas. Fish consumption of once a week or more 
might protect against colorectal cancer, but no statistically significant interactions with SNPs 
in AA-pathway genes could be detected within the study. 
 
 
Introduction 
Colorectal cancer is one of the leading causes of death through cancer in the developed 
world, with over 9500 new patients in The Netherlands in the year 2002 alone (1). 
Epidemiological and experimental evidence indicates that both genetic and environmental 
factors are involved. Lipid metabolism, in particular the arachidonic acid (AA) pathway, 
appears to play a critical role in colorectal tumor development, as reviewed by Jones et al. 
(2).  
The evidence implicating several major genes within this pathway in colon tumorigenesis 
has been discussed previously (3), but is recapitulated in short. Cyclooxygenase-1 and 
cyclooxygenase–2, also known as prostaglandin endoperoxide synthases (PTGSs), are two 
key genes in the AA pathway, encoding enzymes that initiate the synthesis of biologically 
important prostanoids (PGs) and eicosanoids (4). Both genes have been demonstrated to 
be involved in intestinal tumorigenesis and proposed mechanisms include, promoting tumor 
growth, cell proliferation, angiogenesis and inhibiting apoptosis. Phospholipase A2 (PLA2) 
enzymes are a family that, besides other conversions, catalyze the generation of free fatty 
acids, such as AA, from membrane bound phospholipids. Most important in the AA-pathway 
are cytosolic PLA2 (PLA2G4A) and secretory PLA2 (PLA2G2A), which have both been 
demonstrated in mouse models to be involved in tumorigenesis (5,6). Lipoxygenase (ALOX), 
is an enzyme for which AA is one of the substrates. Activation of the enzyme ALOX15 might 
inhibit carcinogenesis via the conversion of linoleic acid into 13-S-hydroxyoctadecadienoic 
(13-S-HODE) acid, which in turn downregulates PPARδ thereby restoring apoptosis (7). 
Peroxisome roliferators-activated receptors (PPARs) play an important regulatory role in 
lipid metabolism and cancer, and PPARs can be activated by a variety of eicosanoids (8,9). 
There are three distinct types of PPARs, α, δ and γ. Both PPARδ and PPARγ have been 
implicated to play a role in colorectal tumorigenesis, by transcriptionally controlling pathways 
involved in cell proliferation, differentiation and survival (8). Moreover, recently the role of 
both PPARδ and PPARγ as focal points of cross-talk between prostaglandin and Wnt 
signaling pathways has been suggested (10,11). Most data of PPARγ suggests a tumor 
suppressive role, however, there is still some controversy about the increase of intestinal 
polyps in ApcMin mice by ligands of PPARγ (12,13).  
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Genetic variants represented by Single Nucleotide Polymorphisms (SNPs) in genes 
encoding these key players of the AA-pathway may contribute to variation in susceptibility to 
colorectal cancer. Recently, the focus of attention has shifted from the use of single genetic 
variants in association studies, to using haplotypes (14). By using information about the 
common SNPs in a particular population, combinations of SNP alleles called haplotypes can 
be estimated, after which differences in frequencies between cases and controls can be 
evaluated (15,16). Haplotypes can also be used to select those SNPs that are 
representative for a certain haplotype, the so-called tagging SNPs (15). 
Among environmental factors, diet appears to play a major role in the risk of developing 
colorectal cancer. Several dietary components have been identified as risk factors, including 
red meat and alcohol, whereas others have been shown to reduce cancer risk, for example 
fruit, vegetables and calcium (17). Additionally, some, but not all animal experimental 
studies and epidemiological studies have shown that fish consumption may decrease the 
risk of colorectal tumors (18-20). The mechanism by which fish may exert its protective 
effect on colorectal tumors might include modulation of the AA pathway, by increasing the n-
3 polyunsaturated fatty acids (PUFAs) content in cellular membranes. The AA pathway 
utilizes both dietary n-3 and n-6 PUFAs to produce eicosanoids. High fish consumption 
might therefore cause a shift in substrates from n-6 to n-3 PUFAs, resulting in a different 
class of eicosanoids. A high ratio of fish fatty acids (Fas) to arachidonic acid (AA) in adipose 
tissue, as a marker for fatty acid intake, has been associated with a lower risk of colorectal 
adenomas (21). SNPs in AA pathway genes may interact with fish consumption by 
influencing the conversion of these PUFAs into eicosanoids. 
In this association study, twenty-three SNPs in genes encoding five enzymes and two 
nuclear receptors have been used. The objective of this study on colorectal cancer was to 
investigate whether SNPs previously found to play a role in adenoma formation, might be 
important in the progression of adenoma to carcinoma, and to evaluate the role of fish 
consumption in this process (3). In addition, a previously reported association between a 
SNP in the 3’ UTR of PTGS2 and colorectal cancer is investigated (22). 
 
 
Materials and Methods 
Study population 
We conducted a nested case-control study using two Dutch studies. The first prospective 
study called Monitoring Project on Cardiovascular Disease Risk Factors (PPHV), conducted 
in three Dutch towns between 1987 and 1991 included over 36000 participants. A detailed 
description of the study was published previously (23). Follow-up for incident cancer for the 
period 1987 to mid 2003 was achieved via computerized record linkage with the Netherlands 
Cancer Registry and with the three regional cancer registries. In total 209 colorectal cancer 
cases (46 prevalent and 163 incident) could be identified. A random sample of controls was 
drawn from the same cohort, frequency matched on age (5 year intervals), gender and 
center, to include 418 subjects. 
The second so-called ‘DOM’ (Diagnostisch Onderzoek Mammacarcinoom) project was 
conducted between 1976 and 1978, where all women born between 1911 and 1925 living in 
the city of Utrecht were invited to participate in a population-based screening program for 
the early detection of breast cancer (24). Each participant provided an overnight urine 
sample which was stored at -20°C. Follow-up for incident cancer from 1976 through linkage 
to the regional cancer registry resulted in a total of 355 colorectal cancer cases. A random 
selection of controls was drawn frequency matched on age at intake (5 year intervals) and 
all were of postmenopausal status, to include 426 subjects. 
 
Fish consumption and other lifestyle factors 
For the PPHV cohort, information about fish consumption and other lifestyle factors was 
obtained using a self-administered questionnaire. Dietary habits were estimated using a 
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validated semi-quantitative food-frequency method (25). Frequency of fish consumption was 
assessed in six categories: never, less than once a month, one to three times monthly, once 
per week, two to four times weekly, and more than four times a week.  
The intake of total energy from this questionnaire was calculated with the computerized 
Dutch food composition table (26). 
 
Genetic analysis 
For participants of the PPHV cohort, genomic DNA was extracted from buffy coats by 
digestion with proteinase K, followed by salting out with potassium acetate and 
chloroform/isoamyl alcohol extraction (27). For participants of the DOM cohort, DNA was 
isolated from 100 ml frozen urine by alcohol precipitation as described earlier (28). 
Twenty-one of the twenty-three SNPs have been selected on the basis of an inventory of the 
genetic variation in the Dutch population of the selected genes as described elsewhere, in 
which fifty-eight polymorphisms were identified (Siezen et al., submitted). The SNP selection 
was based on allele frequency (with some exceptions only those SNPs with a minor allele 
frequency of 5% or higher were considered), position in the gene (when possible evenly 
distributed across the gene), possible impact on protein function (amino acid changes), and 
linkage between the SNPs in one gene (of two or more tightly linked SNPs only one was 
selected). One SNP was selected on the basis of a population study on PTGS1 variants 
(29), and one on a previous association between a SNP in PTGS2 and colorectal cancer 
risk (22). 
PCR and genotyping of twenty-one SNPs has been described previously (3). In short, all 
samples were genotyped using a technique known as PyrosequencingTM (30), using a 
biotinylated single stranded PCR product. Two additional SNPs were genotyped using the 
restriction fragment length polymorphism (RFLP) method. SNP c.136-37G>A in ALOX15 
was genotyped using 2 units of HaeIII (New England Biolabs) and buffer provided, per 10μl 
PCR product. SNP c.3618A>G in PTGS2 was genotyped using 1 unit of Alu and buffer 
provided, per 10μl PCR product. Both mixtures were incubated at 37°C for 2 hours. Each 
PCR plate contained ninety-two DNA samples, one negative (TE) control, and three positive 
controls, one for each genotype if available. 
Primers for twenty-one SNP are described previously (3) and primers for two additional 
SNPs are in table 1 in the appendix. All SNPs were genotyped in the PPHV cohort from 
which DNA was available for 603 participants (204 cases and 399 controls). Based on i) 
these PPHV results, on ii) previously found associations (3), and iii) limited available DNA 
from the DOM cohort, the SNPs in PPARγ and PTGS2 were selected for additional 
genotyping in the DOM cohort. Due to insufficient DNA or failed genotyping, which is not 
unusual for DNA extracted from urine (28), genotypes were determined for 677 participants 
from de DOM cohort (304 cases and 373 controls). 
 
Data analysis 
Analyses were performed on all genotyped participants. Logistic regression analysis was 
performed to calculate odds ratios (Ors) and 95% confidence intervals (95%CI) of separate 
genotypes when possible. If the numbers were too small, analyses were performed using 
pooled heterozygote and homozygote minor genotypes. The matching variables age, gender 
and cohort or centre were considered as potential confounding factors. Only the covariate 
cohort changed the β-estimate by more than 10%, therefore for the genotype analysis with 
pooled cohorts, this was included into the model as a covariate. All other factors were 
assumed to be unrelated to genotype. 
Haplotypes were estimated and Ors calculated using the Hplus program, available online at 
http://qge.fhcrc.org/hplus. Hplus is a SNP analysis tool for performing haplotype estimations, 
according to the distribution of unphased genotypes in a population. It is able to handle 
datasets that include case-control status as well as covariates and SNP location variables 
(31). 
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Multiple logistic regression analysis was performed to evaluate the modifying effect of fish 
consumption in the PPHV cohort. Fish consumption, in 6 categories, was divided in low fish 
consumption (less than once a week) and high fish consumption (once a week or more 
frequent). The low fish consumption group in combination with a homozygote major allele for 
the SNP of interest was considered as reference group. Analysis was performed on incident 
cases only, since prevalent cases could have changed their eating habits after first 
diagnosis. This resulted in 161 cases for analysis. 
The variables age, gender, smoking, aspirin use (ever/never), physical activity at work, 
physical activity in leisure time, education (high/low), insulin use (yes/no), fruit, vegetables, 
meat (all quartiles), total energy intake, alcohol, calcium, β-carotene, vitamin C, vitamin E, 
fiber, total cholesterol, HDL cholesterol and BMI (all continuous) were considered as 
potential confounding factors. No variables were included into the model since none of these 
factors changed the β-estimates by more than 10%.  
To test whether the combination of genotypes and fish consumption deviated from 
multiplicativity, we calculated p-values for interaction in an exploratory way by inclusion of a 
numerical term for genotype, multiplied by fish consumption in 2 categories, low or high fish 
consumption, into our multivariate models. 
The analyses were conducted using Statistical Analysis Software (SAS) for Windows, 
version 8. 
Power calculations were conducted using an online software program provided by the UCLA 
department of statistics (32). 
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Results 
Table 1 shows the characteristics of both study populations. All genotypes of the SNPs 
studied were in Hardy-Weinberg equilibrium, in each cohort separately as well as in the 
combined set.  
 
Table 1: Characteristics of study population 
 PPHV* DOM†
 Cases (n=204) Controls (n=399) Cases (n=304) Controls (n=373) 
Demographic     
   Female (%) 44.1 44.9 100 100 
   Age at baseline, mean (SD) 51.2 (7.53) 52.6 (6.81) 57.3 (4.13) 56.2 (4.14)‡
   Height, cm, mean (SD) 171.5 (9.54) 170.2 (9.30) 162.7 (5.89) 162.1 (10.5) 
   Weight, kg, mean (SD) 77.5 (12.4) 75.0 (12.5) 69.9 (10.7) 68.5 (10.4) 
   BMI, kg/m2, mean (SD) 25.9 (3.68) 25.5 (3.61) 26.5 (3.92) 25.9 (3.53) 
   Total cholesterol, mmol/l (SD) 5.97 (1.23) 6.03 (1.12)   
   HDL cholesterol, mmol/l (SD) 1.22 (0.35) 1.24 (0.33)   
   Total/HDL cholesterol ratio (SD) 5.28 (1.87) 5.24 (1.76)   
     
Lifestyle     
Diet, mean (SD)     
   Fish, frequency per month 2.49 (2.96) 2.89 (3.12)   
   Meat, frequency per day 0.67 (0.29) 0.69 (0.34)   
   Fruit, frequency per day 0.96 (0.66) 1.07 (0.66)   
   Vegetables, frequency per day 1.12 (0.62) 1.13 (0.57)   
   Total energy, kJ/day 6999 (1877) 6918 (2135)   
   Alcohol, g/day 10.1 (13.1) 10.4 (13.8)   
   Calcium, mg/day 969 (387) 957 (405)   
   β-caroteen, mg/day 1.10 (0.56) 1.11 (0.60)   
   Vitamin C, mg/day 55.9 (27.7) 57.4 (25.4)   
   Vitamin E, mg/day 12.2 (5.22) 11.9 (5.18)   
   Fiber, mg/day 17.2 (5.58) 16.4 (5.67)   
Other lifestyle, %     
   Smoking, ever 69.3 71.2 26.8 26.4 
   Education, low 56.9 53.8   
   Regular physical activity leisure time 63.4 71.4‡   
   Regular physical activity work 23.7 32.7‡   
   Use of insulin 2.45 1.00   
   Use of aspirin 33.3 26.8   
49. Monitoring Project on Cardiovascular Disease Risk Factors 
† Diagnostisch Onderzoek Mammacarcinoom 
‡ p≤0.05 Wilcoxon rank test (continuous variables) or Fisher’s exact test (categorical variables) 
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Tables 2 and 3 show the Ors for each genotype, or pooled genotypes and colorectal cancer. 
Subjects with the CC genotype of SNP V102V in PTGS2 have a 63% reduction in colorectal 
cancer risk as compared to those with the GG genotype (OR, 0.37; 95%CI, 0.16-0.87). None 
of the other risk estimates were statistically significant, although the pooled minor genotypes 
of two SNPs in PLA2G4A (c.1336+3G>A and c.2605G>A) showed Ors of over 1.50. 
Analysis with only incident cases did not change the results. 
 
Table 2: PPARγ and PTGS2 variants and colorectal cancer in the PPHV and DOM cohorts 
 PPHV cohort DOM cohort   
Genotype (rs number) (33) Cases 
(n=304) 
Controls 
(n=373) 
Cases 
(n=304) 
Controls 
(n=373) 
OR (95%CI) * Power 
PPARγ       
  P12A (rs1801282) 
    CC 
    CG 
    GG 
 
160 
40 
1 
 
325 
71 
2 
 
387 
92 
8 
 
596 
146 
8 
 
1.00 (ref) 
0.96 (0.72-1.28) 
1.34 (0.50-3.62) 
 
 
0.05 
0.08 
  H477H (rs3856806) 
    CC 
    CT 
    TT 
 
155 
42 
4 
 
307 
79 
4 
 
380 
92 
7 
 
555 
162 
9 
 
1.00 (ref) 
0.82 (0.61-1.10) 
1.14 (0.42-3.11) 
 
 
0.28 
0.04 
PTGS2       
  c.-1329A>G (rs689466)  
    AA 
    AG 
    GG 
 
127 
59 
10 
 
243 
128 
20 
 
283 
132 
19 
 
422 
226 
41 
 
1.00 (ref) 
0.87 (0.67-1.13) 
0.68 (0.39-1.20) 
 
 
0.20 
0.31 
  V102V (rs5277)  
    GG 
    GC 
    CC 
 
142 
56 
5 
 
287 
100 
11 
 
339 
133 
7 
 
521 
195 
28 
 
1.00 (ref) 
1.04 (0.80-1.35) 
0.37 (0.16-0.87) 
 
 
0.05 
0.78 
  c.2242T>C (rs5275)  
    TT 
    TC 
    CC 
 
97 
83 
20 
 
190 
163 
35 
 
216 
171 
55 
 
339 
281 
73 
 
1.00 (ref) 
0.97 (0.75-1.25) 
1.14 (0.77-1.69) 
 
 
0.05 
0.11 
  c.3618A>G (rs4648298)  
    AA 
    AG+GG 
 
194 
5 
 
368 
21 
 
461 
13 
 
699 
36 
 
1.00 (ref) 
0.56 (0.29-1.06) 
 
 
0.49 
49. Univariate adjustment for cohort, analysis of the two cohorts added up 
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The Ors for all major haplotypes and colorectal cancer risk are shown in tables 4 and 5. The 
haplotype representing the minor alleles of c.1336+3G>A and c.2605G>A in PLA2G4A 
(haplotype 1101, also containing the minor allele of c.918+23C>T and the major allele of 
R651K), showed an OR of over 1.50, in line with the pooled genotypes of the separate 
SNPs (OR, 1.54; 95%CI, 0.87-2.71). No statistically significant Ors for any of the haplotypes 
were observed. 
 
Table 4: Haplotypes of PPARγ and PTGS2 and colorectal cancer in the PPHV and DOM 
cohort 
Haplotype* Frequency cases Frequency controls OR (95%CI) † Power 
PPARγ     
 00 0.849 0.847 1.00 (ref)  
 11 0.071 0.079 0.88 (0.64-1.21) 0.13 
 01 0.038 0.044 0.89 (0.57-1.38) 0.08 
 10 0.041 0.030 1.33 (0.85-2.08) 0.25 
PTGS2     
 0000 0.333 0.308 1.00 (ref)  
 0010 0.297 0.276 0.97 (0.79-1.21) 0.05 
 1000 0.195 0.222 0.81 (0.63-1.03) 0.55 
 0100 0.153 0.163 0.85 (0.67-1.08) 0.30 
 0011 0.014 0.024 0.51 (0.23-1.13) 0.51 
 1010 0.005 0.004 0.96 (0.17-5.53) 0.03 
* 0 represents major allele, 1 represents minor allele. SNP order according to table 2 
† Adjusted for cohort 
 
Table 5: Haplotypes of PPARδ, PTGS1, PLA2G4A, PLA2G2A and ALOX15 and colorectal 
cancer risk in the PPHV cohort 
Haplotype* Frequency cases Frequency controls OR (95%CI) Power 
PPARδ     
 00000 0.776 0.777 1.00 (ref)  
 01101 0.137 0.131 1.05 (0.75-1.48) 0.05 
 11110 0.040 0.041 0.97 (0.53-1.77) 0.03 
 01110 0.023 0.027 0.84 (0.38-1.85) 0.07 
 11000 0.010 0.014 0.72 (0.23-2.30) 0.07 
PLA2G4A     
 0000 0.791 0.798 1.00 (ref)  
 1000 0.091 0.102 0.92 (0.62-1.37) 0.06 
 1101 0.059 0.039 1.54 (0.87-2.71) 0.34 
 0010 0.014 0.026 0.79 (0.36-1.73) 0.09 
 1001 0.025 0.020 1.37 (0.61-3.09) 0.12 
 0001 0.011 0.009 1.22 (0.38-3.93) 0.05 
PLA2G2A     
 000 0.639 0.647 1.00 (ref)  
 100 0.224 0.213 1.06 (0.78-1.43) 0.06 
 011 0.064 0.065 1.00 (0.61-1.64) 0.03 
 001 0.042 0.045 0.91 (0.48-1.74) 0.05 
 010 0.031 0.025 1.24 (0.60-2.56) 0.08 
ALOX15     
 000 0.684 0.690 1.00 (ref)  
 100 0.115 0.101 1.14 (0.03-8.77) 0.10 
 010 0.076 0.094 0.85 (0.03-28.7) 0.11 
 101 0.060 0.078 0.78 (0.02-33.6) 0.18 
 001 0.029 0.033 0.89 (0.00-52.4) 0.05 
 111 0.035 0.005 8.29 (0.00-112.8) 0.99 
PTGS1     
 00 0.894 0.879 1.00 (ref)  
 10 0.085 0.079 1.05 (0.69-1.58) 0.04 
 01 0.021 0.042 0.50 (0.23-1.07) 0.50 
* 0 represents major allele, 1 represents minor allele. SNP order according to table 3 
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There was an inverse association between fish consumption of once a week or more and 
colorectal cancer, as compared to less than once a week, although not statistically 
significant (OR, 0.83; 95%CI, 0.57-1.20). The distribution of fish consumption in six 
categories among incident cases and controls is shown in table 6.  
 
Table 6: Distribution of fish consumption among incident cases and controls 
Fish consumption category Cases (n=160)* Controls (n=397)*
Never 13 44 
< once a month 41 82 
1 to 3 times monthly 46 104 
Once a week 54 144 
2-4 times weekly 6 19 
> 4 times weekly 0 4 
*Three cases and two controls had missing data on fish consumption 
 
In an exploratory analysis of the interaction between genotypes and fish, divided into low 
and high consumption, no statistically significant interactions were observed. The 
homozygous minor genotypes of two SNPs in PPARδ (N163N and c.2021T>C) however, 
showed a decrease of 80% in colorectal cancer risk for those with high fish intake only, as 
compared to the major genotypes and low fish intake, although not statistically significant. A 
similar reduction in risk was observed for the pooled CA+AA genotypes of L237M in PTGS1 
and high fish consumption, as compared to the CC genotype and low fish consumption (OR, 
0.19; 95%CI, 0.03-1.45). Nearly 75% risk reduction was seen for the AG+GG genotypes of 
c.3618A>G in PTGS2 only for those with high fish intake, as compared to the AA genotype 
and low fish intake (OR, 0.26; 95%CI, 0.03-2.06) (data not shown). 
 
Discussion 
A number of associations between a variety of SNPs in PTGS2 and colorectal tumors has 
been reported (3,22,34-36). Together with the results from this study, this underlines the 
importance of this gene and the pro-inflammatory AA-pathway in the development of both 
colorectal adenomas and carcinomas. We have previously shown that the heterozygote 
genotype of SNP V102V in exon 3 of PTGS2 has a protective effect on colorectal adenomas 
(3). Even though in the present study the protective effect is only evident when two C alleles 
are present, this result can still be considered as an indication of the importance of this SNP 
in colorectal tumor risk. Just one C allele appears to be sufficient for a reduction in risk of 
colorectal adenomas of 35%, whereas for the later stages of tumor development two alleles 
are needed to confer a risk reduction of 63%. These two inverse associations make it likely 
that there is either some functional effect of this SNP, for example on splicing, or that this 
SNP is in LD with another functional variant. We have so far not been able to demonstrate 
any functionality of this SNP either in silico or experimentally. Our results however, are not in 
line with another study on PTGS2 variants in which this SNP in exon 3 was also tested and 
no association with colorectal cancer was evident (22). This study was performed in a 
Spanish population however who may have a slightly different genetic background 
compared to our Dutch cohorts, which may be one of the factors accounting for the different 
results. When we analyzed the haplotype representing the minor allele of this SNP (0100), a 
slight reduction in risk was apparent (OR, 0.85; 95%CI, 0.67-1.08). This illustrates that two 
copies of this allele are necessary to obtain the strong protective effect seen for the 
homozygous individuals. However, it must be pointed out that these haplotypes are 
estimated and not measured through parent data, which results in less reliable information. 
Although in this study the association between PTGS2 and colorectal cancer was only 
evident for a SNP in the coding region of the gene and one other study has shown an 
association between a coding SNP (V511A) and colorectal cancer (34), most other studies 
on associations between SNPs in PTGS2 and disease observed an effect for SNPs in 
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regulatory regions of the gene, indicating that the effect of PTGS2 on the development of 
colorectal tumors is due to changes in expression levels. This is in line with recent findings 
that the protective effect of NSAIDs might be due to inhibition of NF-κΒ, which is associated 
with down-regulation of PTGS2 expression (37). A SNP in the 3’UTR of PTGS2 
(c.2242T>G) has previously been associated with colorectal adenomas (3), and lung cancer 
(38,39). The involvement of this SNP in colorectal cancer however, could not be 
demonstrated in this study. A possible explanation could be that this SNP is only important 
in the early stages of tumor formation but does not play a role in the development from 
polyps to malignant colorectal tumors. This is in line with another study in which no 
association was found between this 3’UTR SNP and colorectal cancer (22). In this same 
study, a rare SNP in the 3’UTR (c.3618A>G) did show a positive association between the 
minor allele and colorectal cancer risk. This association was not observed in this study. Our 
results even suggest an inverse relation between the minor allele and cancer risk (OR, 0.56; 
95%CI, 0.29-1.06). However, the low minor allele frequency of this SNP (0.02 in controls) 
and therefore the small number of subjects with the minor genotypes might result in chance 
findings. Several studies have investigated the role of SNPs in the promoter of PTGS2 in 
disease risk and several associations have been found (35,36,40-43), indicating direct 
involvement of changes in gene expression on disease etiology. Some null results however, 
have also been reported (22,44). 
We did not find associations between any other SNP and colorectal cancer. The effects we 
have previously shown for genotypes and haplotypes of SNPs in PPARγ, PLA2G2A and 
ALOX15 on adenomas (3) could not be demonstrated in this study on adenocarcinomas. 
This could be due to the difference in study populations, adenoma versus colorectal cancer 
patients, indicating that the SNPs and these genes may only affect the first stages of tumor 
development. Since approximately 5% of adenomas develop further into malignant tumors, 
the association found for adenoma risk might not be evident when the endpoint is 
adenocarcinomas. This is in line with an inverse association found between SNP P12A in 
PPARγ and colorectal adenomas (45). However, the association was stronger for more 
advanced adenomas, and moreover, an inverse association was observed in a colorectal 
cancer population for the minor allele of this SNP (46), although this is not confirmed by our 
data. No clear data is available about the exact stage of tumor development in which 
PLA2G2A and ALOX15 play a role, but our data suggests that they may be most important 
in the early stages. 
We hypothesized that increased fish consumption, as a proxy of n-3 fatty acid intake, can 
influence the risk of colorectal cancer by modulation of the AA-pathway. We found an 
inverse association, although not statistically significant, between fish consumption and 
colorectal cancer (OR, 0.83; 95%CI, 0.57-1.20) for subjects with fish consumption of once a 
week or more frequent as compared to less than once a week. This is in line with a strong 
protective effect of increased fish consumption shown recently in a large European study 
(20). This association between fish consumption and colorectal cancer might be modified by 
polymorphisms in genes involved in the conversion of free fatty acids into prostaglandins. 
We have previously demonstrated the association between SNPs in PPARδ and PTGS2 
and fish consumption in relation to colorectal adenomas (3). In this study however (using 
only the PPHV cohort), we have not been able to show any statistically significant 
interactions with any SNP and fish consumption, even though some substantial reductions in 
cancer risk were observed. This might be the cause of insufficient statistical power due to 
the relatively small population size. There are also some other possible explanations for the 
lack of significant interactions. First, the consumption of fish might be too low in our 
population to be able to measure an effect. We considered fish consumption of once a week 
or more as high fish intake. A large study on the effect of fish consumption on prostate 
cancer detected an inverse association for four or more servings of fish a week, which was 
statically significant (47). Second, the associations were calculated for total fish intake, 
because no distinction was made between the different types of fish in the food frequency 
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questionnaire. If n-3 fatty acids are considered the bioactive agents in fish, it is likely that fish 
high in n-3 fatty acids, for example salmon, mackerel and herring, are more strongly 
associated with cancer than lean fish like cod and haddock. Also, other sources of n-3 fatty 
acids that have not been considered in the analysis since no data was available, can 
influence the results. It has also been suggested that a low ratio n-6/n-3 fatty acids is more 
important than the total amount of n-3 fatty acids (21,48), confirmation of which is awaiting 
ongoing FA analysis. 
Our PPHV cohort included both incident and prevalent cases. We repeated the analysis for 
genotypes with only incident cases, but this did not change our results. However, prevalent 
cases might have changed their dietary habits after the first time they developed cancer, 
therefore these cases where excluded in the gene-diet interaction analysis.  
Consideration must be given to some potential limitations of the study. First, the use of self-
administered questionnaires can give rise to uncertainties, especially since the answer 
categories were limited to six options. The dietary intake data is therefore less accurate than 
when a more open questionnaire is used. Measurements of specific fatty acid content in 
plasma samples might be more accurate, and is currently ongoing. Second, for the gene-
diet interactions several potential confounders were tested. None of the variables tested 
effected the association, but it cannot be ruled that other factors for which no data was 
collected could cause confounding. Third, the lack of interaction between the SNPs tested 
and fish consumption does not rule out any interaction between these genes and fish 
consumption. It is possible there are other SNPs present in the genes, that have low minor 
allele frequencies and have therefore not been tested in this study, that modify the 
association. Fourth, we were not able to investigate gene-gene interactions due to small 
sample size, therefore associations between a combination of SNPs within two genes and 
colorectal cancer would not have been detected by our study if the effect of the single SNPs 
were negligible. Fifth, due to the small sample size, which is especially the case for the fish 
consumption data, there is a substantial lack of power to detect interactions. This is also the 
case for some main effects when allele or haplotype frequencies are low. And last, chance 
findings can never be excluded, especially when multiple testing is considered. However, we 
opted not to correct for multiple testing, since at this stage and with this sample size 
Bonferroni corrections were considered punitively conservative (49). 
In conclusion, we have confirmed a previously found inverse association between SNP 
V102V in PTGS2 and colorectal adenomas, in this study on colorectal cancer. Although the 
association between increased fish consumption and colorectal cancer was inverse, there 
were no statistically significant interactions between the SNPs investigated and fish 
consumption.  
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 Appendix 
 
Table 1: Primer sequences of two additional SNPs 
Gene/SNP rs number  Strand Sequence (5’-3’) 
ALOX15  c.136-37G>A rs11568141  Forward cccgatacgtctcctcctct 
  Reverse tccggtacttccaccttgag 
PTGS2   c.3618A>G rs4648298  Forward ttcttttccacatctcattgtca 
  Reverse tcagagaggtaaccccaaagaa 
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Abstract 
Dietary polyunsaturated fatty acids (PUFAs) may influence the etiology of colorectal tumors. 
It is believed that n-3 PUFAs, derived mainly from fish, are anti-carcinogenic and are 
associated with a decreased risk of colorectal cancer, whereas n-6 PUFAs are not. Single 
nucleotide polymorphisms (SNPs) in genes involved in fatty acid metabolism, including 
cyclooxygenases (COX) and peroxisome proliferator-activated receptors (PPAR) may 
modify these associations. Therefore we evaluated fatty acid-SNP associations in colorectal 
adenoma risk in a case-control study with 344 cases and 397 endoscopy controls. 
Linoleic acid (LA) as well as total n-6 PUFAs was positively associated with colorectal 
adenomas. The odds ratio (OR) of the third tertile (T3) was 1.69 (95% confidence interval 
(CI), 1.09-2.61) for total n-6 PUFAs and 1.78 (95%CI, 1.15-2.76) for LA as compared to the 
first tertile (T1), with a statistically significant trend (0.02 and 0.008 respectively). Total n-3 
PUFAs were inversely, although not statistically significantly associated with colorectal 
adenomas, (OR and 95% CI T3 versus T1: 0.71; 0.46-1.10). Results for EPA and DHA 
separately were similar. The ratio of total n-6/n-3 PUFAs was not associated with colorectal 
adenoma risk. None of the SNPs tested modified these associations. 
In conclusion, our results suggest that increased serum LA levels increase colorectal 
adenoma risk. Increased EPA, DHA and total n-3 PUFA content may decrease adenoma 
risk. Interactions of other pathways with the arachidonic acid pathway may explain these 
observations. 
 
 
Introduction 
Colorectal cancer is the second leading cause of death due to cancer in the Western world 
(1). Differences in geographic incidence rates suggest that environmental influences play an 
important role. Besides a high consumption of red or processed meat, saturated fat was 
previously hypothesized to increase colorectal cancer risk (2,3). More recently, it was 
suggested that the dietary intake of polyunsaturated fatty acids (PUFAs) may be more 
important (4). Long chain PUFAs, in particular n-3 PUFAs, can inhibit carcinogenesis and 
reduce the risk of colorectal cancer (5). N-3 PUFAs are obtained mainly through the intake 
of fish in the form of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), but 
they are also present in some vegetable oils including flaxseed and soybean oil mainly as α-
linolenic acid (ALA). N-6 PUFAs are present in eggs and meat, predominantly in the form of 
linoleic acid (LA), although they also contain arachidonic acid (AA) (6,7).  
Dietary PUFAs are converted by elongases and desaturases in a pathway known as the 
arachidonic acid (AA) pathway, into eicosanoid precursors, the n-6 AA and the n-3 EPA. 
These are in turn converted into prostanoids (PG) and leukotriens (LT) utilizing 
cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. The n-6 PUFA derived 
eicosanoids are in general pro-inflammatory and are associated with tumor progression, 
whereas the n-3 derived eicosanoids are thought to contain anti-inflammatory properties (8). 
There are several proposed mechanisms by which n-3 PUFAs can exert their protective 
effect on tumor formation, as reviewed by Larsson et al. (5). One of the major mechanisms 
leads to the suppression of n-6 PUFA derived eicosanoids. Higher intake of n-3 PUFAs 
compared to the n-6 variety would mean a decrease in available AA for eicosanoid 
production through the incorporation of the n-3 PUFAs into membrane phospholipids (9). 
This effect is further enhanced by competition between n-3 and n-6 PUFAs for the 
elongases and desaturases that convert these PUFAs, since n-3 PUFAs have a higher 
affinity for these enzymes (8). N-3 PUFAs can also directly inhibit COX2 (also known as 
prostaglandin-endoperoxide synthase-2 PTGS2), one of the key enzymes in the AA pathway 
(10,11) and compete with n-6 PUFAs for COX2 to form prostanoids (12).  
We have previously shown that, although fish consumption did not significantly decrease 
colorectal adenoma risk, it did interact with a number of SNPs in genes involved in the AA-
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pathway, thereby modulating the risk (13). We therefore used the previously genotyped 
twenty-one SNPs in seven genes involved in the AA pathway in a case-control study using 
patients with colorectal adenomas (13), and considered the modifying effect of these 
genotypes on the association between serum cholesterylester n-3 fatty acid composition as 
a proxy for fish consumption as well as serum cholesteryl n-6 fatty acids and colorectal 
adenomas. 
 
 
Materials and Methods 
Study population 
A retrospective case-control study was conducted in the Netherlands, between 1997 and 
2001. The study design has been previously described (14,15). In short, this case-control 
study was designed to examine the association between various dietary and other lifestyle 
factors, genetic susceptibility and colorectal adenomas. All participants underwent 
endoscopy in one of ten participating hospitals because of routine screening for colorectal 
adenomas or gastrointestinal complaints. Cases had one or more adenomas at index 
endoscopy or in their past. Controls had no adenomas at index endoscopy, nor ever in their 
past. 
The total study population included 1,477 subjects (16). The study was approved by the 
Medical Ethical Committees of all participating hospitals and all participants provided written 
informed consent. 
 
Data collection 
Information about dietary habits was obtained using a validated food-frequency 
questionnaire (17,18). Participants were requested to recall their dietary and lifestyle habits 
of the year previous to their last endoscopy. Information on demographic and lifestyle 
factors, like smoking habits, physical activity level (19) and family history, was obtained from 
a self-administered questionnaire. 
The intake of total energy and of various nutrients from this questionnaire was calculated 
with a computerized Dutch food composition table. 
 
Serumcholesteryl fatty acid analysis 
Non-fasting venous blood samples were obtained for measurement of serum cholesteryl 
esters. Serum was obtained by low-speed centrifugation for 10 minutes. Serum samples 
were stored within 2 h at -80°C until analysis. 
Serum cholesterylester fatty acids were analyzed largely as described previously (20). Three 
ml of isopropanol and 1.0 ml of distilled water were added to 0.65 ml serum. After mixing, 3 
ml of n-octane was added. After centrifugation for 5 min at 1580g the (upper) octane layer 
was removed and evaporated to dryness in a stream of nitrogen. The residue was 
redissolved in hexane/diethyl ether (39:1 v/v%) and cholesterylesters were selectively eluted 
from a 500 mg silicacolumn using hexane/diethylether (39/1 v/v%) as eluens. The 
cholesteryl esters were redissolved in 0.5 ml chloroform and methylated with 4 ml 4% H2SO4 
in methanol for 1h at 90°C. One ml distilled water and 0.5 ml hexane, containing 0.25 mg 
butylated hydroxytoluene per ml, were added and the mixture was shaken for 2 min. After 
centrifugation for 3 min at 1580g the hexane layer was removed for analysis. The fatty acid 
methylesters were separated by gas chromatography (Hewlett Packard 5890), using a 25 m 
WCOT fused silica column (inside diameter 0.25 mm) coated with 0.2 µm CP Wax 58 
(Chrompack, Middelburg, The Netherlands), using splitless injection. The injection volume 
was 0.5 µl. Hydrogen was used as carrier gas at a flow of 1.5 ml/min. The oven temperature 
was programmed to rise first from 60 °C to 180°C at a rate of 30°C/min, followed by a rise at 
a rate of 1.2°C/min to 215°C, thereafter at a rate of 40°C/min to 245°C. Total run time was 
45 minutes. The temperature of the injector was 275°C and that of the hydrogen flame 
ionisation detector was 265°C. Peak areas were measured with GC Chemstation software 
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(Rev. A.09.03, Agilent  Technologies, Palo Alto, CA, USA). Fatty acids were identified by 
comparison with known standards (Chrompack, Middelburg, the Netherlands). Ten % of all 
samples were analyzed in duplicate.  To monitor analytical performance over time, a serum 
control sample was analyzed in duplicate in each run. Within-run and between-run 
coefficients of variation were respectively 2.4% and 2.4% for LA, 6.2% and <1% for ALA, 
3.0% and 2.2% for AA, 3.8% and 3.7% for EPA, and 5.1% and 2.9% for DHA. 
 
Genetic analysis 
SNP selection and genotyping of twenty-one SNPs in PLA2G2A, PLA2G4A, PTGS1, 
PTGS2, ALOX15, PPARδ and PPARγ have been described previously (13). In short, 
genotyping of the SNPs was carried out using a technique known as PyrosequencingTM (21) 
with a biotinylated single stranded PCR product. Primers for each SNP are described 
previously (13) Sequence primers for the pyrosequence reaction were designed using 
software available online (21). SNPs were determined using DNA from 808 randomly 
selected participants from the case-control study. Genotyping failed in one of these DNA 
samples. 
 
Statistical analysis 
Serum of 66 participants was not available for fatty acid analysis, therefore data analysis 
included 741 participants, 344 cases and 397 controls. 
From all fatty acids analyzed, the median of the percentage in cholesterol esters and 
interquartile range was calculated for cases and controls separately. Differences between 
cases and controls were determined with a T-test. 
Odds ratios (Ors) for the presence of colorectal adenomas and 95% confidence intervals 
(95% Cis) were estimated for total n-6 PUFAs, total n-3 PUFAs, n-6/n-3 ratio, LA, ALA, AA, 
EPA and DHA by using the lowest tertile of the fatty acid in question as a reference group. 
For this the values were divided into tertiles according to the distribution among controls.  
The variables age, BMI, family history of colorectal cancer, gender, indication of endoscopy, 
insulin use, physical activity, education level, smoking, NSAID use, daily energy intake and 
intake of alcohol, calcium, fiber, fruit, red meat, poultry, processed meat, vegetables, β-
carotene, vitamin C and vitamin E were considered as potential confounding factors. 
Besides the variables age and gender, also indication for endoscopy and alcohol 
consumption were included in the model, since only these factors changed the β-estimates 
by more than 10%. 
To test for linear trend, we modeled the tertile of fatty acid content as a continuous variable 
in the logistic regression model, in which each tertile was assigned its median value.  
Risk estimates stratified for genotypes, were calculated with separate genotypes where 
possible, with the lowest tertile in combination with the homozygote major allele of the SNP 
of interest considered as reference group. If the numbers were insufficient heterozygote and 
homozygote minor genotypes were pooled. To test whether the combination of genotypes 
and fatty acid content deviated from multiplicativity, we calculated p-values for interaction by 
inclusion of a numerical term for genotype, multiplied by total or specific fatty acid content as 
a continuous variable into our multivariate models. 
The analyses were conducted using Statistical Analysis Software (SAS) for Windows, 
version 8.2 (SAS institute, Cary, NC). 
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Results 
Characteristics of cases and controls are shown in table 1. Cases and controls were similar 
with respect to family history of colorectal cancer, total energy intake and fish consumption. 
The variables age and gender differed among cases and controls. The median age for 
cases was 59.1 and for controls 50.9, and 53.2% of cases was female versus 37.6% of 
controls. With regard to the fatty acid analysis, significant differences between cases and 
controls were seen for the rare fatty acids C16:2n-4, C18:3n-6 (γ-linolenic acid) and C22:5n-
3 (docosapentaenoic acid). A more detailed description of the study population 
characteristics was published previously (14,15).  
 
Table 1: Characteristics of study population 
Characteristic Common name Cases (n=344) Controls (n=397) 
Female (%)  46.8a 62.4 
Age (mean ± SD)  59.1a ± 10.5 50.9 ± 14.0 
Family history of CRC b (%)  23.8 18.6 
 
Dietary intake (mean ± SD) 
   
   Energy (KJ/day)  8779 ± 2431 8681 ± 2600 
   Fish (g/day)  10.82 ± 9.90 11.31 ± 11.55 
 
PUFAs c (median ± SD) 
   
   n-3 PUFAs  1.98 ± 0.74 1.94 ± 0.74 
     C18:3n-3 α-Linolenic acid 0.52 ± 0.18 0.51 ± 0.18 
     C20:5n-3 Eicosapentaenoic acid 0.85 ± 0.54 0.81 ± 0.55 
     C22:5n-3 Docosapentaenoic acid 0.00 ± 0.03 d 0.00 ± 0.03 
     C22:6n-3 Docosahexaenoic acid 0.57 ± 0.19 0.56 ± 0.20 
   n-6 PUFAs  62.28 ± 4.62 61.85 ± 4.31 
     C18:2n-6 Linoleic acid 53.13 ± 5.17 52.92 ± 4.99 
     C18:3n-6 γ-Linolenic acid 0.98 ± 0.37 d 0.92 ± 0.36 
     C20:3n-6 Dihomo-γ-Linolenic acid 0.77 ± 0.17 0.79 ± 0.18 
     C20:4n-6 Arachidonic acid 6.99 ± 1.53 7.04 ± 1.61 
   n-6/n-3 ratio  31.28 ± 11.72 31.48 ± 12.35 
 
Other Fas c (median ± SD) 
   
     C15  0.17 ± 0.05 0.16 ± 0.05 
     C16  Palmitic acid 11.09 ± 0.87 11.04 ± 0.84 
     C16:1  Palmitoleic acid 3.00 ± 1.43 2.98 ± 1.51 
     C16:2n-4  0.00 ± 0.03 d 0.00 ± 0.04 
     C16:3n-4  0.26 ± 0.15 0.25 ± 0.16 
     C17  Margaric acid 0.10 ± 0.05 0.10 ± 0.06 
     C18 Stearic acid 0.81 ± 0.17 0.79 ± 0.18 
     C18:1n-9 Oleic acid 16.53 ± 2.29 16.84 ± 2.17 
     C18:1n-7 Vaccenic acid 1.00 ± 0.25 1.03 ± 0.25 
     C20:1n-9 Gadoleic acid 0.15 ± 0.06 0.16 ± 0.06 
a p<0.001, chi square for gender, t-test for age 
b Colorectal cancer 
c % of total cholesterol esters 
d p<0.05 t-test 
 
The association between total and specific fatty acid composition and colorectal adenomas 
is shown in table 2. There was an increase in adenoma risk with increasing 
serumcholesteryl LA content. The OR reached 1.78 (95%CI, 1.15-2.76) in the third tertile 
(T3) of LA content as compared to the first tertile (T1), with a statistically significant trend 
towards increased risk. In accordance with this, total n-6 PUFA content showed a positive 
association with adenomas, with the OR in T3 reaching 1.69 (95%CI, 1.09-2.61), and a 
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statistically significant trend. AA content in cholesterol ester fractions was not associated 
with colorectal adenoma risk.  
Total n-3 PUFAs were inversely, although not statistically significantly associated with 
colorectal adenomas, the OR for those in T3 was 0.71 (95% CI 0.46-1.10) as compared to 
T1. There was no statistically significant trend towards decreased risk. Both EPA and DHA 
content were inversely associated with adenoma risk, although not statistically significant. 
There was a reduced risk of colorectal adenomas of about 25 to 30% for those in the second 
and third tertile of EPA content, as compared to the first tertile. The third tertile of DHA 
content reached 0.67 (95%CI, 0.43-1.04), as compared to T1. The association between 
serum n-3 PUFAs and colorectal adenomas was seen for both sexes, although it was 
somewhat stronger in women than in men (data not shown). ALA content was not 
statistically significantly associated with adenoma risk, although a moderate increase in risk 
with increasing ALA content was observed (OR T3 vs T1, 1.35; 95%CI, 0.88-2.07. A similar 
result is shown for the n-6/n-3 ratio (OR T3 vs T1, 1.36; 95%CI, 0.88-2.11). Our study 
population included both incident and prevalent cases. Since prevalent cases might have 
changed their diet after first diagnosis of cancer, we repeated the analysis with incident 
cases only, but this did not change the results (data not shown). 
 
Table 2: Serum fatty acids and colorectal adenoma risk 
 Fatty acid tertile  
 T1  T2  T3   
Fatty acid Cases/ 
controls 
OR (95%CI)a Cases/ 
controls 
OR (95%CI) a Cases/ 
controls 
OR (95%CI) a p for 
trend 
  LA 111/133 1.00 (ref) 106/131 1.08 (0.68-1.70) 127/133 1.78 (1.15-2.76) 0.008 
  AA 114/132 1.00 (ref) 110/133 0.97 (0.63-1.50) 120/132 0.99 (0.65-1.52) 0.98 
n-6 PUFAs 105/133 1.00 (ref) 108/131 1.22 (0.78-1.91) 131/133 1.69 (1.09-2.61) 0.02 
        
  ALA 98/133 1.00 (ref) 126/129 1.14 (0.73-1.76) 120/135 1.35 (0.88-2.07) 0.17 
  EPA 100/133 1.00 (ref) 109/132 0.73 (0.47-1.13) 135/132 0.69 (0.44-1.08) 0.12 
  DHA 108/133 1.00 (ref) 123/131 0.88 (0.57-1.35) 113/133 0.67 (0.43-1.04) 0.07 
n-3 PUFAs 107/132 1.00 (ref) 105/132 0.62 (0.40-0.98) 132/133 0.71 (0.46-1.10) 0.16 
        
n-6/n-3 ratio 134/132 1.00 (ref) 95/132 0.83 (0.53-1.30) 115/133 1.36 (0.88-2.11) 0.11 
a Multivariate adjustment for age, gender, indication of endoscopy and alcohol consumption. 
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The association between total n-3 PUFAs, total n-6 PUFAs,  and colorectal adenomas, 
stratified for genotype of SNPs in genes previously shown to interact with fish consumption, 
is shown in tables 3 and 4 respectively. There were no statistically significant interactions 
between any of the SNPs genotyped and any of the fatty acids analyzed. 
 
Table 3: Serum n-3 level and colorectal adenoma risk stratified for genotypes of SNPs in 
PPARδ and PTGS2 
 Total n-3 serum levela  
 T1  T2  T3   
Genotype Cases/ 
controls 
OR (95%CI)b Cases/ 
controls 
OR (95%CI)b Cases/ 
controls 
OR (95%CI)b p for 
trend 
PPARδ        
  c.-789C>T        
    CC 97/111 1.00 (ref) 93/117 0.59 (0.37-0.94) 110/118 0.68 (0.43-1.06) 0.11 
    CT+TT 7/10 0.81 (0.22-2.97) 8/9 0.76 (0.24-2.42) 13/13 0.71 (0.27-1.90) 0.35 
p for interaction       0.97 
  N163N        
    TT 73/77 1.00 (ref) 66/82 0.54 (0.31-0.93) 74/84 0.57 (0.33-0.98) 0.08 
    TC 29/48 0.53 (0.26-1.05) 35/46 0.41 (0.20-0.83) 45/45 0.54 (0.28-1.03) 0.60 
    CC 7/8 0.82 (0.24-2.86) 5/4 0.52 (0.09-2.96) 9/3 1.29 (0.28-6.05) 0.85 
p for interaction       0.42 
  c.2021T>C        
    TT 72/80 1.00 (ref) 71/84 0.60 (0.35-1.03) 79/89 0.61 (0.36-1.05) 0.14 
    TC+CC 37/52 0.66 (0.35-1.26) 35/47 0.38 (0.19-0.78) 50/43 0.59 (0.31-1.15) 0.57 
p for interaction       0.44 
  c.2589G>A        
    GG 98/122 1.00 (ref) 98/117 0.65 (0.41-1.04) 117/116 0.73 (0.46-1.15) 0.25 
    GA+AA 11/11 1.05 (0.35-3.11) 8/15 0.29 (0.09-0.96) 12/16 0.54 (0.21-1.43) 0.11 
p for interaction       0.81 
  c.2806C>G        
    CC 80/92 1.00 (ref) 74/95 0.58 (0.35-0.96) 85/103 0.59 (0.36-0.97) 0.08 
    CG+GG 27/41 0.63 (0.31-1.25) 29/34 0.46 (0.21-0.99) 41/27 0.74 (0.36-1.52) 0.85 
p for interaction       0.29 
PTGS2        
  c.-1329A>G        
    AA 67/83 1.00 (ref) 64/85 0.55 (0.32-0.97) 65/83 0.57 (0.33-0.99) 0.03 
    AG 33/41 1.16 (0.60-2.24) 33/39 0.78 (0.40-1.50) 50/40 1.06 (0.57-1.94) 0.92 
    GG 7/6 1.45 (0.36-5.87) 4/4 0.66 (0.12-3.76) 9/6 1.28 (0.35-4.69) 0.33 
p for interaction       0.74 
  V102V        
    GG 79/95 1.00 (ref) 73/79 0.77 (0.45-1.31) 95/91 0.82 (0.49-1.35) 0.28 
    GC 24/33 1.07 (0.52-2.19) 32/46 0.46 (0.23-0.91) 29/38 0.49 (0.24-1.00) 0.30 
    CC 6/5 1.92 (0.36-9.15) 1/7 0.11 (0.01-2.26) 5/3 1.20 (0.22-6.49) 0.34 
p for interaction       0.64 
  c.2242T>C        
    TT 42/59 1.00 (ref) 43/66 0.49 (0.25-0.94) 54/67 0.56 (0.29-1.05) 0.20 
    TC 58/58 1.02 (0.55-1.90) 53/52 0.83 (0.44-1.59) 61/50 0.92 (0.49-1.73) 0.74 
    CC 8/12 1.01 (0.33-3.13) 9/13 0.42 (0.12-1.52) 11/13 0.51 (0.16-1.65) 0.11 
p for interaction       0.84 
a Tertiles of total n-3 level as percentage of total cholesterol esters: 0.62-1.71, 1.71-2.14 and 2.14-7.63. 
b Multivariate adjustment for age, gender, indication of endoscopy and alcohol consumption. 
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Table 4: Serum n-6 level and colorectal adenoma risk stratified for genotypes of SNPs in 
PPARδ and PTGS2 
 Total n-6 serum levela  
 T1  T2  T3   
Genotype Cases/ 
controls 
OR (95%CI)b Cases/ 
controls 
OR (95%CI)b Cases/ 
controls 
OR (95%CI)b p for 
trend 
PPARδ        
  c.-789C>T        
    CC 94/113 1.00 (ref) 89/120 1.13 (0.71-1.80) 117/113 1.68 (1.08-2.63) 0.02 
    CT+TT 6/13 0.41 (0.11-1.61) 15/7 2.68 (0.98-7.37) 7/12 1.18 (0.34-4.08) 0.03 
p for interaction       0.72 
  N163N        
    TT 64/81 1.00 (ref) 64/83 1.11 (0.63-1.94) 85/79 1.66 (0.97-2.84) 0.07 
    TC 32/46 0.53 (0.25-1.12) 38/44 1.13 (0.58-2.18) 39/49 1.14 (0.59-2.22) 0.08 
    CC 8/6 1.43 (0.35-5.90) 6/4 2.21 (0.55-8.90) 7/5 1.28 (0.28-5.74) 0.95 
p for interaction       0.64 
  c.2021T>C        
    TT 66/83 1.00 (ref) 70/89 1.17 (0.68-2.01) 86/81 1.68 (0.99-2.85) 0.07 
    TC+CC 39/50 0.61 (0.30-1.22) 38/42 1.16 (0.60-2.24) 45/50 1.20 (0.63-2.27) 0.10 
p for interaction       0.16 
  c.2589G>A        
    GG 99/116 1.00 (ref) 95/119 1.23 (0.77-1.98) 119/120 1.59 (1.01-2.52) 0.05 
    GA+AA 6/17 0.32 (0.09-1.21) 13/12 1.26 (0.49-3.23) 12/13 1.32 (0.45-3.84) 0.01 
p for interaction       0.68 
  c.2806C>G        
    CC 71/98 1.00 (ref) 77/96 1.24 (0.75-2.05) 91/96 1.60 (0.97-2.62) 0.04 
    CG+GG 34/32 0.94 (0.45-1.97) 29/33 1.20 (0.58-2.48) 34/37 1.14 (0.57-2.30) 0.72 
p for interaction       0.51 
PTGS2        
  c.-1329A>G        
    AA 55/84 1.00 (ref) 62/86 1.44 (0.81-2.55) 79/81 2.07 (1.18-3.63) 0.01 
    AG 42/39 2.05 (1.07-3.94) 36/41 1.92 (0.98-3.76) 38/40 2.18 (1.11-4.31) 0.96 
    GG 4/5 0.96 (0.18-5.11) 7/3 3.74 (0.69-20.2) 9/8 3.11 (0.92-10.5) 0.13 
p for interaction       0.47 
  V102V        
    GG 75/89 1.00 (ref) 83/80 1.54 (0.91-2.62) 89/96 1.47 (0.87-2.47) 0.18 
    GC 24/39 0.61 (0.29-1.31) 24/44 0.61 (0.28-1.33) 37/34 1.73 (0.89-3.38) 0.03 
    CC 6/5 1.62 (0.34-7.70) 1/7 0.96 (0.17-5.42) 5/3 1.59 (0.15-17.4) 0.88 
p for interaction       0.92 
  c.2242T>C        
    TT 47/67 1.00 (ref) 38/64 0.88 (0.45-1.72) 54/61 1.75 (0.94-3.26) 0.07 
    TC 47/50 1.22 (0.63-2.34) 57/59 1.72 (0.94-3.17) 68/51 2.10 (1.13-3.90) 0.14 
    CC 9/15 0.52 (0.14-1.96) 12/6 2.90 (0.86-9.82) 7/17 0.92 (0.30-2.81) 0.29 
p for interaction       0.86 
a Tertiles of total n-6 level as percentage of total cholesterol esters: 45.9-60.1, 60.1-63.4 and 63.4-79.6. 
b Multivariate adjustment for age, gender, indication of endoscopy and alcohol consumption. 
 
 
Discussion 
In this case-control study, LA and total n-6 PUFAs were positively associated with colorectal 
adenomas. Total n-3 PUFAs and EPA and DHA separately were inversely associated with 
colorectal adenomas, although not statistically significant. None of the SNPs tested modified 
these associations. 
We found that individuals with an increased LA and total n-6 PUFA content, but not 
increased AA content, have an increased risk of colorectal adenomas. Previous findings on 
the relation between n-6 PUFAs such as LA and AA and colorectal carcinogenesis have 
been inconsistent. While our results are in line with most studies showing an increased risk 
of colorectal adenomas for those with a high n-6 PUFA dietary intake (22), other studies 
have reported no effect or even a tumor inhibiting effect of increased dietary LA (23), and n-
6 PUFA levels in serum (24), and in in vitro studies a pro-apoptotic effect of AA has been 
shown (25). Our results show that increased AA content does neither reduce nor increase 
the risk of colorectal adenomas, but rather that its precursor LA might have a stimulating 
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effect on tumor formation. This suggests that additional pathways besides the AA pathway 
may be involved in the pro-carcinogenic effect of LA. This is in line with findings that LA 
intake of over 2.5% of total energy, which is below the typical average of 5-6% of energy, 
does not result in increased conversion to AA and PGs due to saturation of Δ-6 desaturase, 
the rate limiting enzyme in this pathway (26). Therefore the level of AA would not change 
much as a consequence of changes in LA intake. What other biochemical pathway might 
involve LA in tumor formation remains to be elucidated, but several other pathways have 
been indicated, including pathways involved in cellular proliferation, apoptosis, angiogenesis 
and metastasis (5).  
 
Our results indicate that increased n-3 PUFA content, in particular EPA and DHA content 
decreases the risk of colorectal adenomas. As with n-6 PUFAs, studies with n-3 PUFAs 
have been inconsistent. Some epidemiological studies that have investigated the 
association between fish consumption as a proxy for n-3 PUFA intake and cancer found 
inverse associations (27-30), while others have not (31-33). In studies using nutrient 
calculations from food frequency questionnaires from which n-3 PUFA intake is deduced, 
the same inconsistency is observed. One case-control study showed an inverse association 
between n-3 PUFA intake and colorectal cancer (34), whereas two studies showed no 
association (35,36). Only one recent prospective study has used actual serum 
measurements of fatty acids to investigate associations with colorectal cancer, and found an 
inverse association between total n-3 PUFA, EPA and DHA content and colorectal cancer, 
although only in women (24). This selective effect on women was also seen in a study 
where n-3 PUFA intake was calculated from a food frequency questionnaire (34).  
Several animal and in vitro studies indicate more consistently that n-3 PUFAs suppress the 
development of cancer, as reviewed by Roynette et.al (6). It has been shown that 
supplementation of the diet with fish oil decreases tumor number in animals with chemically 
induced colorectal tumors (37) as well as in mouse models of intestinal cancer (ApcMin and 
ApcΔ716) (38,39). N-3 PUFAs have also been shown in cancer cell lines to induce apoptosis 
and suppress cell growth (40,41). In human subjects, supplementation with fish oils 
containing n-3 PUFAs in patients with sporadic adenomatous polyps resulted in reduced 
intestinal hyperproliferation (42,43). These data taken together suggest a protective role of 
n-3 PUFAs against colorectal tumorigenesis, which is in line with our results. Our study did 
not show a significant effect of n-6/n-3 ratio on colorectal adenoma risk. Although a 
protective effect of a high ratio of n-3 fatty acids to AA in adipose tissue on colorectal 
adenomas has been shown previously(44), our result is in line with a large study in which 
fatty acid intake was calculated from a food frequency questionnaire and no protective effect 
of a high n-3/n-6 ratio was demonstrated (45).  
It is hypothesized that n-3 and n-6 PUFAs have an effect on colorectal tumor formation via 
modulation of the AA pathway, by changing the substrates and products or by a direct effect 
on the genes involved in this pathway. We tested whether any of the fatty acids analyzed 
interacted with one or more of the twenty-one SNPs in genes involved in the AA pathway, 
and found that there were no statistically significant interactions at all (data not shown). This 
might point to interaction with other pathways that utilize n-3 PUFAs in addition to the AA 
pathway, for example activation of PPARγ (46), inhibition of NF-κΒ activation (47) or 
lowering of ras oncogene activation (48). However, although none of the SNPs analyzed 
interacted with n-3 PUFAs in modulating colorectal adenoma risk, there might be rare SNPs 
in the same genes with detrimental effects that could interact with the fatty acids (49). Also 
decreased statistical power due to stratification by genotypes might be a reason for not 
reaching statistical significance, although no trend was observed. 
We have previously shown that SNPs in genes in the AA pathway interact with fish 
consumption modulating cancer risk. We found that the estimates of fish consumption based 
on the food frequency questionnaires were properly reflected by the n-3 fatty acid 
composition of analyzed sera. Although the Pearson correlation coefficients were relatively 
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low, they were statistically significant (data not shown). We hypothesized that n-3 PUFAs in 
fish were the bioactive compounds in this interaction. Our result with n-3 PUFAs however, 
do not confirm this and indicate that there may be other bioactive compounds in fish that 
interacts with AA pathway genes. A candidate for this could be vitamin D which is also 
abundant in fatty fish, and for which compelling epidemiological and experimental evidence 
is accumulating regarding its cancer protective effects (50,51). In its active form, 
1,25(OH)2D3, it restrains cell proliferation and induces apoptosis and cell differentiation, the 
latter by interfering with β-catenin signaling (52). 
In conclusion, our results indicate that increased LA but not AA content might increase 
colorectal adenoma risk. Increased EPA, DHA and total n-3 PUFA content might decrease 
adenoma risk. Although n-3 PUFA content can act as a proxy for fish consumption, n-3 
PUFAs do not interact with SNPs in AA pathway genes in the same way as fish 
consumption does, indicating the involvement of other pathways and possibly the 
involvement of another active agent in fish.  
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Abstract 
Epidemiological and animal studies have suggested that a high ratio of n-3 fish fatty acids to 
Arachidonic acid (AA), might protect against colorectal carcinogenesis. Competition of n-3 
and n-6 fatty acids, especially AA, for the enzyme cyclooxygenase-2 may be responsible for 
this effect. 
To examine the relation between fish intake and colorectal adenomas, data from a Dutch 
case-control study were analysed. All 52 cases and 57 controls filled out a food 
questionnaire, underwent a full colonic examination and have had a fat biopsy from the 
buttock.  
Intake of fish and fish fatty acids was inversely associated with colorectal adenomas 
although not statistically significant. For the ratio of fish fatty acids to AA, the Ors in the 
second and third tertile were 1.2 and 0.8 (p-trend = 0.78). 
Tissue levels of fish fatty acids were inversely associated and tissue levels of AA were 
positively associated with adenomas, although not statistically significant. However, the OR 
for the ratio of fish fatty acids to AA was 0.2 in the second and third tertile (p-trend = 0.002)). 
In line with the hypothesis, a high ratio of fish fatty acids to AA in adipose tissue was 
associated with a lower risk of colorectal adenomas.   
 
 
Introduction 
Both epidemiological and experimental studies suggest that consumption of fish and fish oil 
correlates with a reduced risk of colorectal cancer. Ecological studies show that Alaskan and 
Greenland Eskimos have a lower incidence of colorectal cancer than other North Americans 
(1). Furthermore some coastal populations have a lower incidence of colorectal cancer 
compared to urban dwellers (2), and a report from 24 European countries shows an inverse 
relation between fish consumption and colorectal cancer risk (3). All these ecological 
observations might be attributed to high consumption of marine food rich in n-3 
polyunsaturated fatty acids. 
In case-control and cohort studies evidence that fish reduces the risk of colon cancer is less 
clear, probably due to the low range in fish consumption and inaccurate measurement of fish 
consumption (4-10). Nevertheless, a few case-control studies show protective effects of fish 
consumption against colorectal cancer (11-14). Based on a comprehensive review of 
epidemiological studies a recent panel report concluded that fish consumption possibly 
protects against cancer of the colon (15). 
Intervention studies in humans indicate a protective effect of n-3 PUFA. For example, Anti et 
al. showed that supplementation with fish oil significantly reduced the mucosal cell 
proliferation in high-risk patients (16); a similar finding has been reported for healthy 
subjects (17). 
Also a number of animal experiments show that fish oil consumption reduces the risk of 
colorectal cancer (18-22). Moreover these experiments suggest that the mechanism by 
which n-3 PUFA exert their protective effect might be through the cyclooxygenase 2 (COX-
2) pathway. The COX-2 enzyme is involved in the formation of prostanoids from free PUFAs 
(23-25). It converts n-6 PUFAs such as arachidonic acid (AA) into the 2 series prostanoids 
and n-3 PUFAs into the 3 series prostanoids. The 2 series prostanoids promotes cell 
proliferation and decreases apoptosis and immune response, while the 3 series prostanoids 
inhibit tumorgenesis (26).  
Several mechanisms have been proposed to explain how n-3 PUFAs, especially fish fatty 
acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), could protect 
against adenoma formation. One mechanism is the competition between n-3 fish fatty acids 
and n-6 PUFAs for COX-2 activity (27), leading to a decreased production of the 2-series 
prostanoids and an increase in 3-series products, inhibiting tumorgenesis (28;29). In 
addition to competition for COX-2, the n-3 and n-6 PUFAs are also competing for the 
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desaturases and elongases that convert the precursors Linoleic acid (LA) into AA and α-
linoleic acid (ALA) into EPA (30). Therefore a high ratio of n-3 to n-6 PUFAs may lead to a 
decreased production of AA and 2-series prostanoids. This mechanism can also account for 
the antitumorgenic effect of a high ratio of fish fatty acids (EPA and DHA) to AA in animal 
models (31). 
With regard to n-6 fatty acids alone, Zock and Katan concluded in a review article that 
animal studies show some evidence that n-6 fatty acids promote the growth of colorectal 
tumors, but the data are inconsistent (32). In addition case-control, prospective cohort 
studies and comparison of populations showed no consistent association between n-6 fatty 
acids and colorectal cancer risk (32).  
We hypothesize that a high intake of fish fatty acids and a low intake of AA, i.e. a higher 
ratio of fish fatty acids to AA, might protect against colorectal adenomas. We investigated 
this hypothesis in a small case-control study in the Netherlands. In most epidemiological 
studies food questionnaires are used to assess intake of fish and n-3 and n-6 fatty acids. In 
this study the fatty acid composition in adipose tissue was used as a marker of fatty acid 
intake. Given the postulated mechanism this measure of fatty acid exposure is more directly 
of biological relevance as compared to estimated intake. Moreover, the fatty acids are 
determined specifically and problems of validity and reproducibility of food questionnaires 
and food tables are avoided. 
 
 
Materials en Methods 
Study population 
For the present analysis, data from a case-control study are used. The study was conducted 
between 1995 and 1998 in the Netherlands to investigate the role of dietary factors and 
genetic susceptibility in sporadic and hereditary colorectal adenomas (33). The study was 
approved by the medical ethical committees of Wageningen University and the Nijmegen 
University Hospital. All participants were Dutch-speaking and of Western European origin, 
diagnosed before the age of 75, without a history of colorectal carcinomas, colon resection, 
polyposis coli, or inflammatory bowel disease. All underwent a full colonic examination 
(colonoscopy or sigmoidoscopy combined with barium enema) to assess presence of 
adenomas. The study population included sporadic subjects i.e., without a clear familial 
background of colon cancer as well as subjects with a familial background of HNPCC 
according the Amsterdam criteria. In both groups cases are subjects who had an adenoma 
removed during the colonic examination. 
Sporadic subjects were recruited by the Department of Gastroenterology of the Nijmegen 
University Hospital. Sporadic cases were excluded if they had previous adenomas more 
than 3 years before entrance to the study. Sporadic controls were examined at the hospital 
for various reasons, for example abdominal pain, rectal blood loss or constipation. 
HNPCC subjects were persons who came to the hospital for screening purposes. They were 
recruited in a similar fashion, either by the Nijmegen University Hospital or by the 
Netherlands Foundation for the Detection of Hereditary Tumors which keeps a registry of 
HNPCC families in The Netherlands. 
This resulted in 137 eligible subjects. A total of 13 subjects decided not to participate in the 
study. So 124 subjects received a set of questionnaires at endoscopy and have had a fat 
biopsy from the buttock, by needle aspiration during endoscopy (34). Of the 124 subjects 12 
did not return the questionnaires. Additionally, laboratory analyses of three biopsies was not 
successfully completed. This resulted in 109 subjects with complete data, i.e. 52 cases and 
57 controls. 
 
Fatty acid analysis 
Gas-liquid chromatography was used to determine the fatty acid content of samples after 
saponification, petroleumether-extraction, and methylation of fatty acids. Chromatographic 
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analysis used split-injection, temperature-programmed runs with a CP-WAX-58 column with 
an inside diameter of 0.25 mm and 25 m length, with hydrogen serving as the carrier gas 
(35). 
 
Food questionnaire 
To quantify energy and nutrient intake a validated semi-quantitiative food frequency 
questionnaire was used, which was developed for the Dutch cohorts of the EPIC study 
(European Prospective Investigation into Cancer and Nutrition) (36;37). Frequency of 
consumption of food groups was based on the habitual consumption of 178 food items 
during the year before endoscopy. Nutrient intake was quantified for each individual using 
an extended version of the 1993 computerised Dutch food composition table. In the present 
analyses this EPIC questionnaire was used for information on nutrient intake and fish 
consumption. 
With respect to the study hypothesis, the questionnaire asks for the frequency of fish 
consumption and type of fish consumed (subdivided in lean fish, fatty fish and other 
seafood). Comparing the questionnaire with the 24 hour recalls as gold standard it appears 
that the validity and reproducibility of total fat intake was generally good (36), but was not 
specified according to specific fatty acids (e.g. fish fatty acids and Arachidonic acid). 
However, validity was poor for fish consumption in men (r = 0.32) and woman (r = 0.37). 
Also reproducibility was low in men (r = 0.49), but slightly better in women (r = 0.61).  
 
Data analysis 
Means of demographic parameters (age, sex, height and weight), medical parameters 
(complaints and familial background), lifestyle characteristics (aspirin use and smoking 
habits), energy and fat intake were computed for cases and controls separately. Odds 
Ratios and corresponding 95% confidence intervals were computed for fish intake, fatty acid 
intake and fatty acids in the fat biopsy. 
To identify possible confounders, the relation between exposure of n-3 fish fatty acids and 
the above mentioned variables was computed. Also other variables such as aspirine use 
and dietary variables (e.g. fibre, fat, fruit, vegetable and nutrient intake) were evaluated.  
When a variable differs between cases and controls and there was a relation between that 
variable and exposure to fish fatty acids we verified in further analyses whether substantial 
confounding was present. 
Ors and corresponding 95% confidence intervals were computed using logistic regression 
models with fatty acids classified in tertiles, based on the distribution among controls. 
Because of the study design, sex and familial background (sporadic or HNPCC) were 
included as covariates in all analysis. Furthermore we adjusted for energy intake to account 
for differences in nutrient intake related to the differences in energy intake. 
In addition, logistic regression was used to adjust for confounding, with fatty acid intake 
included as a continuous variable. For these continuous variables the exposure contrast 
represents the difference between the middle of the third and first tertile. When the 
regression coefficient obtained from a model with the potential confounder differed by more 
than 10% from the coefficient obtained from the model without that confounder we adjusted 
for that variable in all analyses. This resulted in adjustment for age and energy intake (as 
continuous variable) and for sex and familial background (as indicator variable).  
The test for trend was conducted by scoring the subsequent categories of intake from 1 to 3 
and entering this score as a continuous variable in the logistic regression model. 
Finally, we verified whether other nutritional risk factors of colorectal carcinogenesis (fibre, 
proteins, alcohol, calcium, vitamin E, aspirin intake and saturated fatty acids intake) might 
have confounded our results. To decide whether substantial confounding by these factors 
was present we used the above-mentioned criteria, applied to logistic regression models 
with vs. without this additional variable. Using this procedure it appeared that dietary fibre 
needed to be added, together with the above-mentioned confounders for exposure to the 
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fatty acid AA. Ors and corresponding 95% confidence intervals for fish intake were adjusted 
for the same confounders as Ors for fatty acid intake. 
All analysis were conducted using the statistical analysis system (SAS version 6.12, SAS 
institute). 
 
 
Results 
General characteristics of cases and controls were shown in Table 1. Weight, height and the 
percentage of subjects with bowel complaints were similar for cases and controls. Among 
cases age, energy intake and percentage of man was higher than in controls. The 
percentage of HNPCC subjects was higher in controls. Fat intake was slightly higher among 
cases. After adjustment for energy intake, nutrient intake did not differ between cases and 
controls (data not shown), except for intake of fibre and animal protein, which was slightly 
higher among cases. 
 
Table 1:  General characteristics of adenoma cases and controls. 
Variables Cases (n=52)  Controls (n=57)  
 Mean ± SD  Mean ± SD 
Demographic  
   Age (year) 53 ± 12  42 ± 13 
   Weight (kg) 77 ± 12  75 ± 12 
   Height (cm) 173 ± 9  173 ± 10 
   Gender (%man) 52  37 
    
Medical     
   Complaints (%yes) 57  55 
   Familial background (%HNPCC) 17  40 
    
Lifestyle   
   Aspirin use (%yes) 72  70 
   Current smoking (%yes) 67  67 
    
Diet    
   Energy intake (MJ) 9.6 ± 2.5  9.3 ± 2.8 
   Total fat intake (g/day) a 94.7 ± 31.2  90.7 ± 33.3 
     Saturated fat (g/day) 36.0 ± 11.5  34.6 ± 12.3 
     Monounsaturated fat (g/day) 34.2 ± 11.4  32.5 ± 12.6 
     Polyunsaturated fat (g/day) 20.4 ± 9.3  19.3 ± 8.5 
Total n-6 fatty acids 17.3 ± 8.3   16.3 ± 7.6 
Arachidonic acid 0.03 ± 0.02  0.03 ± 0.02 
Total n-3 fatty acids 1.8 ± 0.9  1.8 ± 0.7 
Fish fatty acids 0.11± 0.09  0.14 ± 0.10 
a Fat intake expressed as % of energy intake was 36.4 % among cases and 36.0 %  
among controls respectively. 
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Table 2 shows that total fish intake and the frequency of fish intake were inversely related 
with colorectal adenomas although not significantly. 
 
Table 2:  Association between fish consumption and occurrence of colorectal adenomas. 
Fish consumption Number of 
cases/controls 
Crude OR  
(95% CI ) 
Adjusted OR 
(95% CI)a
p-value  
for trend 
Frequency fish      
<1/month b 14    10 1.0  1.0 0.25 
1/month-1/week 22    26 0.6  (0.2, 1.6) 0.6  (0.2, 1.8)  
>1/week 16    21 0.5  (0.2, 1.5) 0.5  (0.2, 1.6)  
     
Total fish intake (g/day)     
<6.4 b 23    18 1.0 1.0 0.12 
6.4-14.0  15    20 0.6  (0.2, 1.5) 0.4  (0.2, 1.3)  
≥14.0 c 14    19 0.6  (0.2, 1.5) 0.4  (0.2, 1.3)  
a adjusted for energy intake, age, familial background and gender. 
b reference category 
c 14 g/day roughly corresponds to 1 serving per week 
 
Adjusted Ors of colorectal adenomas were calculated for fatty acid intake and fatty acid 
composition of adipose tissue. Regarding intake of fatty acids, Table 3 shows that n-3 intake 
and intake of fish fatty acids (EPA and DHA) was associated with a decreasing risk of 
colorectal adenomas, and n-6 intake with an increasing risk, but these associations were not 
statistically significant. Like in other epidemiological studies we also computed the ratio of n-
3 and n-6 fatty acids; this ratio was not statistically significant associated with a decreasing 
risk of colorectal adenomas. 
Regarding fatty acid patterns in the fat biopsy Table 3 shows that n-3 and fish fatty acids 
(EPA and DHA) were associated with an decreasing risk of colorectal adenomas (p-value for 
trend 0.30 and 0.07 respectively). AA was positively, but not statistically significant 
associated with colorectal adenomas (p-value for trend = 0.42) and the ratio of fish fatty 
acids to AA was inversely associated with colorectal adenomas (p-value for trend = 0.002). 
These results were similar when fish fatty acids and AA status were entered in the logistic 
model as continuous variables. 
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Discussion 
When the fatty acid composition in adipose tissue was used as a biomarker of fatty acid 
status, adenoma risk tended to be associated with fish fatty acids (inversely) and AA 
(positively), while their ratio showed a significant inverse association with risk. Intake of fish 
and fish fatty acids were inversely associated with colorectal adenomas, although these 
associations were not statistically significant.  
Selection and recruitment of study subjects and methods of data collection may have 
affected the results. The study population contained sporadic and HNPCC cases and 
controls with similar background. HNPCC cases and controls, both belonging to an HNPCC 
family, are generally more aware of their risk, but this is irrespective of their adenoma 
history; for this reason, sporadic and HNPCC cases were compared to controls with similar 
familial background. Because the size of our study is relatively small we were unable to see 
whether familial background might affect adenoma risk differently in both groups. Since 
COX-2 expression may be of less importance in HNPCC than in sporadic adenomas, this 
may have diluted the association (38). However this is one of the first studies to examine the 
relation between intake of fish and the risk of colorectal adenomas in which fish intake is 
measured by analysis of the fatty acid composition of adipose tissue. 
Recall of dietary habits is expected to be similar in cases and controls. The cases came to 
the same endoscopy work up and the questionnaire asked for the food consumption during 
the whole year before endoscopy. So, at the time of filling out the questionnaires most 
patients are unaware of their diagnosis with respect to adenomas. Furthermore, the 
prevalence of complaints was similar in cases and controls. Results for dietary intake were 
less clear than for the biomarker. This may be due to the use of the food frequency 
questionnaire, which had a low validity and reproducibility for fish consumption. Fatty acid 
composition of adipose tissue is considered to be a marker of fatty acid intake of the past 2-
3 years (39) and is less likely to be affected by recent dietary changes because of preclinical 
symptoms of adenomas. Moreover several studies found a high correlation between fish 
fatty acid (namely EPA and DHA) intake and these fatty acids in adipose tissue (40-42). 
Therefore, we give more confidence to the fatty acid composition of adipose tissue as a 
biomarker of fish consumption than to the food questionnaire. Moreover the correlation 
between intake of arachidonic acid and levels in adipose tissue is weak, probably due to 
conversion of linoleic acid to arachidonic acid (41). To investigate the effect of arachidonic 
acid on colorectal adenomas we give more confidence to the levels of arachidonic acid in 
adipose tissue, reflecting the availability of arachidonic acid in the human body, than to the 
food questionnaire. 
Possibly due to the imperfect measurement of the intake of fish and n-3 fatty acids, most of 
the epidemiological studies did not find clear inverse associations (4-6; 8-11). Furthermore, 
results from epidemiological studies are not consistent, possibly due to the low range of fish 
consumption within study populations. The use of objective long-term biomarkers may have 
compensated for this, because of increased precision in exposure assessment. Despite this, 
some case-control studies show a protective effect of fish consumption on colorectal 
adenomas or carcinomas (7;13;14). 
Similar to our results, Fernandez et al.(12) found an OR of 0.6 (0.5, 0.7) when comparing 
fish consumption higher than twice a week with lower than once a week. Although our 
results are not statistically significant they suggest a protection of fish intake to colorectal 
adenomas. To our knowledge no published papers have yet reported on fatty acid 
composition of adipose tissue (particular fish fatty acids) and the risk of colorectal 
adenomas.  
The n-3 PUFAs exerts their protective effect most likely through the COX-2 pathway. 
However, the mechanism by which COX-2 modulation is involved in tumor development is 
not clear. One of the possibilities is the competition between n-3 and n-6 PUFAs. It has been 
shown that mice heterozygous for the ApcMin/+ mutation, have a decreased number of 
intestinal tumors when fed a diet rich in the fish fatty acid EPA. These mice also have a 
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 decrease in tissue AA and its metabolic products (21). Studies that have also examined 
COX-2 activity and apoptosis in animals that were fed different diets provide another link 
between n-3 PUFAs and COX-2. Animals fed a diet rich in n-6 PUFAs showed increased 
COX-2 activity and reduced apoptosis (43) Furthermore, a study in human volunteers 
showed that an increase in the ratio of n-3 to n-6 PUFA resulted in suppression of 2-series 
prostanoids production in the human rectal mucosa (17) These studies add further evidence 
for the hypothesis that n-3 PUFAs reduce the amount of AA and 2-series prostanoids in the 
tissues due to a reduced COX-2 activity, resulting in an increase in apoptosis.  
In line with a role of n-3 PUFAs is a study on cPLA2 knock-out mice; cPLA2 liberates AA 
from the cell membrane making it available for metabolism. ApcMin/+ mice lacking this gene 
showed a decrease in tumor number compared to mice wild type for cPLA2 (44). Together 
with the Apcmin/+ COX-2 knock-out mouse mentioned before, this suggests that a reduced 
amount of 2 series prostanoids has a protective effect on tumor development. It is clear that 
the mechanism by which n-3 PUFAs protect against colon cancer is likely to be a complex 
picture with many other genes involved, some of which may not have been identified yet. 
Some other potential target mechanisms identified so far are the upregulation of PPARδ, the 
Wnt signaling pathway (45) and the expression of the p21RAS oncogene, which is increased 
in mammary and colon tumor cells (46). Rats fed a high n-3 PUFA diet showed decreased 
expression of this oncogene compared to rats fed a n-6 diet. On top of this, a protein 
involved in post-translational modification, farnesyl protein transferase, has also been shown 
to be inhibited by n-3 PUFAs, thereby reducing the amount of active p21RAS protein (47).  
In conclusion, despite limited numbers, our results suggest, in line with our hypothesis and 
the scientific literature that high tissue levels of fish fatty acids in adipose tissue, are 
associated with a lower risk of colorectal adenomas. Moreover, based on the competition 
between fish fatty acids (EPA and DHA) and AA for COX-2 activity, a higher ratio of fish fatty 
acids to AA is associated with a decreasing risk of colorectal adenomas. 
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Abstract 
OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a 
decreased risk of colorectal tumors. Single nucleotide polymorphisms (SNPs) in target 
genes of NSAID action, and their haplotypes, might modulate this protective effect. 
A case-control study including 724 cases and 682 controls was used to evaluate the effect 
of NSAIDs on colorectal adenoma risk in the Netherlands, a country in which NSAID use is 
relatively low. METHODS: Cases and controls were classified according to presence or 
absence of endoscopy-proven, pathology-confirmed colorectal adenomas, ever in their lives. 
Thirteen SNPs in four genes (PPARδ, PPARγ, PTGS1 and PTGS2) were genotyped in 787 
subjects (384 cases and 403 controls).  
RESULTS: Compared to non-regular users (<12 times/year), regular users of NSAIDs (≥12 
times/year) had a lower risk of colorectal adenomas (odds ratio (OR): 0.75, 95% confidence 
interval (CI): 0.56-0.99). The results were similar for aspirin only. We found an interaction 
between SNP c.-789C>T in PPARδ and NSAID use (p=0.03). The protective effect of 
NSAIDs was strengthened for regular users with the PPARδ CT or TT genotypes (OR: 0.35, 
95%CI: 0.11-1.13), whereas a positive association was observed for non-regular users with 
these genotypes (OR: 2.24, 95%CI: 1.06-4.73) as compared to non-regular users with the 
CC genotype. Also, a statistically significant interaction between a major haplotype 
containing the minor allele of this SNP and NSAID use was observed. 
CONCLUSIONS: This study confirms the protective effect of NSAIDs and suggests a 
modulating effect of a SNP in the promoter of PPARδ. 
 
 
Introduction 
Cancer is the second leading cause of death in the Netherlands and most other developed 
countries. Incidence rates for colorectal cancer in the Netherlands are among the higher 
rates in the world and resemble the rates in other North-Western European countries and 
North America (1).  
There is a large body of evidence, both from observational and intervention studies, 
suggesting that nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a 
reduced risk of colorectal carcinomas. Also, a 30-50% reduction has been observed for 
sporadic adenomatous polyps, the presumed precancerous lesion, as reviewed in Thun et 
al. (2).  
The precise mechanism by which NSAIDs may prevent colorectal tumors is still unclear, but 
the enzyme prostaglandin-endoperoxide synthase (PTGS), also known as cyclooxygenase 
(COX), which catalyzes the first step in the conversion of arachidonic acid (AA) to 
prostaglandins, appears to play a major role. It has been suggested that blocking of the 
PTGS2 isoform is responsible for promotion of apoptosis and inhibition of tumor 
angiogenesis in colorectal cancer (3). Several studies have shown that treatment with 
selective PTGS2 inhibitors in mouse models for colorectal cancer resulted in reduced 
numbers of tumors (4,5). Randomized trials in patients with the inherited condition familial 
adenomatous polyposis have demonstrated that the selective PTGS2 inhibitor celecoxib can 
significantly regress existing adenomas (6). Since inhibition of the constitutively expressed 
PTGS1 isoform is responsible for adverse gastro-intestinal effects, selective PTGS2 
inhibitors are preferred.  It has been suggested however that both PTGS1 and PTGS2 are 
important in intestinal tumorigenesis as illustrated by the dose dependent decrease in polyp 
number in rats and mice after treatment with a selective PTGS1 inhibitor (7). 
Besides the effect on the PTGS enzymes, NSAIDs have been shown to inhibit or stimulate 
other players both within the AA-pathway as well as in other pathways like the nuclear 
factor-κΒ (NK-κΒ) pathway (8). Two subtypes of the nuclear receptor peroxisome 
proliferator-activated receptors (PPARs), which are activated by the products of the AA 
pathway, can also act as direct targets of NSAIDs. The NSAID sulindac can bind to PPARδ 
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after which its activity and protein expression is down-regulated, inducing apoptosis (9). 
NSAIDs can also act as ligands for another receptor subtype, PPARγ (10). In contrast to 
PPARδ, this subtype has been shown to be activated by sulindac, which resulted in growth 
inhibition and apoptosis of cancer cells (11,12). 
Individual differences in drug response might be due to genetic variation. The importance of 
the PTGS and PPAR genes in the protective mechanism of NSAIDs gives rise to the 
question whether single nucleotide polymorphisms (SNPs) and accompanying haploypes in 
these genes influence the effect of NSAIDs on colorectal tumorigenesis. To test this, we 
genotyped 12 SNPs in subjects participating in a case control study conducted in the 
Netherlands, a country in which NSAID use is relatively low. The combined effect of these 
SNPs, their haplotypes and regular intake of NSAIDs on colorectal adenoma risk was 
evaluated. 
 
 
Methods 
Study population 
A retrospective case-control study was conducted in the Netherlands, between 1997 and 
2001. The study design has been previously described (13,14). In short, this case-control 
study was designed to examine the association between various dietary and other lifestyle 
factors, genetic susceptibility and colorectal adenomas. All participants underwent 
endoscopy in one of ten participating hospitals because of routine screening for colorectal 
adenomas or gastrointestinal complaints. Cases had one or more adenomas at index 
endoscopy or in their past. The proportion of prevalent cases was 41% with a mean time 
since diagnosis of 4 years (range 0-23 years). Controls had no adenomas at index 
endoscopy, nor ever in their past. 
The total study population included 1,477 subjects. The study was approved by the Medical 
Ethical Committees of all participating hospitals and all participants provided written 
informed consent. 
 
Data collection 
Information on use of NSAIDs, both for analgesic and other purposes, was obtained from a 
self-administered questionnaire including frequency of use, duration of use and brand name. 
Frequency of use was recorded as times per day/week/month/year/or less than once a year. 
Duration of use was recorded as number of years. For those who used NSAIDs for other 
purposes besides analgesics, duration of use was not recorded. Information on other 
lifestyle and demographic factors was obtained by the same questionnaire. 
Participants were asked to recall their lifestyle habits in the year previous to their last 
endoscopy, or, in case they had changed their lifestyle habits because of complaints, the 
year before these complaints began. Separately, information on dietary habits was collected 
using a validated food frequency questionnaire (15,16). 
 
Genetic analysis 
On the basis of an inventory of the genetic variation of the selected genes in the Dutch 
population, as described elsewhere (Siezen et al. submitted), eleven SNPs were selected. 
This inventory included 100 unrelated randomly selected healthy individuals from the Dutch 
population. The SNP selection was based on allele frequency (with some exceptions only 
those SNPs with a minor allele frequency of 5% or higher were considered), position in the 
gene (when possible evenly distributed across the gene), possible impact on protein function 
(amino acid changes), and linkage between the SNPs in one gene (of two or more tightly 
linked SNPs only one was selected). One SNP was selected on the basis of another 
population study on PTGS1 variants (17), and one was selected on the basis of a previously 
found interaction with NSAID use and colorectal adenomas (18). 
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Genotyping of twelve of the thirteen SNPs was carried out using a technique known as 
PyrosequencingTM. Each PCR contained 5μl 2x Hotstar master mix (Qiagen), 1μM of one 
primer, 0.1μM of a second primer containing a so-called universal tail of 23 nucleotides, 
0.9μM of a third primer with the same sequence as the tail and labeled with biotin, and 10 ng 
genomic DNA, in a total volume of 10μl. PCR reactions were carried out in a Perkin-Elmer 
9600 thermal cycler under the following conditions: 95ºC for 15 min, 40 cycles of 94ºC for 45 
s, 57ºC for 45 s, 72ºC for 1 min, followed by 72ºC for 10 min. From the biotinylated PCR 
products single stranded DNA’s were prepared and subsequently genotyped using the PSQ 
96MA system and SNP reagent kit (Pyrosequencing AB) (19), as previously described (20). 
Primers for each SNP are described previously (21) Sequence primers for the pyrosequence 
reaction were designed using software available online (19). The c.-765C>G SNP in PTGS2 
was genotyped on a 7500 Realtime PCR System using the Taqman SNP genotyping assay 
c__11997909_10 and Taqman Fast Universal PCR Master Mix (Applied Biosystems), and 
10 ng genomic DNA. Cycling was 95ºC for 20 seconds followed by 40 cycles of 95ºC for 3 
seconds and 60ºC for 30 seconds. The post-read was performed at 60ºC for 30 seconds. 
DNA was available from 787 participants. 
 
Statistical analysis 
Seventy-one participants who only filled in a short version of the questionnaire were 
excluded because of incomplete data on NSAID use. Analyses on NSAID use were 
therefore performed including data from 1,406 participants, 724 cases and 682 controls. 
Analyses with genotypes were performed on 787 participants, 384 cases and 403 controls. 
Aspirin and NSAIDs containing salicylic acid were grouped and analyzed separately. We 
considered use of 12 times per year or more as regular use. We assumed that persons who 
did not fill out the questions about frequency of analgesic use were not regular users. 
Duration of use was divided into tertiles among regular users according to distribution 
among controls. Those with missing data on duration of use were treated as a separate 
category. The analysis was repeated excluding these individuals, but this did not change the 
results. 
Odds ratios (ORs) for the presence of colorectal adenomas and 95% confidence intervals 
(95% CIs) were estimated using the non-regular users of the type of drug in question as a 
reference group. Risk estimates stratified for genotypes, were calculated with separate 
genotypes where possible, with the non-regular users in combination with the homozygote 
major allele of the SNP of interest considered as reference group. If the numbers were 
insufficient heterozygote and homozygote minor genotypes were pooled.  
The presence of effect modification by sex, smoking (ever/never), family history of colon 
cancer (yes/no) and intake of total and fatty fish (high/low) was evaluated by stratified 
analyses. 
As confounding factors were considered: age (continuous), sex, body mass index 
(continuous), family history of colon cancer (yes/no), smoking (ever/never), duration of 
smoking (continuous), use of (other) NSAIDs (regular/non-regular), diabetes (yes/no), 
constipation (once a month or more, yes/no), use of hormone replacement therapy (yes/no), 
physical activity level (medium split, high/low), use of acetaminophen (non-regular/regular), 
use of antibiotics (more/less than 10 times/lifetime), education level (4 levels), indication for 
endoscopy (bowel complaints, screening, other/unknown), gastrointestinal symptoms 
(yes/no), change in dietary habits (yes/no), daily energy intake and intake of fat, fish, dietary 
fiber, vegetables, fruit, alcohol and coffee (all continuous). Variables were included in the 
multivariate model if they changed the OR by 10% or more. This applied to age, sex, 
duration of smoking and main indication for endoscopy.  
To test whether the combination of genotypes and NSAID use deviated from multiplicativity, 
we calculated p-values for interaction by inclusion of a numerical term for genotype 
assuming either a dominant effect (homozygote major allele=1 and heterozygote or 
homozygote minor allele=2), a recessive effect (homozygote major allele or heterozygote =1 
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and homozygote minor allele=2), or a co-dominant effect (two interaction terms) multiplied 
by a numerical term for NSAID regular use into our multivariate models. The p-value for 
interaction was calculated by chi-square test comparing the -2LL values of the models with 
and without NSAIDs use*genotype interaction term. A p-value lower than .05 was 
considered statistically significant. 
Haplotypes were estimated and ORs calculated using the Hplus program, available online 
(22). Hplus is a SNP analysis tool for performing haplotype estimations, according to the 
distribution of genotypes in a population. It is able to handle datasets that include case-
control status as well as covariates and SNP location variables (23). 
All other analyses were conducted using Statistical Analysis Software (SAS, version 8.2, 
SAS institute, Cary, NC). 
 
 
Results 
A detailed description of the total study population characteristics (14) and the subset 
genotyped (13,24) was published previously.  
Adjusted ORs of the association between colorectal adenomas and frequency of use of total 
NSAIDs and aspirin are shown in table 1. Regular NSAID use confers a reduction in 
adenoma risk of 25%. This protective effect became more pronounced as duration of use 
increased, to nearly 40% in the second tertile of duration. However, there was no additional 
protective effect in the third tertile of duration, which includes subjects that have used 
NSAIDs for more than 12 years. For aspirin, a similar protective effect was observed for 
regular use. There was no apparent trend for duration of use of aspirin. The protective effect 
of aspirin even seemed diminished for individuals in the first and third tertiles, but this is 
likely due to chance since the number of individuals per group was small and the protective 
effect was retained in the second tertile. 
 
Table 1: Regular use of NSAIDs and colorectal adenoma risk  
 Cases (n=724) Controls (n=682) OR (95%CI)a
Total NSAIDs    
Non-regularb 531 480 1.00 (ref) 
Regularc 193 202 0.75 (0.56-0.99) 
     <5 years durationd 40 43 0.95 (0.56-1.63) 
     5-12 years durationd 32 45 0.61 (0.34-1.10) 
     >12 years durationd 40 40 0.73 (0.42-1.27) 
     missinge 81 74 0.73 (0.48-1.10) 
Aspirin 
   
Non-regularb 608 586 1.00 (ref) 
Regularc 116 96 0.71 (0.49-1.02) 
     <5 years durationd 17 17 1.19 (0.53-2.65) 
     5-15 years durationd 19 17 0.57 (0.24-1.34) 
     >15 years durationd 21 16 1.06 (0.49-2.32) 
     missinge 57 41 0.60 (0.36-1.01) 
a Multivariate adjustment for age, gender, indication for endoscopy and duration of smoking. 
bNon-regular use defined as <12 times per year. 
cRegular use defined as ≥12 times per year. 
dDuration of use divided in tertiles according to distribution among controls. 
eFor participants who used NSAIDs for other purposes besides analgesics, data on duration of use was 
not collected. These were treated as a separate category in the analysis. 
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Genotype-NSAIDs interaction 
All genotypes were in Hardy Weinberg Equilibrium. Main effects of these genotypes have 
been reported previously (21). Table 2 shows ORs and 95% confidence intervals for the 
associations between NSAIDs and colorectal adenoma risk, stratified for the genotypes of 
12 SNPs.  
 
 Table 2: Regular use of NSAIDs and adenoma risk, stratified by genotype 
 Non-regular usea 
(n=569) 
Regular useb 
(n=218) 
 
Genotype Cases/controls 
(280/289) 
OR (95%CI)c Cases/controls 
(104/111) 
OR (95%CI)c p for interaction 
(dominant, recessive 
or co-dominant effect) 
PPARδ      
c.-789C>T (submitted to dbSNP)             
   CC 241/254 1.00 (ref) 92/97 0.77 (0.51-1.17)  
   CT+TT 23/19 2.24 (1.06-4.73) 9/14 0.35 (0.11-1.13) 0.03 (dominant effect) 
N163N (rs2076167)d     
   TT 173/180 1.00 (ref) 67/65 0.79 (0.49-1.28)  
   TC 91/100 0.86 (0.56-1.33) 30/43 0.48 (0.25-0.92)  
   CC 15/9 1.39 (0.48-4.01) 7/6 0.88 (0.24-3.21) >0.05 
c.2021T>C (rs3734254)d     
   TT 179/187 1.00 (ref) 70/69 0.76 (0.48-1.22)  
   TC 91/94 0.85 (0.55-1.32) 27/39 0.46 (0.23-0.91)  
   CC 10/7 1.38 (0.40-4.73) 7/5 1.13 (0.29-4.39) >0.05 
c.2589G>A (rs1053046)d     
   GG 254/263 1.00 (ref) 93/98 0.74 (0.49-1.12)  
   GA+AA 26/26 1.27 (0.63-2.53) 11/16 0.54 (0.21-1.42) >0.05 
c.2806C>G (rs9794)d     
   CC 193/209 1.00 (ref) 79/84 0.71 (0.45-1.10)  
   CG+GG 79/77 0.86 (0.54-1.36) 25/29 0.63 (0.30-1.31) >0.05 
PPARγ      
P12A (rs1801282)d     
   CC 209/217 1.00 (ref) 72/80 0.70 (0.44-1.11)  
   CG+GG 68/72 1.11 (0.71-1.73) 30/34 0.73 (0.39-1.40) >0.05 
H477H (rs3856806)d     
   CC 202/194 1.00 (ref) 74/69 0.75 (0.47-1.20)  
   CT+TT 64/87 0.71 (0.45-1.11) 27/38 0.52 (0.27-1.00) >0.05 
PTGS1      
W8R (rs1236913)d     
   CC 241/239 1.00 (ref) 93/100 0.68 (0.46-1.03)  
   CT+TT 31/41 0.90 (0.49-1.65) 8/12 0.84 (0.28-2.49) >0.05 
L237M (rs5789)d     
   CC 222/238 1.00 (ref) 78/94 0.65 (0.42-1.00)  
   CA+AA 8/10 0.86 (0.28-2.67) 6/2 2.25 (0.32-15.96) >0.05 
PTGS2      
c.-1329A>G (rs689466)d     
   AA 162/180 1.00 (ref) 56/75 0.56 (0.33-0.93)  
   AG 91/92 1.20 (0.78-1.84) 40/30 1.27 (0.68-2.39)  
   GG 16/12 0.95 (0.34-2.65) 6/4 2.22 (0.55-8.89) >0.05 
c.-765C>G (rs20417)d     
   CC 172/195 1.00 (ref) 65/79 0.70 (0.43-1.12)  
   CG+GG 74/68 1.12 (0.70-1.78) 26/26 0.71 (0.34-1.48) >0.05 
V102V (rs5277)d     
   GG 214/194 1.00 (ref) 70/73 0.68 (0.43-1.08)  
   GC+CC 66/95 0.65 (0.42-1.01) 34/41 0.46 (0.24-0.87) >0.05 
c.2242T>C (rs5275)d     
   TT 116/141 1.00 (ref) 43/55 0.72 (0.41-1.27)  
   TC 132/116 1.30 (0.86-1.98) 53/46 0.95 (0.53-1.68)  
   CC 27/28 1.15 (0.55-2.41) 7/10 0.56 (0.16-2.00) >0.05 
a Non-regular use defined as <12 times per year. 
b Regular use defined as ≥12 times per year. 
c Multivariate adjustment for age, gender, indication for endoscopy and duration of smoking. 
d rs number according to dbSNP (25)  
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A statistical significant interaction (p=0.03) was found in the dominant model between SNP 
c.-789C>T in PPARδ and regular NSAID use. Among non-regular users, CT+TT pooled 
genotypes increased colorectal adenoma risk (OR, 2.24; 95%CI, 1.06-4.73) compared to the 
CC genotype, while regular use was most strongly inversely related to risk among CT and 
TT genotypes although not statistically significant (OR, 0.35; 95%CI, 0.11-1.13). For the 
other SNPs in PPARδ, benefit for NSAID regular users was also more apparent among 
those with the minor alleles. However, no statistically significant interactions were observed. 
The protective effect of NSAIDs was only apparent with the major AA genotype of SNP c.-
1329A>G in PTGS2, while those with AG and GG genotypes did not appear to benefit from 
regular NSAID use. Interactions between regular NSAID use and SNPs in PTGS2 however, 
were not statistically significant.  
No statistically significant interactions were observed between any SNPs in PPARγ or 
PTGS1. Due to apparent selectivity of several NSAIDs for PPAR subtypes (26), interactions 
between ibuprofen use and SNPs in PPARδ, and interactions between indomethacin and 
diclofenac use and SNPs in PPARγ were analyzed separately, but no significant interactions 
were observed (data not shown). 
An additional nine SNPs in three other genes involved in the AA pathway (15-lipoxygenase 
(ALOX15), secreted phospholipase A2 (PLA2G2A) and cytosolic phospholipase A2 
(PLA2G4A)) were genotyped but no interactions with NSAID use and colorectal adenoma 
risk were observed (data not shown). The rs numbers (according to dbSNP (25)) and minor 
allele frequencies of these additional SNPs are presented in table 3. 
 
Table 3: Additional SNPs genotyped 
Gene SNP (rs number)a Minor allele frequency 
  Cases (n=384) Controls (n=403) 
ALOX15 c.-217G>C (rs2664593) 0.134 0.154 
 T485T (rs743646) 0.092 0.124 
PLA2G2A c.-180C>G (rs11573156) 0.235 0.251 
 T32T (rs2236771) 0.082 0.098 
 c.665C>T (rs11677) 0.115 0.104 
PLA2G4A c.918+23C>T 
(rs2307200) 
0.179 0.172 
 c.1336+3G>A 
(rs6661772) 
0.052 0.067 
 R651K (rs2307198) 0.021 0.024 
 c.2605G>A (rs12720707) 0.075 0.090 
a rs number according to dbSNP (25) 
 
Haplotype-NSAID interaction 
For regular users only, the ORs of haplotypes corresponding to the 12 SNPs are shown in 
table 4. There was a statistically significant interaction between haplotype 11110 in PPARδ 
(the minor alleles of c.-789C>T, N163N, c.2021T>C and c.2589G>A, and the major allele of 
c.2806C>G) and regular NSAID use. Individuals with this haplotype had a statistically non 
significant reduced risk of adenomas of 66% as compared to the major haplotype. A very 
large significant reduction in risk of 73% was also seen for haplotype 01 in PPARγ (C allele 
for P12A and T allele for H477H) in regular NSAID users compared to the major haplotype 
00. However, the interaction between this haplotype and NSAID use was not statistically 
significant. 
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Table 4: Regular use of NSAIDs and adenoma risk, stratified by haplotype 
 Regular use of NSAIDsa  
Haplotypeb Frequency 
among cases 
Frequency among 
controls 
OR (95% CI)c p value for 
interaction 
PPARδ     
  00000 
  01101 
  01110 
  11110 
0.780 
0.146 
0.018 
0.029 
0.781 
0.139 
0.028 
0.025 
1.00 (ref) 
0.89 (0.44-1.79) 
0.92 (0.27-3.17) 
0.34 (0.08-1.37) 
 
0.81 
0.37 
0.04 
PPARγ     
  00 
  11 
  01 
  10 
0.825 
0.095 
0.038 
0.042 
0.787 
0.103 
0.070 
0.040 
1.00 (ref) 
1.00 (0.42-2.39) 
0.27 (0.07-0.95) 
0.73 (0.26-2.09) 
 
0.74 
0.49 
0.44 
PTGS1     
  00 
  10 
0.924 
0.053 
0.912 
0.070 
1.00 (ref) 
1.24 (0.39-3.94) 
 
0.64 
PTGS2     
  0000 
  1000 
  0010 
  0001 
  0101 
0.273 
0.236 
0.146 
0.185 
0.151 
0.308 
0.196 
0.187 
0.175 
0.125 
1.00 (ref) 
2.29 (1.16-4.54) 
1.05 (0.50-2.17) 
1.43 (0.65-3.12) 
1.45 (0.55-3.82) 
 
0.12 
0.42 
0.61 
0.69 
aRegular use defined as ≥12 times per year. 
b0 represents major allele, 1 represents minor allele, SNP order according to table 2. 
c Multivariate adjustment for age, gender, indication for endoscopy and duration of smoking. 
 
 
Discussion  
This case-control study in a population with relatively low intake of NSAIDs supports an 
inverse association between use of NSAIDs and colorectal adenomas. We observed that 
participants who used NSAIDs 12 times a year or more were about 25% less likely to 
develop colorectal adenomas than those using NSAIDs less than 12 times per year. This 
observation corresponds to findings from other studies (27). 
All genes investigated in this study have been shown previously to be involved in colorectal 
tumorigenesis by being indirect or direct targets of NSAIDs (5,7,9,10). Some of the SNPs 
investigated have also been shown to modify the risk of colorectal adenomas (21). We have 
investigated whether these SNPs could modify the protective effect of NSAIDs on colorectal 
adenomas, and observed that some SNPs did have a modifying effect.  
The statistically significant interaction observed between SNP c.-789C>T in the promoter of 
PPARδ and regular NSAID use is in line with previous findings that PPARδ is a direct target 
of NSAIDs. We have shown previously that this same SNP in the promoter of PPARδ 
interacts with fish consumption in the risk for colorectal adenomas (21). These two findings 
taken together strongly suggest a functional effect of the SNP when the gene interacts with 
a ligand. The mechanisms by which PPAR proteins are activated by ligands are becoming 
better understood (28). These same ligands could also be involved in regulating the 
expression of the PPAR genes, and may therefore interact with the promoter. We have 
investigated the possibility that this SNP interferes with a transcription factor binding site 
using the Genequest part of the Lasergene software package and the online tool 
TFSEARCH (29), but found no known consensus sites around the SNP position. Haplotype 
11110 confirms the effect of SNP c.-789C>T in PPARδ. This haplotype is the major 
haplotype containing the minor allele of c.-789C>T (and the minor alleles of N163N, 
c.2021T>C and c.2589G>A, and the major allele of c.2806C>G). The interaction between 
haplotype 11110 and NSAID use was statistically significant.  
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PPARδ activity is suppressed in cells treated with the NSAID sulindac, by disrupting its 
DNA-binding ability (9). The role of PPARδ was further investigated by Kojo et al. (26), who 
tested 7 different NSAIDs and their selectivity for PPAR subtypes. They found that ibuprofen 
was the only NSAID tested that had an effect on PPARδ. We found however, that selecting 
for ibuprofen regular use only, did not strengthen the interactions with any SNP in PPARδ 
(data not shown). To our knowledge, no other studies have been reported in the literature on 
the interaction between SNPs in PPARδ and NSAIDs and their effect on colorectal 
adenomas.  
The protective effect of NSAIDs was diminished in people with the G allele for SNP c.-
1329A>G in PTGS2, as confirmed with the haplotype representing this allele (haplotype 
1000). This effect is most likely due to the minor allele of the SNP or chance findings, and 
not due to an interaction, since this was not statistically significant. Moreover, a positive 
effect was seen for both regular and non-regular users, although the effect for regular users 
was somewhat stronger. No other SNPs in either PTGS1 or PTGS2 showed any interaction 
with NSAID use. This was unexpected, since the PTGS enzymes are well established 
targets of NSAID action. An explanation for this might be that there are other unknown SNPs 
in these genes, for example in intronic regions, or SNPs with a minor allele frequency below 
5% and thus not tested, which interact with NSAID use. The c.-765C>G SNP in PTGS2 was 
previously shown to interact with NSAID use in relation to colorectal adenomas (18). This 
result could not be replicated by us. In line with our results, in a study on PTGS1 variants no 
interaction was observed between the two SNPs that correspond to the SNPs in our study. 
An interaction was found however, between a SNP (P17L) not genotyped in our study due to 
the low minor allele frequency reported, and NSAID use (30).  
We found a decrease in risk of 80% for individuals with the 01 haplotype in PPARγ among 
regular users, as compared to the major haplotype. However, the interaction between this 
haplotype and NSAID use was not statistically significant, therefore the likely explanation for 
this is a cumulative effect of two protective effects provided by the haplotype and NSAIDs 
separately. A study on different NSAIDs and their selectivity for PPAR subtypes identified 
indomethacin and diclofenac as selective agonist for PPARγ (26). However, in our study, 
analysis with indomethacin and diclofenac use, albeit with limited numbers, did not 
strengthen the results for either SNP in PPARγ as compared to total NSAID use (data not 
shown). To our knowledge there have been no other studies reporting on the interaction 
between SNPs or haplotypes in PPARγ genes and NSAID use. 
There are some limitations to the study that need to be addressed. Firstly, it cannot be ruled 
out that there are other genes or other SNPs in the genes studied that could interact with 
NSAIDs. However, we have genotyped nine other SNPs in three other genes involved in the 
AA pathway (ALOX15, PLA2G2A and PLA2G4A), and found no interaction between any of 
the SNPs and NSAID use. Recently, the more upstream target NF-κΒ has been implicated 
as one of the main regulators of NSAID action (31), therefore variants in genes encoding 
this transcription factor complex or within its pathway might modulate the protective effect of 
NSAIDs. 
Second, although it is usually assumed that adenomatous polyps remain asymptomatic, in 
this study more cases than controls had suffered from rectal bleeding (29.0% vs 17.9%, 
respectively). If cases reduced their aspirin intake after observing such bleeding, because 
they are aware bleeding can be an aspirin side-effect, this could have falsely strengthened 
our results. Regular or non-regular use of aspirin, however, did not correlate with anal 
bleeding (25% of non-regular users experienced anal bleeding vs 23% of regular users).  
Third, our case-definition included incident as well as prevalent cases. It is possible that the 
latter changed their eating and other lifestyle habits after diagnosis of their first polyp. We 
repeated the analyses with only incident cases, and this even strengthened results.  
Fourth, some controls (39%) did not undergo a full colonoscopy. Therefore, it is still possible 
that some of the control subjects had an adenoma in the proximal colon. However, repeating 
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the analyses with only controls that had full colonoscopy did not change our conclusions. 
Last, the power of this study to detect statistically significant interactions may be limited, 
since stratification into genotypes according to NSAID use results in small numbers per 
group. 
In conclusion, our results indicate a protective effect of NSAIDs against colorectal 
adenomas. We have shown for the first time that this effect is modulated by a polymorphism 
in PPARδ which is apparent by analyzing the single SNP and its accompanying haplotype. 
However, further studies are needed to confirm our results and to explain the mechanism by 
which this polymorphism might interact with NSAIDs. 
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In the last two decades, family based linkage studies on colorectal cancer have been 
successful in identifying high penetrance genes giving rise to familial syndromes. The best 
known examples are the APC gene, mutations in which are the cause of FAP, and MMR 
genes, predisposing mutations carriers to HNPCC. However, mutations in these genes are 
rare as they only account for a small part of the familial clustering (3-5%) observed among 
colorectal cancer cases. This indicates that the majority of familial cases is likely to be the 
result of the interaction of many genetic variants each with a modest individual effect on 
tumor susceptibility, the so-called low penetrance alleles. Therefore, since a wealth of 
information has become available to researchers with the completion of the human genome 
project, much research has focused on the identification of low penetrance alleles. Genetic 
association studies comprise the majority of these efforts, generally evaluating the effect of 
single SNPs on colorectal cancer risk. 
The research described in this thesis was aimed at the identification of low penetrance 
alleles for colorectal cancer in seven candidate genes involved in the arachidonic acid 
pathway. We evaluated the influence of these SNPs on colorectal adenomas and 
carcinomas in retrospective and prospective studies respectively. We investigated whether 
the observed associations were modified by fish consumption, n-3 serum levels and regular 
use of NSAIDs. 
 
 
Main findings 
 
Chapter 2 
In an attempt to evaluate the genetic variation in our seven candidate genes, PTGS1, 
PTGS2, PPARδ, PPARγ, ALOX15, PLA2G2A and PLA2G4A, we identified fifty-eight single 
nucleotide polymorphisms (SNPs), including thirteen newly described SNPs. On the basis of 
allele frequency, position within the gene, linkage with other SNPs, and possible effect on 
protein function, we selected 24 SNPs to use in studies investigating associations between 
genotypes and risk of colorectal cancer All SNPs were used to construct haplotypes, some 
with higher resolution than the haplotype structures available online at that time in HapMap. 
 
Chapter 3 
First, we genotyped these SNPs in a case-control cohort, the POLIEP study, including 384 
subjects with one or more adenomas and 403 controls, and considered the modifying effect 
of fish consumption on the observed associations. A protective effect on colorectal 
adenomas was found for the CT genotype of SNP H477H in PPARγ and the GC genotype of 
SNP V102V in PTGS2 (OR, 0.63; 95%CI, 0.45-0.89 and OR, 0.65; 95%CI, 0.46-0.92 
respectively) when compared to the homozygote major genotypes. An increase in adenoma 
risk was observed for the TC genotype of SNP c.2242T>C in PTGS2 (OR, 1.47; 95%CI, 
1.07-2.00) compared to the TT genotype. Analysis with estimated haplotypes confirmed 
these associations and revealed three additional associations with PTGS2, PLA2G2A and 
ALOX15 haplotypes. Fish consumption modified the associations with PTGS2 and PPARδ 
genotypes. For SNP c.-789C>T in PPARδ, the major genotype showed a decrease in 
adenoma risk for those in the highest tertile of fish consumption (T3), as compared to the 
lowest tertile (T1) (OR, 0.65; 95%CI, 0.41-1.02). Protective effects were also observed for 
SNPs V102V and c.2242T>C in PTGS2 and high fish intake. The interaction between fish 
consumption and c.2242T>C was statistically significant, with an OR for the TT genotype 
and high fish consumption of 0.52 (95%CI, 0.27-1.01) as compared to low fish intake and 
the TT genotype.  
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Chapter 4 
The study described in Chapter 4 was conducted to test whether the associations described 
in the previous chapter for colorectal adenomas could be reproduced for colorectal cancer. 
To this aim we used a nested case control design in a prospective cohort with 16 years of 
follow up, including 209 colorectal cancer cases and 418 controls frequency matched on age 
and sex with the cases, and only reproduced the association between SNP V102V in 
PTGS2 and CRC risk. A protective effect of the minor allele of this SNP (CC genotype, OR, 
0.37; 95%CI, 0.16-0.87) was found. However, in contrast to the adenoma study no 
statistically significant interactions between fish consumption and any of the SNPs analyzed 
were shown in this prospective study on colorectal cancer. 
 
Chapter 5 
As the interaction shown between fish consumption and SNPs for colorectal adenomas is 
based on the hypothesis that fish consumption acts as a proxy for n-3 PUFAs, we 
investigated whether the SNPs interacted in the same way with serum n-3 PUFA levels. 
First, we examined the association between several PUFAs, analyzed in serum, and 
colorectal adenomas. We found that linoleic acid as well as total n-6 PUFAs (which consists 
of about 85% linoleic acid) was positively associated with colorectal adenomas. The OR of 
the highest tertile (T3) was 1.69 (95%CI, 1.09-2.61) for total n-6 PUFAs and 1.78 (95%CI, 
1.15-2.76) for LA as compared to the lowest tertile (T1), with a statistically significant trend 
(0.02 and 0.008 respectively). Total n-3 PUFAs were inversely, although not statistically 
significant associated with colorectal adenomas, (OR and 95% CI T3 versus T1: 0.71; 0.46-
1.10). Results for EPA and DHA separately were similar. However, none of the SNPs tested 
modified these associations. 
 
Chapter 6 
In Chapter 6, we demonstrated that the ratio of n-3/n-6 fatty acids as analyzed from a fat 
biopsy is an important factor influencing the risk of colorectal adenomas both in sporadic as 
well as in genetically predisposed (HNPCC) cases. A high ratio of fish fatty acids to AA 
showed an OR of 0.2 in the third tertile (95%CI, 0.1-0.5), although fish intake was not 
significantly associated. 
 
Chapter 7 
Lastly, the modifying effect of our selected SNPs on the association between NSAIDs on 
colorectal adenomas was evaluated in Chapter 7. Compared to non-regular users (<12 
times/year), NSAID regular users (≥12 times/year) showed a lower risk of colorectal 
adenomas (OR: 0.75, 95%CI: 0.56-0.99). The results were similar for aspirin only. We found 
an interaction between SNP c.-789C>T in PPARδ and NSAID use (p=0.03), which is the 
same SNP that was previously shown to interact with fish consumption. The protective effect 
of NSAIDs was strengthened for regular users with the PPARδ CT or TT genotypes (OR: 
0.35, 95%CI: 0.11-1.13), whereas a positive association was observed for non-regular users 
with these genotypes (OR: 2.24, 95%CI: 1.06-4.73) as compared to non-regular users with 
the CC genotype. Also, a statistically significant interaction between a major haplotype 
containing the minor allele of this SNP and NSAID use was observed. 
 
In summary, we can conclude that we have successfully identified low penetrance alleles in 
the PPARγ, PLA2G2A and ALOX15 genes, conferring differential colorectal adenoma risk, 
and two such alleles in the PTGS2 gene, one of which is also involved in colorectal cancer 
risk. These results, also in view of the interactions found between some SNPs and fish 
consumption and NSAID use, reinforce the importance of the role of the AA pathway in 
colorectal tumorigenesis, and indicate that some of these modifying alleles might contribute 
to a proportion of sporadic colorectal cancer cases, although the exact underlying 
mechanisms involved are not understood yet.  
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Remaining Questions 
 
Low penetrance allele candidates 
As mentioned in the introduction, there are some promising candidates in the search for low 
penetrance alleles associated with CRC risk. However, one of the main problems 
investigators keep facing is the lack of consistency between genetic association studies. 
What are the main factors causing these inconsistent results? These issues are extensively 
discussed in several recent reviews (1-3) and are shortly summarized here. From a 
statistical point of view inconsistent study results can be caused by false positives or false 
negatives. In the case of a false positive result or a type I error, the subsequent studies fail 
to replicate this result simply because it was due to chance. This is especially the case with 
studies showing borderline significance with confidence intervals including 1. It is however 
also possible that the first positive study is correct and subsequent studies are false 
negatives (type II error). This is nevertheless unlikely since subsequent studies contain 
generally larger cohorts. 
These limitations are not insurmountable however, and can be minimized by better and 
more stringent statistics including corrections for multiple testing, use of haplotype tagging 
SNPs so as to capture all the common variation in the candidate gene, and large cohorts. 
Moreover, these limitations should not discourage scientists from performing genetic 
association studies, because studies with relatively small population sizes could still 
contribute to the overall evaluation of a low penetrance allele. This is illustrated by a recent 
meta-analysis of a variant in the Aurora/STK15 gene in which various cancer types were 
considered (4). Interestingly, the majority of the 15 studies included in this meta-analysis, did 
not reach statistical significance on their own, but when the studies were combined to 
include 9549 cases and 8326 controls a statistically significant cancer promoting effect of 
the minor allele was suggested. 
With regard to the studies described in this thesis, there are several lines of evidence 
indicating that the observed low penetrance alleles in PTGS2 are plausible candidates. First, 
other studies have found similar associations, as discussed in Chapters 3 and 4. Very 
recently, another study on PTGS2 variants reproduced the positive association with SNP 
c.2242T>C and colorectal adenomas (5). Notably, in line with our study, the increased risk 
was observed for the heterozygous genotype. Among males, the risk of colorectal 
adenomas was increased with the heterozygous genotype, although the distinction between 
heterozygotes and homozygotes was lost when males and females were considered as one 
group. However, this does point to an important and possibly functional role for the PTGS2 
c.2242T>C SNP, or for a nucleotide change in strong LD with it. The 3’UTR of PTGS2 
contains AU rich elements (ARE) which play an important role in stabilization of the 
transcript when translational regulatory factors are bound to them (6). The location of this 
SNP, within an ARE involved in mediation of transcript degradation in the 3’UTR of the 
gene, suggests that it might affect the binding affinity of regulatory factors, and thus modify 
the stability and expression of the PTGS2 transcript (7). Since an increased risk is observed 
for the minor allele of this SNP, it is plausible that this allele results in a more stable 
transcript. The apparent effect of the heterozygous genotype in our and in the previously 
mentioned study, suggest there might be an interaction between the two alleles, though the 
exact nature of this and the reason why these allelic variants would affect colorectal 
adenoma risk remains to be elucidated. Further studies are needed to investigate the true 
functionality of this SNP. 
Second, we have demonstrated a protective effect of SNP V102V in PTGS2 in two 
independent cohorts. In the case control cohort on colorectal adenomas only the C allele 
appears to be sufficient for a reduction in risk of 35%, whereas for the later stages of tumor 
development two alleles are needed to confer a risk reduction of 63%, as analyzed in the 
prospective cohort. These two inverse associations make it likely that there is either some 
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functional effect of this SNP, for example on splicing, or that this SNP is in close LD with 
another functional variant, as discussed previously for SNP c.2242T>C. So far we have not 
been able to suggest any functional role of this SNP either in silico or experimentally. 
However, it cannot be ruled out that this SNP might interfere with other regulatory regions or 
consensus sequences within exons. 
 
Haplotypes 
An ongoing difficulty for molecular epidemiologists is the optimal selection of the number of 
genetic variants for their association studies. To date there is still insufficient knowledge 
about the functionality of SNPs, in particular non-coding or synonymous SNPs, and because 
of the sheer abundance of genetic variants, methods are required to aid in this selection 
process. Even though the number of SNPs within a gene region might be considerable, 
some of these SNPs will be in linkage disequilibrium, thus creating a limited number of 
common haplotypes per gene region. The number of SNPs that can discriminate these 
haplotypes is considerably less than the total number of SNPs in that region, and can 
therefore serve as so-called haplotype tagging (ht) SNPs. This is defined as the indirect 
approach to select candidate SNPs. The great advantage to this approach is that it 
optimizes the amount of genetic variation included in the association study.  
In this thesis, several results also support the importance of analyzing haplotypes. First, 
there was an apparent lack of associations between single SNPs in PLA2G2A and 
colorectal tumors. However, when all SNPs were combined and haplotypes estimated, the 
haplotypes containing the minor allele of SNP c.665C>T located in the 3’UTR of the gene, 
was positively associated with colorectal adenomas.  
Secondly, analysis of the haplotype containing the major allele of P12A and the minor allele 
of H477H strengthened the association found between the H477H SNP in PPARγ and the 
risk of colorectal adenomas. The importance of the haplotypes encompassing both SNPs 
was also illustrated by two other studies on the association between risk alleles and body 
weight and type 2 diabetes. However, the statistically significant association in the second 
study concerned the haplotype containing the minor allele of P12A and the major allele of 
H477H (also known as C1431T) (8,9). This does indicate however, a likely functional effect 
resulting from the combination of these SNPs, either on protein function or on the relative 
amount of protein expressed. 
No previous studies have been reported evaluating associations between SNPs or 
haplotypes at the anticarcinogenic ALOX15 gene and colorectal tumors. However, 
associations with a specific haplotype in another subtype of the lipoxygenase enzyme, the 
procarcinogenic ALOX5 gene, have been reported recently (10), indicating again the 
importance of this family of enzymes in colorectal tumorigenesis. 
 
Fish consumption and biomarkers of fish intake 
We investigated retrospectively as well as prospectively whether increased fish consumption 
has a protective effect on colorectal tumor formation and have not demonstrated a clearly 
inverse association. In a relatively small case-control study on colorectal adenomas, we 
observed an inverse, though not statistically significant association (OR 0.4; 95%CI, 0.2-1.3, 
T3 vs T1) between fish consumption and colorectal adenomas (Chapter 6), which could not 
be confirmed when this study was extended and contained a larger population (OR 0.98; 
95%CI, 0.72-1.32, T3 vs T1) (Chapter 3). A non-significant inverse association was 
observed between fish consumption and colorectal cancer in a prospective cohort study (RR 
0.83; 95%CI, 0.57-1.20, high vs low) (Chapter 4). Fatty acid levels as measured from fat 
biopsies and serum samples were analyzed for their association with colorectal adenomas. 
Whereas increased n-3 PUFAs content in serum suggested a slight protection against 
adenomas (OR 0.71; 95%CI, 0.46-1.10, T3 vs T1) (Chapter 5), the ratio of EPA+DHA/AA 
seemed most important as protective factor when fat biopsies were analyzed (OR 0.2; 
95%CI, 0.1-0.5, T3 vs T1) (Chapter 6). These apparent inconsistencies might be the result 
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of small population sizes, or the limited range of intake and relatively low fish consumption in 
the study populations investigated. However, inconsistencies similar to our findings have 
been reported in the literature. Some prospective epidemiological studies investigated the 
association between fish consumption and cancer and found inverse associations (11-15), 
whereas other studies have not (16-22). The same inconsistencies apply to studies using 
nutrient calculations from food frequency questionnaires from which n-3 PUFA intake is 
deduced. One case-control study showed an inverse association between estimated n-3 
PUFA intake and colorectal cancer though exclusively in women (23), whereas two 
additional studies showed no association (24,25). Only one recent prospective study has 
employed serum measurements of fatty acids and found an inverse association between 
total n-3 PUFA, EPA and DHA content and colorectal cancer, also only in women (26). 
Recently, a meta analysis of 38 studies evaluating consumption of n-3 PUFAs and its effect 
on tumor incidence provided no evidence for a protective effect on any tumor type studied, 
including colorectal tumors (27). 
Several animal and in vitro studies indicate more consistently that n-3 PUFAs suppress the 
development of cancer, as reviewed by Roynette et.al (28). It has been shown that diet 
supplementation with fish oil decreases tumor number in animals with chemically induced 
colorectal tumors (29) as well as in genetically engineered mouse models of intestinal 
cancer (ApcMin and ApcΔ716) (30,31). In search of a mechanism of action by which n-3 
PUFAs might exert its effect on tumorigenesis, it has been shown that treatment of cancer 
cell lines with n-3 PUFAs  induces apoptosis and suppresses cell growth (32,33). In 
humans, supplementation with fish oils containing n-3 PUFAs in patients with sporadic 
adenomatous polyps resulted in reduced intestinal hyperproliferation (34,35). In summary, 
these experimental data suggest a protective role of n-3 PUFAs against intestinal 
tumorigenesis, which has not been consistently confirmed in human observational studies 
(27). 
 
Comparing fish consumption and n-3/n-6 PUFAs 
A second remaining question concerning fish consumption and biomarkers of fish intake, 
arises from the discrepancy between the results obtained from the analysis with SNPs and 
fish consumption (Chapter 3), and the analysis with SNPs and n-3 PUFAs (Chapter 5). We 
found that fish consumption interacted with SNPs in PPARδ and PTGS2, while n-3 PUFA 
levels did not. One can debate whether serum is the most appropriate medium for 
measuring fatty acids as a biomarker for dietary intake. It has been shown that adipose 
tissue is the most suitable medium for the reflection of long-term dietary intake (36). 
However, adipose tissue samples are difficult to obtain and might lead to reduced power due 
to small sample size because of non-responders. The most practical medium for fatty acid 
measurements is therefore considered to be serum, of which the cholesterol and 
phospholipids fractions reflect the dietary intake over the last few days (36). This time 
window might be representative for long-term intake however, as also supported by our 
observation of a clear correlation between fish consumption as assessed from food 
frequency questionnaires and n-3 PUFA serum levels. Therefore, the different results 
obtained from fish consumption and fatty acid analysis in sera could indicate that there may 
be another bioactive agent in fish that interacts with the genes in the AA pathway. Although 
it is far from clear which agent that might be, we hypothesize that vitamin D could be one of 
the candidate bioactive agents present in fish, as explained hereafter. 
Vitamin D has been shown to be associated with colorectal cancer risk in several 
epidemiological studies which is supported by in vitro and animal studies. The 
epidemiological studies conducted so far that have solely considered diet as a source of 
vitamin D have been inconsistent. Studies also considering vitamin D supplements or those 
examining circulating levels of the intermediate metabolite 25(OH)D3 in serum are more 
consistent and most show significant decreases in colorectal cancer or adenoma risk among 
individuals with increased vitamin D intake or serum 25(OH)D3 levels, as reviewed by Grant 
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and Garland (37). Numerous animal studies have also implicated a role of vitamin D as a 
bioactive compound with a protective potential in intestinal tumorigenesis. Where 
supplementation with vitamin D in the diets of rodent models has been shown to decrease 
tumor numbers in the intestine, low vitamin D status resulted in increased tumor numbers 
(38).  
Vitamin D is either ingested with the diet where it is present in fatty fish, meat and eggs, or 
as a precursor (pre-vitamin D3) it can be produced endogenously in the skin after exposure 
to UVB. The actions of vitamin D are mediated by binding of its metabolite (1,25(OH)2D3) to 
the vitamin D receptor (VDR) which is part of the nuclear hormone-receptor superfamily and 
is present in normal colon as well as in colorectal tumor cells (39). Activated VDR forms a 
complex with the retinoic X receptor (RXR) which in turn binds to a vitamin-D response 
element (VDRE) present in the promoter of target genes, inducing their expression. Recently 
it has been shown that PPARδ is a direct target gene of activated VDR thereby causing 
increased expression of this gene in breast and prostate cells lines (40). Another study 
however has demonstrated that vitamin D inhibits β-catenin signaling which in turn leads to 
decreased expression of Wnt target genes, including PPARδ (41). Recently PPARδ has 
been identified as a focal point of crosstalk between prostaglandin and Wnt signaling 
pathways (42). How and if known effects of vitamin D on cell proliferation, differentiation and 
apoptosis are the results of interactions with these or other pathways has to be addressed in 
future research. Although the above mentioned studies are contradictory regarding the effect 
of vitamin D on PPARδ expression, they do indicate that there may be an interaction 
between vitamin intake and the PPARδ gene, which may account in part for the interaction 
found between a SNP in the PPARδ promoter and fish consumption. Whereas there is an 
interaction between vitamin D and PTGS2 remains to be elucidated in future research. It 
should be noted that the role of vitamin D as active agent in fish is a hypothesis, and that 
other agents present at high concentrations in fish, e.g. selenium, might also be important. 
 
N-6 polyunsaturated fatty acids 
It has been widely accepted that n-3 PUFAs not only have a protective effect on colorectal 
cancer but also on cardiovascular disease. The health effects of n-6 PUFAs however are 
less unequivocal. It has been hypothesized that intake of PUFAs, including n-6 PUFAs, 
instead of saturated fatty acids, lowers LDL cholesterol and therefore reduces the risk of 
cardiovascular diseases (43). Although several studies have supported this hypothesis by 
investigating the association between total PUFAs and cardiovascular disease (43), the role 
of n-6 PUFAs in tumorigenesis is cause for concern. We have shown that an increased 
amount of LA results in an increased risk of colorectal adenomas as compared to low LA 
content (chapter 6). This is line with several studies indicating a tumor promoting role of n-6 
PUFAs (44,45). LA is an essential fatty acid and therefore needs to be present in the diet. 
The conflicting effects of n-6 PUFAs on human health however, suggest that it should be 
present in limited amounts, and at a ratio with n-3 PUFAs closer to 1:1 instead of the current 
average of 15:1 (46). 
 
NSAIDs 
We have shown an inverse association between regular NSAID use and colorectal 
adenomas (OR, 0.75), which is further strengthened by the minor allele of SNP c.-789C>T in 
PPARδ (OR, 0.35) (Chapter 7). As with n-6 PUFA intake, the effect of certain NSAIDs on 
health status seems to be tissue specific. Whereas n-6 PUFAs seem to have a positive 
effect on the cardiovascular system, high amounts are also likely to be tumor promoting. In 
contrast, PTGS2 selective inhibitors, the so-called Coxibs, have been proven to be 
protective against colorectal tumors. However recent data about serious cardiovascular 
side-effects have resulted in the withdrawal of rofecoxib (Vioxx) off the market by its 
manufacturer Merck (47). Clearly, a more tailored advice aimed at individual circumstances 
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is necessary to obtain maximum efficiency and safety. This is also illustrated by several 
studies, including the study described in Chapter 7 of this thesis, describing the role of 
differences in genetic background between individuals in modulating the extent of the 
preventive effect of NSAIDs. 
 
Gene-environment interactions and CRC 
The above mentioned inconsistencies observed in genetic association studies might also be 
due to population heterogeneity between studies. In this respect, we must consider not only 
population admixture due to different ethnic backgrounds, but also differences in 
environmental or lifestyle factors (for example diet) that could influence the effect of the 
allele. Examples of interactions in relation to colorectal cancer found by two or more studies, 
although in most cases not consistently in all studies, have been summarized in table 2.  
 
Table 2: Gene-environment interactions in relation to colorectal cancer 
Gene symbol Variant Environmental factor Nature of interaction Ref 
MTHFR C677T Folic acid Homozygotes Val allele are 
at different risk with low 
folate intake 
(48) 
TS High vs low 
expression 
Folic acid Decrease in risk due to 
increased folate intake only 
for allele conferring 
increased expression of TS 
(49) 
ADH3 γ2 Alcohol/Folic acid Increased risk for γ2 allele in 
combination with high 
alcohol and low folate intake 
(50) 
NAT2 Rapid vs slow 
acetylator 
Heterocyclic amines in 
cooked meat 
Stronger association with 
red meat intake among rapid 
acetylators 
(51) 
mEH High vs low 
activity 
Meat intake  High activity in combination 
with well done meat 
increases risk 
(52) 
XRCC1 Arg194Trp and 
Arg399Gln 
MUFAs Arg/Arg and Glu/Glu only 
protective with low levels of 
MUFAs 
(53) 
VDR Bsm1 and long 
vs short poly-A 
site 
Calcium Reduced risk with BB and 
SS genotypes only with low 
calcium intake 
(54) 
UGT1A6 Slow vs fast 
metabolizing 
Aspirin Increased benefit of aspirin 
use for slow metabolizers 
(55) 
 
The results from this thesis add to the associations and interactions found so far for 
candidate low penetrance alleles and environmental factors. We found an interaction 
between SNPs c.-789C>T and N163N in PPARδ and fish consumption that modified the risk 
of colorectal adenomas. Our original hypothesis was that n-3 PUFAs present in fish are 
converted into eicosanoids, including prostaglandins. Since prostaglandins act as ligands for 
PPARδ (56), fish consumption may interact with PPARδ by modifying the spectrum of PPAR 
ligands. This can be influenced by SNPs, explaining the interactions founds between SNPs 
in PPARδ and fish consumption. A third interaction was shown between SNP c.2242T>C in 
PTGS2 which also modified adenoma risk. A high concentration of n-3 PUFAs, which could 
result from high fish consumption, has been shown to directly inhibit PTGS2 causing a 
decrease in the overall production of prostaglandins (57), as measured in mammary gland 
tissue. SNPs in PTGS2 might interfere with these processes.  
However, we were unable to replicate the interaction found for adenomas between the 
PPARδ and PTGS2 alleles and fish consumption, for colorectal cancer. Neither were we 
able to show this interaction with n-3 PUFA levels measured in serum instead of fish 
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consumption in the same population. This does not necessarily mean that the observed 
interactions are false positive results, since, as previously discussed, n-3 PUFAs might not 
be the active agent in fish that interacts with these genes. Moreover, what is important in the 
early stages of tumor initiation might not be as important in tumor progression. It is clear that 
it is difficult to demonstrate gene-environment interactions in a consistent manner, and to 
establish interactions beyond reasonable doubt. Clearly, at present only a small proportion 
of cases can be explained by specific low penetrance alleles and their interaction with 
environmental factors, and more research is still needed. 
 
Concluding remarks 
In the studies described in this thesis we have been able to make a number of comparisons. 
First, we have been able to assess candidate low penetrance alleles within the AA pathway 
and their influence on colorectal adenoma risk, after which these candidates were evaluated 
for their role at later stages of tumor development. We found that the minor allele of V102V 
in PTGS2 indeed influenced the risk of both adenomas and adenocarcinomas, thus 
suggesting that other low penetrance alleles in PTGS2 and PPARγ are only involved in 
modulating adenoma risk. Second, as previously discussed here (Chapter 5), we have also 
been able to compare fish consumption as a marker of n-3 PUFA intake with actual serum 
fatty acid analysis from the same subjects as a biomarker. We found that fish consumption 
correlates with n-3 PUFA content in serum, but their quantitative effects on adenoma risk 
are different. These comparisons add extra value as compared to other molecular 
epidemiology studies that only evaluate one endpoint or environmental (dietary) factor. 
Although we have attempted the evaluation of specific gene-environment interactions, we 
have not considered gene-gene interactions simply because the number of individuals 
carrying a combination of alleles is too small to properly analyze the data. Therefore, we 
cannot rule out that some of the SNPs for which we could not demonstrate an association 
with colorectal adenomas or cancer, could still have an important influence on adenoma or 
carcinoma risk when combined with SNPs in other genes. 
In conclusion, despite its limitations, this thesis represents a first attempt to identify low 
penetrance alleles in genes in the AA pathway, including their interactions with fish fatty 
acids and NSAIDs.  
 
Future prospects 
Currently, most genetic association studies employ the pathway-driven candidate gene 
approach, in which one or more candidate genes are chosen for their biological relevance in 
pathways important to the disease, and polymorphisms in these genes are tested for allele 
or genotype frequency differences between cases and controls. As technology improves and 
genotyping becomes affordable, the ultimate goal of whole genome association studies 
might become a realistic possibility. As the current total of deposited SNPs in public 
databases approaches 10 million, it is clear that for a whole genome scan a selection needs 
to be made to exclude redundant SNPs. At present there are no set rules for this but certain 
SNP characteristics can be taken into consideration. One could for example opt for selecting 
SNPs exclusively within coding regions, which would reduce the total number to around 
20,000 SNPs, and increase the possibility of including SNPs with functional effects. It has 
been shown however, that evolutionary conservation within non-coding regions is as strong 
as within exonic sequences, thus indicating the putative functional relevance of SNPs within 
these regions (58,59). A more robust approach would be to capture the major variation 
within the genome by the creation of a haplotype map, which is currently underway (60). It 
has recently been shown that the human genome is organized in discrete haplotype blocks 
spanning tens to hundreds of kilobases bounded by recombination hotspots (61). Within the 
blocks little or no recombination occurs resulting in a limited number of common haplotypes 
(2 to 4), despite the large number of SNPs within each block. The haplotypes can be 
identified by genotyping only a small subset of the SNPs within a block, termed haplotype 
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tagging (ht) SNPs. It is estimated that approximately 300,000 htSNPs are sufficient to cover 
all of the common variation within the genome (62) but estimates of 100,000 to 200,000 
htSNP have also been mentioned (60).  
Although the whole-genome haplotype approach has the advantage that no prior hypothesis 
is needed about candidate genes or SNPs within them, and if strong risk or protective alleles 
exist it is likely that they, or a SNP in LD with the causal variant, are genotyped, some 
limitations are also evident. The so called common disease common variant (CDCV) 
hypothesis states that common variants are more likely to contribute substantially to 
common disease than rare variants (63), but opponents of this hypothesis warn that rare 
variants might have a detrimental effect on for example protein function and when these 
SNPs are not taken into consideration, substantial information is missed (64). Another point 
to consider is the effect of gene-gene interactions, which will be missed when the single 
alleles do not show a main effect on their own. It has even been suggested that genetic 
predisposition to sporadic cancer is the result of a network of interacting tumor susceptibility 
alleles (65), which will be virtually impossible to determine through genotyping alone, even if 
all the genetic variation in the network is included. New strategies to overcome this problem 
still need to be developed.  
Another potential problem of a whole-genome scan is the reduction of power due to multiple 
testing. This problem becomes even greater when gene-gene and gene-environment 
interactions are also considered. Including prior biological knowledge about the gene or the 
effect of the SNP (Bayesian statistics) might help to make the associations more plausible, 
and in the same way, biologically credible interactions make statistical interactions more 
plausible. Nevertheless, small effects of single SNPs remain difficult to detect, and large 
studies are needed to generate sufficient power to reach statistical significance. 
 
In the case of colorectal cancer, before whole genome studies become feasible, future 
genetic association studies should focus on candidate genes from important colorectal 
cancer pathways, such as Wnt-, TGF-β-, RTK driven ERK MAPK- and PI3K/AKT signaling 
pathways. The Wnt signaling pathway, which is deregulated in virtually every colorectal 
tumor, could be a prime target for such association studies. Moreover, one should not just 
consider the main players in this pathway, the APC and β-catenin genes, but also include 
genes encoding other proteins capable of modulating the levels of the β-catenin/TCF 
transcription complex, e.g. GSK3-β and TCF-1. Another major pathway involved in 
colorectal tumorigenesis is the transforming growth factor (TGF) β signaling pathway. The 
SMAD genes involved in TGF-β signaling are also promising target genes for genetic 
association studies, as well as the TGF-β receptor and specific TGF-β signaling target 
genes. One of the pathways that plays an important part in colorectal cancer progression is 
the receptor tyrosine kinase induced extracellular-signal-regulated mitogen-activated protein 
kinases (ERK MAPK) pathway, which could form the basis of a candidate gene association 
study. A pathway found to be activated in many cancers, including colorectal cancer, is the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This pathway provides a link between 
metabolic signals and other pathways (for example PGE2 and the activation of PPARδ (66)), 
and is therefore another prime target for association studies.  These pathways are only 
examples towards the identification of possible future candidates, and merely represent a 
selection of important colorectal cancer pathways which should also include pathways 
involving RAS, p53 and cytochrome p450, among others. At present, much research is 
aimed at identifying and refining pathways involved in colorectal carcinogenesis which may 
not only be useful in the identification of novel drug targets but may also act as candidate 
low penetrance genes for genetic association studies. 
In the field of nutrigenomics in relation to colorectal cancer risk, where gene-diet interactions 
are evaluated, future efforts will be considerably improved once more knowledge on the 
effects on gene expression of specific food components is obtained. This might again be 
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achieved by micro-array experiments using genetically engineered mouse models of 
colorectal cancer, as well as human intervention studies . 
 
Exciting recent research in the field of lipid metabolism has further linked two of the 
environmental factors investigated in this thesis, n-3 PUFAs and NSAIDs, with regard to 
inflammation. It is now hypothesized that increased n-3 PUFA intake not only results in 
decreased production of pro-inflammatory eicosanoids due to competition with AA , but also 
produces mediators with potent anti-inflammatory effects of their own (67). Moreover, new 
evidence suggests that acetylation of PTGS2 by aspirin does not only result in complete 
inhibition of the COX activity of the enzyme, but induces a conformational change resulting 
in a shift to a lipoxygenase function, producing potent lipoxins (68). This prompted Serhan 
and colleagues to study the effect of n-3 PUFA metabolites derived from acetylated PTGS2 
on inflammation. They found that these mediators could resolve inflammation, and 
subsequently called them resolvins (69). An orphan receptor ChemR23 was identified as a 
specific receptor of the EPA derived resolvin RvE1, which inhibits activation of NF-κΒ by 
TNF-α, and is among other tissues also expressed in the gastrointestinal tract (70). It is 
likely that these mediators play an important role in reducing inflammation in the GI tract, 
and that n-3 PUFAs and aspirin exert their protective effect on colorectal cancer partly 
through this pathway. In relation to this thesis, it would be useful to analyze the combination 
of regular aspirin use and high levels of plasma n-3 PUFAs to test whether this has a greater 
protective effect then expected from simply adding the two effects. The modulating effects 
on PTGS2 of other NSAIDs should be evaluated, after which more n-3 PUFA derived 
mediators can be identified and assessed on their function on inflammation and colorectal 
cancer.  
 
In conclusion, although together with other fields like animal modeling and in vitro analysis, 
the whole genome approach holds great promise in the identification of low penetrance 
alleles, this does not necessarily represent the ultimate goal every scientist should aim for. 
The immense costs and infrastructure needed to implement such a project makes it not 
affordable for most laboratories. With increased knowledge about interactions between 
specific pathways and the environment, a more educated selection of candidate genes can 
be made. Prior knowledge about gene function and regulation in normal and tumor cells, 
from for example expression profiling studies, will also aid in gene selection. We will also 
need larger sample sizes, implying collaboration among different laboratories, and improved 
statistical methods allowing correct interpretation the data. The time when we will unravel 
the role of all genetic and environmental factors and their interactions in the etiology of 
complex diseases might still be some distance away, but it is safe to assume that these 
studies will significantly contribute to the achievement of this goal. 
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Dikke darmkanker is één van de meest voorkomende soorten van kanker en is de oorzaak 
van meer dan 4000 sterfgevallen per jaar in Nederland. Net als bij andere soorten kanker 
het geval is, ontstaat een darmtumor in een stapsgewijs proces waarbij in tumorcellen 
steeds meer genen ontregeld raken door zowel genetische (DNA mutaties) als 
epigenetische (inactivering van genen via onder andere promoter hypermethylering) 
oorzaken. In het geval van darmkanker ontstaat er in een eerste fase een zogenaamd 
goedaardig adenoom, ook wel poliep genoemd. Deze poliep kan dan uitgroeien tot een 
kwaadaardig adenocarcinoom, die uiteindelijk in de laatste fase van het kankerproces kan 
uitzaaien (metastaseren). Het samenspel tussen (epi)genetische factoren en 
omgevingsfactoren, waaronder voeding, lijkt van invloed op zowel de eerste als de latere 
fasen in het ontstaan van darmkanker. 
Bij erfelijke gevallen van darmkanker worden specifieke mutaties in bekende kankergenen 
overgedragen aan het nageslacht wat de kans op het verkrijgen van darmkanker sterk 
verhoogd. Deze mutaties kunnen echter maar een klein gedeelte van het aantal patiënten 
met een familiehistorie van darmkanker verklaren, en soms is het zelfs niet duidelijk of er 
meer darmkanker in de familie voorkomt dan gemiddeld. Het optreden van darmkanker in 
deze patiënten, maar ook bij de meerderheid van patiënten met ‘sporadische’ darmtumoren, 
kan wellicht verklaard worden door een combinatie van vele kleine variaties in ons DNA. 
Kortweg door de genetische verschillen tussen individuen. De meest voorkomende vorm 
van kleine verschillen in ons DNA zijn verschillen van een enkele nucleotide, ofwel single 
nucleotide polymorphisms (SNPs). Hierbij kunnen op een specifieke positie in het DNA twee 
verschillende nucleotiden voorkomen, resulterend in twee verschillende allelen. Deze SNPs 
vormen tegenwoordig vaak de basis voor genetische associatie studies. In deze studies 
wordt onderzocht of er een verschil bestaat in de frequentie van de allelen van een SNP 
tussen mensen met een ziekte (patiënten), en mensen zonder ziekte (controles).  
 
Resultaten van zowel epidemiologisch als experimenteel onderzoek geven aan dat het 
metabolisme van vetzuren, in het bijzonder het arachidonzuur metabolisme, een belangrijke 
rol speelt bij het ontstaan van (dikke) darmkanker. Hieruit is de hypothese geformuleerd dat 
polymorphismen in genen op sleutelposities in dit metabolisme de gevoeligheid voor het 
ontstaan van darmkanker zouden kunnen beïnvloeden. In dit proefschrift is onderzocht wat 
de invloed is van SNPs in arachidonzuur metabolisme genen op de kans op het verkrijgen 
van darmkanker. De genen die geselecteerd zijn voor dit onderzoek betreffen een zevental 
kandidaatgenen die coderen voor eiwitten die onder andere betrokken zijn bij het omzetten 
van vetzuren uit het dieet naar prostaglandinen en leukotrienen (het arachidonzuur 
metabolisme), moleculen betrokken bij onder andere ontstekingsreacties en tumorvormende 
processen. Vetzuren uit ons dieet worden in eerste instantie omgezet naar fosfolipiden, die 
worden ingebouwd in celmembranen. Deze lipiden kunnen weer worden vrijgemaakt door 
de fosfolipase-A2 familie van enzymen. De genen PLA2G2A en PLA2G4A coderen twee 
vormen van deze enzymen. De vrijgekomen vetzuren worden daarna omgezet door cyclo-
oxygenase enzymen (gecodeerd door PTGS1 en PTGS2) in prostaglandinen en door 
lipoxygenase enzymen (onder andere ALOX15) in leukotrienen. Deze producten kunnen, 
naast de vetzuren zelf, fungeren als liganden voor twee nucleaire receptoren (PPARδ en 
PPARγ), die de expressie van andere genen kunnen regelen. 
 
Behalve de invloed van genetische factoren op het risico op het ontstaan van darmkanker, 
zijn er een aantal risicofactoren die de kans vergroten, waaronder een Westerse voeding en 
leefwijze (darmkanker komt meer voor in Westerse landen). Dit laatste wordt geïllustreerd 
met  roken, weinig lichaamsbeweging en overgewicht. Ook zijn er (voedings)factoren die 
beschermend kunnen werken, waaronder het eten van vis en regelmatig gebruik van 
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nonsteroide ontstekingsremmers (NSAIDs), waar aspirine en ibuprofen bekende 
voorbeelden van zijn. Deze twee factoren en de wijze waarop ze het risico op darmkanker 
kunnen beïnvloeden, al dan niet in combinatie met genetische variaties in genen betrokken 
bij het arachidonzuur metabolisme, zijn eveneens onderzocht in dit proefschrift. 
 
Ten eerste hebben we de genetische variatie van de zeven kandidaatgenen in de vorm van 
SNPs in kaart gebracht voor de Nederlandse bevolking, door de basevolgorde van alle 
coderende en regulatoire gebieden te bepalen in het DNA van 100 willekeurig geselecteerde 
Nederlandse personen. Van de gevonden 58 variaties hebben we er 21 geselecteerd voor 
verder onderzoek. Vervolgens hebben we, in een cohort van ongeveer 400 patiënten met 
darmpoliepen en 400 controles (POLIEP cohort), de genotypen van de geselecteerde SNPs 
bepaald. Er zijn verschillen in de verdeling van genotype tussen patiënten en controles 
waargenomen voor een aantal SNPs. Een SNP in exon 3 van PTGS2 kwam minder vaak 
voor in patiënten, en mensen die het minst voorkomende allel minstens één keer bevatten 
hebben een verlaagde kans op darmkanker van 35%. Een andere SNP in PTGS2, in een 
regulatoir gebied, resulteerde in een verhoging van het risico met ongeveer 50%. Deze 
SNPs hebben dus mogelijk invloed op de functie van het gen en zorgen ervoor dat het 
proces van omzetting minder goed of juist beter verloopt. Ook een SNP in PPARγ gaf een 
verlaging in risico van ongeveer 35%. Eveneens werden verschillen waargenomen in 
distributie van combinaties van allelen, genaamd haplotypes, in PTGS2, PLA2G2A en 
ALOX15. Ook werd onderzocht of visconsumptie, als proxy (benadering) voor n-3 
meervoudig onverzadigde vetzuren die omgezet worden door bovengenoemde enzymen, 
het effect van deze allelen en genotypes kon beinvloeden. Bij mensen met het meest 
voorkomende genotype van een SNP in PPARδ was het risico verlaagd voor het ontstaan 
van darmkanker in combinatie met een relatief hoge consumptie van vis. Ook mensen met 
het meest voorkomende genotype van de eerder genoemde SNP in het regulatoire gebied 
van PTGS2 hadden een sterk verlaagd risico als ze veel vis aten. Om te onderzoeken of de 
bovengenoemde associaties voor darmpoliepen (adenomen) ook in patiënten met 
dramkanker (adenocarcinomen) aanwezig zijn, werden de genotypen van dezelfde SNPs, 
en twee bijgevoegde SNPs, in twee cohorten (DOM en PPHV cohorten) met een totaal van 
ongeveer 600 patiënten en 800 controles bepaald. Ook in deze cohorten werd een 
associatie tussen de SNP in exon 3 van PTGS2 en darmkanker gevonden, wat aangeeft dat 
deze SNP wellicht ook een rol speelt in de latere fase van progressie van darmpoliepen 
naar kwaadaardige tumoren. Er werden echter, waarschijnlijk door het kleine aantal 
patiënten (161) waar visconsumptie data van beschikbaar waren, geen interacties 
aangetoond tussen deze SNPs en visconsumptie. 
Onze hypothese was dat de n-3 meervoudig onverzadigde vetzuren de darmkanker 
beschermende bestanddelen zijn in vis, en dat deze vetzuren een interactie aangaan met de 
eerder genoemde genen. Om dit te onderbouwen hebben we de n-3 en n-6 vetzuurgehaltes 
gemeten in het serum van de 400 patiënten met darmpoliepen en 400 controles. Hoewel de 
op deze wijze bepaalde vetzuurgehaltes representatief zijn voor de vetzuurinname van de 
laatste paar dagen, werd aangetoond dat serum n-3 vetzuren representatief waren voor 
visconsumptie zoals deze was aangegeven door de deelnemers zelf in een 
voedselvragenlijst. Bovendien leek een verhoogd n-3 vetzuurgehalte beschermend te 
werken tegen darmpoliepen, terwijl een verhoogd n-6 vetzuurgehalte, met name in de vorm 
van linolzuur, een verhoogd risico op darmpoliepen teweeg bracht. De n-3 vetzuren hadden 
echter niet dezelfde interactie met de SNP in PPARδ als visconsumptie. Een van de 
mogelijke verklaringen hiervoor kan zijn dat de actief beschermende bestanddelen in vis, die 
een interactie aangaan met PPARδ en PTGS2, niet de n-3 meervoudig onverzadigde 
vetzuren zijn. Desondanks is uit andere metingen gebleken dat de verhouding van n-3/n-6 
vetzuren een informatieve parameter kan zijn voor het risico op darmkanker. Gemeten 
waardes van deze vetzuren in vetweefsel afkomstig van een kleiner aantal patiënten met 
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darmpoliepen en controles liet zien dat een hoge n-3/n-6 verhouding resulteerde in een 
verlaging van het risico op darmkanker met 80%.  
De 400 patiënten met darmpoliepen en controles uit de POLIEP studie hadden aangegeven 
op hun vragenlijst hoeveel NSAIDs ze slikten, en het bleek dat mensen die meer dan 12 
keer per jaar een tablet slikten, 25% minder kans op het krijgen van darmkanker hadden. Dit 
resultaat bevestigd wat al eerder gevonden is in andere studies en populaties. De SNP in 
PPARδ, die ook een interactie liet zien met visconsumptie, moduleert ook het effect van 
NSAIDs op darmpoliepen. Mensen met de minst voorkomende genotypen waren extra 
beschermd als ze regelmatig NSAIDs slikten, terwijl deze mensen juist een verhoogd risico 
hadden als ze weinig slikten. Deze resultaten suggereren dat deze SNP zich op een voor 
PPARδ belangrijke positie in de promoter bevindt.  
Samenvattend kan worden geconcludeerd dat sommige genetische polymorphismen in een 
aantal genen betrokken bij het arachidonzuur metabolisme van invloed lijken op het 
ontstaan van darmkanker, zowel in vroege als latere fasen. Met name allelen in PPARγ, 
PLA2G2A, ALOX15 en PTGS2 lijken van invloed op het risico voor het ontstaan van 
darmpoliepen. Hetzelfde PTGS2 allel lijkt ook van invloed op het risico voor darmkanker. In 
combinatie met de interacties die werden aangetoond tussen een SNP in PPARδ en 
visconsumptie en gebruik van NSAIDs, ondersteunt dit zowel nader onderzoek naar de 
functionaliteit van deze SNPs als onderzoek naar bevestiging van de in deze studie 
aangetoonde associaties in veel grotere cohorten.  
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